WASHINGTON, DC–(Marketwire – October 14, 2010) –  Despite the promise of a new era of health care in which medicine has shifted from treating conditions to emphasizing prevention fueled by individualized care, a significant gap remains in realizing its benefits because of outmoded attitudes, protocols and procedures targeted for treating mass populations. Such is the core argument and motivation behind the “Personalized Health Manifesto,” released today to kick off the 2010 Translational Medicine Alliance Forum (TMAF) at the Mandarin Oriental. 

Written by journalist and best-selling author David Ewing Duncan and funded by the Ewing Marion Kauffman Foundation, the manifesto is “an old-fashioned call to arms and action plan for a new age of health care” that takes direct aim at the challenges of integrating and implementing personalized health care in the United States and seeks to accelerate the incorporation of personalized health into the current health care system.

“Making this shift to personalized health is a formidable task that will take many years to accomplish, but having scientists and health care leaders sign on to a comprehensive plan is a powerful place to start,” Duncan said. “Launching a new era of personalized health will not require the creation of a radical new blueprint for change. We can use existing plans and reforms that individuals inside and outside of government have already proposed.”

“The manifesto is a fitting catalyst for conversation about how we can better and more quickly get cures to patients amid the billions being spent on research and drug development,” said Lesa Mitchell, vice president of advancing innovation at the Kauffman Foundation. “It directs us to focus on what we need to treat a patient, what we need to change in policy, what do we need to change in process, and how we need to more broadly share data to get the patient what he or she needs.” 

The manifesto’s “action plan” aims to set a new direction for health care, emphasizing prediction, prevention, individualized care and healthy wellness to ensure that the best medicines make it to the marketplace and optimize patient care. By focusing on the whole human organism, the manifesto challenges the prevailing use of drugs and protocols to target populations and averages rather than individuals. It further outlines the necessary groundwork for speeding up the process of moving from research to new drugs and other products and treatments by introducing more effective models that will ultimately improve health and reduce health care costs.

The manifesto was prepared with input from life science leaders representing medicine, business, government, patients, law and the media. Although the work is solely that of the author, these advisors have endorsed the manifesto, and many of them are convening at the TMAF today. The manifesto organizers hope to acquire the endorsement of at least 500 life science leaders by the end of the year. Anyone who reads the manifesto can add their name to the list of endorsers and leave comments by visiting www.kauffman.org/healthmanifesto.

The full manifesto is available at www.kauffman.org/manifesto.

The Ewing Marion Kauffman Foundation is a private nonpartisan foundation that works to harness the power of entrepreneurship and innovation to grow economies and improve human welfare. Through its research and other initiatives, the Kauffman Foundation aims to open young people’s eyes to the possibility of entrepreneurship, promote entrepreneurship education, raise awareness of entrepreneurship-friendly policies, and find alternative pathways for the commercialization of new knowledge and technologies. It also works to prepare students to be innovators, entrepreneurs and skilled workers in the 21st century economy through initiatives designed to improve learning in math, engineering, science and technology. Founded by late entrepreneur and philanthropist Ewing Marion Kauffman, the Foundation is based in Kansas City, Mo. and has approximately $2 billion in assets. For more information, visit www.kauffman.org, and follow the Foundation on www.twitter.com/kauffmanfdn and www.facebook.com/kauffmanfdn.

David Ewing Duncan is an award-winning, best-selling author of seven books published in 19 languages; he is a journalist and a television, radio and film producer and correspondent. His most recent book is the bestseller Experimental Man: What one man’s body reveals about his future, your health, and our toxic world. He is Chief Correspondent of public radio’s Biotech Nation and a columnist for Fortune. He is the Director of the Center of Life Science Policy at UC Berkeley. He has been a commentator on NPR’s Morning Edition, and a contributing editor for Wired, Discover and Conde Nast Portfolio. David writes for The New York Times, National Geographic, Harper’s, Atlantic Monthly, the San Francisco Chronicle, and many other publications. He is a former special correspondent and producer for ABC Nightline and a correspondent for NOVA’s ScienceNOW! He has won numerous awards including the Magazine Story of the Year from the American Association for the Advancement of Science. His articles have twice been cited in nominations for National Magazine Awards, and his work has appeared twice in The Best American Science and Nature Writing. He is a graduate of Vassar College and now lives in San Francisco.

The Translational Medicine Alliance Forum, hosted by the Kauffman Foundation, the Council for American Medical Innovation and FasterCures, convenes with the common interest of accelerating translational research to the patient. The Forum brings together leaders from academia, government agencies, and pharmaceutical, biotechnology, and venture industries to work toward developing a deeper understanding of effective models to enable and accelerate the progress of translational medicine. Through focused, dynamic sessions and exclusive networking opportunities, attendees have the opportunity to learn about breakthrough approaches and progress on current best practices in translational medicine collaborations. This Forum will focus on the following topics: regulatory science, lessons from the most experienced translational models, how and why rare disease and pediatric medicine are changing the landscape, transparency and access to data, and reverse engineering translational science starting with the patient.

Click here to see all recent news from this company

MADISON, WI–(Marketwire – October 14, 2010) –  TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for cancer care, announced today that it will release its 2010 third quarter results on Thursday, October 28, 2010 at 3:00 p.m. CDT.

TomoTherapy will hold an investment community conference call on Thursday, October 28, 2010 beginning at 4:00 p.m. CDT. Fred Robertson, M.D., CEO, and Thomas Powell, CFO, will review third quarter performance and discuss the company’s strategies. To join the conference call, dial 1-800-638-4817 (international 1-617-614-3943) and enter passcode 19539609. A replay of the conference call will be available one hour after the call ends through 10:59 p.m. CDT on November 4, 2010. To access the replay, dial 1-888-286-8010 (international 1-617-801-6888) and enter passcode 40905886.

For individual investors, a live Webcast of the conference call will be available on the Investor Relations page of TomoTherapy.com. Institutional investors can access the Webcast through a password-protected site www.streetevents.com. An archived Webcast of TomoTherapy’s conference call will be available for two weeks.

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art^® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD^™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

SAN FRANCISCO, CA–(Marketwire – October 14, 2010) –  Mindjet®, the leading provider of software and web-based applications for visually organizing and managing information and ideas, today announced the successful implementation of MindManager™ version 9 with MedMan, a leading medical management services company based in Boise, Idaho. MedMan was looking for a solution to help get closer alignment on internal operations and access to customer information for its 25 remote working employees so they could drive more strategic business plans for their dispersed medical practice client base. MedMan deployed MindManager to help employees create and organize all vital business documents, such as client rosters, HR documents and new hire information, in MindManager so information is easy to access, update and share. Using MindManager, MedMan is able to better serve its clients by providing in-depth and interactive strategy plans that foster idea generation and increase productivity.

MedMan provides administrative and business assistance and consultation for clinics, physician-owned and private medical practices. With numerous clients across multiple states and a workforce that is spread across the country, the business was difficult to keep on track. MedMan needed an easy-to-use and understand platform for tracking key pieces of information related to its clients and business.

“The methodology behind MedMan’s business is helping our clients prioritize needs and establish operational efficiencies to more effectively manage their medical practices,” said Jim Trounson, President of MedMan. “The beauty of MindManager is that we can easily create an actionable business plan with goals, owners and deadlines and work in real-time with the client to show progress and quickly revise the plan when needed. This allows us to the make decisions quicker and faster, making business better for our clients and MedMan.”

MedMan has also taken advantage of the new features in MindManager version 9 including the enhanced integration with Microsoft Outlook, the resource availability feature and the Gantt Project View to understand when clients have available assets and how MedMan can effectively use those to better a client’s business.

“Resource and project management is something that is essential to the survival of any business, whether providing services to clients or providing healthcare to patients,” said Scott Raskin, CEO of Mindjet. “MedMan’s use of MindManager demonstrates the power of visualizing pieces of information that are critical to everyday business function and we are excited to help MedMan provide a unique and necessary service to medical professionals.”

By using MindManager’s extensive visual environment and its innate ability to organize and manage all forms of data and information, MedMan has created elaborate maps that contain all pieces of relevant information for any client, ranging from current business plans, to action items to client rosters. With MindManager, MedMan has been able to strengthen its relationship with existing clients, acquire new ones and provide all clients the service needed to keep business thriving.

MindManager’s visual information maps start with a central theme, and then add branches with ideas, notes, images, tasks, hyperlinks and attachments. Users can easily import from all types of information sources. MindManager maps are used to capture and organize information, and quickly transform thoughts and ideas into fine-tuned visual representations, documents, compelling presentations and winning strategies. MindManager provides a better way to brainstorm, organize facts, plan projects, and communicate results. Users have access to tight integration with Microsoft Outlook and Office to keep the constant stream of information for a project organized in one easy-to-access location, and a visualization and dashboard tool for SharePoint environments with MindManager Explorer for SharePoint. Collaboration tools, real-time map co-editing and web based document storage with Mindjet Catalyst is also available.

For more information visit: www.Mindjet.com

About MedMan
Founded by Jim Trounson in 1977, MedMan’s business model was based on Jim’s experience with outsourcing management companies that were improving the efficiency of hospitals by centralizing and computerizing many of their management functions. MedMan’s goal is to positively affect healthcare delivery to one million patients per year by 2015, based on a proven ability to provide an elite team of professional practice administrators to physician-driven medical clinics.

About Mindjet
Mindjet provides productivity software that helps business professionals visually organize and act upon ideas, information, and resources to drive productivity, team effectiveness, and business innovation. Mindjet products include industry-leading software and online services centered on information mapping, as well as applications that incorporate Mindjet’s innovative visualization technology to improve the usability of leading business applications, including Microsoft® SharePoint® and Salesforce.com. More than 1.5 million people around the world use Mindjet software to clarify thinking, efficiently analyze information, increase team productivity, and make better-informed decisions.

Used by business professionals in 44 of BusinessWeek‘s® 50 “World’s Most Innovative Companies,” Mindjet solutions dramatically boost productivity and team effectiveness. Surveys across several industries show that Mindjet can increase productivity by up to 25 percent by making meetings, common communications, and project management tasks more efficient and effective. Mindjet products are available for free trial or purchase at www.mindjet.com/products/overview, through salesforce.com AppExchange, and through an extensive partner network at www.mindjet.com/community/partners/overview. Mindjet is headquartered in San Francisco and has offices throughout the U.S., Europe and Asia.

id=”nav_links”>

CHICAGO, IL–(Marketwire – October 13, 2010) –  Ziegler (PINKSHEETS: ZGCO) kicked off its 13^th annual Ziegler Senior Living Finance + Strategy Conference at The Hyatt Regency Resort & Spa in Bonita Springs, Florida on Wednesday, September 29, 2010.

The three-day, invitation-only educational conference attracted over 500 attendees and presented cutting-edge finance and strategic positioning trends and issues in senior living and the senior living capital markets. Tom Paprocki, President and CEO of The Ziegler Companies, welcomed the senior living providers, institutional investors, and other industry professionals and introduced the conference facilitator, Dan Hermann, Senior Managing Director & Head of Ziegler Senior Living Finance.

The Ziegler banking team conducted pre-conference workshops allowing attendees to enhance their knowledge of the senior living sector. Such workshops included “Senior Living Finance 101,” “Financial Risk Management 101,” a legal roundtable and a senior living-focused board development workshop. The Ziegler CFO Workshop Series(SM) provided CFOs a roundtable and networking session. All workshops were well attended and provided a general overview of the vast capabilities Ziegler offers.

The opening general session led by a team of capital markets experts laid the foundation for the conference curriculum. The session was a tightly narrated review of the trends unfolding across the senior living continuum and current capital markets investors’ and lenders’ landscapes. Mr. Hermann and Kathryn Brod, Ziegler’s Senior Vice President-Research, and Mike McDaniel, Ziegler’s Senior Managing Director of Sales & Trading, reviewed key trends; Ron Mintz (Vanguard) and Jim LeBuhn (FitchRatings) provided perspectives from the investor and rating agency, respectively. Each educational session of the conference was introduced, tying each to the trends and setting the context for the conference curriculum that would follow.

An array of breakout sessions was offered to attendees. Some hot topics of the conference included case studies of creative solutions for overcoming housing market challenges; key marketing tools for invigorating occupancy; case studies of providers offering services beyond their boundaries; wellness initiatives; and the impact of healthcare reform on the sector. Sessions also included discussions in trends focusing on repositionings and new campus development. Institutional investor, banking, and architects’ panels were also featured. Educational sessions were offered in areas such as investment policymaking, mergers and acquisitions, and corporate structure. All sessions were lead by industry leaders, key associates from senior living providers and Ziegler team experts.

The conference concluded with a panel discussing senior living today, tomorrow and scenarios of the future. For further information on Ziegler or the conference, please visit our website at www.zieglerseniorlivingfinance.com.

About Ziegler:
The Ziegler Companies, Inc. (PINKSHEETS: ZGCO) together with its affiliates (Ziegler) is a specialty investment bank with unique expertise in complex credit structures and advisory services. Nationally, Ziegler is ranked as one of the leading investment banking firms in its specialty sectors of healthcare, senior living, religion and education finance, as well as corporate finance and FHA/HUD. Headquartered in Chicago, IL with regional and branch offices throughout the U.S., Ziegler creates tailored financial solutions including bond financing, advisory, private placement, seed capital, M&A, risk and asset management. Ziegler serves institutional and individual investors through its wealth management and capital markets distribution channels.

Certain comments in this news release represent forward-looking statements made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are subject to a number of risks and uncertainties, in particular, the overall financial health of the securities industry, the strength of the healthcare sector of the U.S. economy and the municipal securities marketplace, the ability of the Company to underwrite and distribute securities, the market value of mutual fund portfolios and separate account portfolios advised by the Company, the volume of sales by its retail brokers, the outcome of pending litigation, and the ability to attract and retain qualified employees.

MELVILLE, NY–(Marketwire – October 13, 2010) – FONAR Corporation (NASDAQ: FONR), The Inventor
of MR Scanning™, today announced its financial results for the fiscal
year ending June 30, 2010. Total revenues were $31.8 million for the fiscal
year ended June 30, 2010 as compared to $39.7 million for fiscal 2009. The
net loss for the fiscal year ended June 30, 2010, was $3.0 million, as
compared to a net income of $1.1 million for fiscal 2009. The net loss per
share (basic and diluted) for the fiscal year ended June 30, 2010 was
$0.61, as compared to a net income per share (basic and diluted) of $0.21
for the fiscal year ended June 30, 2009.

Revenues from the management of the UPRIGHT® Multi-Position™ MRI
Centers was at $11.1 million for the year ended June 30, 2010 as compared
to $10.3 million one year earlier.

Revenues from UPRIGHT® MRI service and repair fees increased to $11.1
million for the fiscal year ended June 30, 2010 as compared to $10.5
million one year earlier.

Revenues from product sales of the FONAR UPRIGHT® Multi-Position™ MRI
scanners were $9.1 million in the fiscal year ended June 30, 2010, as
compared to $17.2 million in the fiscal year ended June 30, 2009. On June
30, 2010 there were 143 FONAR UPRIGHT® Multi-Position™ MRI scanners
installed in the United States and around the world.

“Total costs and expenses related to operations decreased 15%, from $40.4
million in the fiscal year ended June 30, 2009, to $34.4 million in the
fiscal year ended June 30, 2010,” said Raymond Damadian, M.D., Chairman and
President of Fonar Corporation. “The Company has taken strenuous steps to
controlling costs while continuing to run its business including producing
the FONAR UPRIGHT® Multi-Position™ MRI scanner. These cost cutting
programs were first begun over two years ago.”

At June 30, 2010, total assets were $21.6 million, total current assets
were $14.7 million, total current liabilities were $24.7 million, total
stockholders’ deficiency was $5.8 million and total long-term liabilities
were $2.7 million. Total cash and marketable securities were $1.3 million.
The backlog for MRI product was $14.9 million.

Dr. Damadian remarked, “FONAR has been faced with an ongoing recession and
uncertainty with regard to reimbursement and health care reform. Perhaps
most significant is the prevention of FONAR customers to obtain credit in
this difficult banking environment. Subsequently, FONAR has had to make a
massive amount of cost cuts. Reductions have been made in many categories
most significantly in research and development (R&D), and selling, general
and administrative (S, G & A) areas. Overall, R&D and S, G & A expenses
were reduced over 15% to $14.4 million for the fiscal year ending June 30,
2010 as compared to $17.0 million during the fiscal year ending at June 30,
2009.”

Dr. Damadian said, “FONAR’s prospects have much improved since our nation’s
financial difficulties last year and our customers’ uncertainties regarding
the Deficit Reduction Act (DRA) have eased. Over the past few years, the
medical evidence continues to grow indicating that the FONAR UPRIGHT®
Multi-Position™ MRI is the best MRI for diagnosing spinal problems such
as low back pain or motor vehicle whiplash injuries of the neck as well as
symptoms in other weight-bearing structures of the human body (e.g. knee,
hip, ankle, foot, shoulder, etc.). So as pent-up demand for MRI scanners
surfaces, we look forward to rising sales.”

Fiscal Year Highlights

Dr. Damadian said, “Many of the 2010 fiscal year highlights included
UPRIGHT® MRI installations, an important journal research paper and
significant increases in the patient scan totals among the 9 UPRIGHT®
Multi-Position™ (STAND-UP® MRI) imaging centers managed by FONAR’s
subsidiary Health Management Corporation of America (HMCA). In fact for
fiscal 2010, the scanning centers are now performing collectively
approximately 300 scans per month at each of the nine centers, a 16%
increase over that of the previous year.”

The July 2010 issue of the medical journal “Brain Injury”
(www.fonar.com/news/072110.htm) published a very significant study of 1200
neck pain patients comparing the FONAR UPRIGHT® Multi-Position™ MRI to
a conventional recumbent MRI and the ability to diagnose whiplash trauma
from a motor vehicle accident. The 1200 neck pain patients were divided
into 4 groups, consisting of 2 control neck pain groups that did not
experience whiplash trauma and 2 neck pain groups that did. The
radiologists who read the study images were blinded as to which images were
the patient images and which were the control images. The patients were
examined in both the upright and recumbent positions. The recumbent MRI
images were obtained in a conventional recumbent MRI and the upright images
were obtained in the FONAR UPRIGHT® MRI. The “Brain Injury” study showed
that the fallen cerebellar tonsils (CTE) caused by motor vehicle whiplash
injuries were being missed 60% of the time where the patient was scanned
recumbent-only in a conventional “lie-down MRI” and not scanned upright.
As a result of this study, the medical evidence indicated that the fallen
cerebellar tonsils of a whiplash injury patient can now be reliably
visualized by using the FONAR UPRIGHT® Multi-Position™ MRI. In fact a
customer who recently purchased the FONAR UPRIGHT® MRI said that ‘From
our point of view, here in Germany, the newly published 1200 patient study
in “Brain Injury” sets a “new standard of care” for whiplash injury
patients.’ (www.fonar.com/news/080310.htm)

During the fiscal year ended June 30, 2010, FONAR added to its world-wide
installed base of FONAR UPRIGHT® Multi-Position™ MRIs. Among them was
an installation at Hospital ZorgSaam Zeeuws-Vlaanderen, Terneuzen, The
Netherlands. This 340-bed hospital performs a significant amount of
orthopedic and spine surgery. In addition, it is one of the biggest
centers in The Netherlands for the treatment of bariatric patients. The
UPRIGHT® MRI was sold by Tecserena GmbH, FONAR’s European distributor
since 2006. At the time of the sale, radiologists at Hospital ZorgSaam
Zeeuws-Vlaanderen said they sought the advanced technology provided by the
FONAR UPRIGHT® Multi-Position™ MRI to increase the diagnostic
precision of the images of weight-bearing anatomy, establishing for their
hospital a new standard of excellence throughout Europe for orthopedic
surgical outcomes.

The year was also a big year for North Carolina installations. Prior to
this year there were no FONAR UPRIGHT® Multi-Position™ MRIs in the
state. This year UPRIGHT® MRIs were installed in Charlotte and Durham.
Introducing the FONAR UPRIGHT® Multi-Position™ MRI in North Carolina
was a lengthy process as that state has certificate of need laws designed
to limit the number of advanced medical equipment units entering the state.

Pocatella, Idaho, Las Vegas, Nevada, and Duluth, Minnesota were also
recipients of the UPRIGHT® MRI scanner. For Minnesota, this is the third
scanner purchased by the Center for Diagnostic Imaging (CDI), one of the
nation’s premier diagnostic center businesses. In addition, as the fiscal
year ended, installation of the first UPRIGHT® MRI scanner in Africa was
nearing completion.

Dr. Damadian said, “We are delighted with the results of our efforts on
‘selling scans’ at the nine UPRIGHT® Multi-Position™ MRI, aka
STAND-UP® MRI, managed sites. Currently, the Company manages nine
STAND-UP® MRIs and an earlier model FONAR QUAD™ MRI through its
wholly-owned subsidiary, HMCA (Health Management Corporation of America;
www.hmca.com). The centers’ performance improved steadily monthly. In fact,
the nine STAND-UP® MRIs performed a record 3,183 scans during the month
of March, 2010, an average of 354 per scanner. This is a 35% increase as
compared to 2,354 scans done during the month of March 2009, one year
earlier.”

“We are delighted with the response of referring physicians to the
STAND-UP® MRI. It is becoming increasingly obvious to referring
physicians that scanning patients without the force of gravity, which is
the case with all single-position, recumbent-only MRI scanners, results in
missed, critical pathology,” said Dr. Damadian. “These physicians are now
referring their patients to the scanner and experiencing more accurate
diagnoses and better outcomes for their patients as a result of scanning
them upright and fully weight-bearing in the exact position that generates
their symptoms, which the FONAR UPRIGHT® Multi-Position™ MRI makes
possible. Additionally, patients themselves appreciate the spacious,
non-claustrophobic process of being seated comfortably while watching
television throughout their scan. Mothers can enter the scanner with their
infant on their laps. The infant watching his favorite television cartoon
throughout the scan, remains motionless thereby avoiding the need for
anesthesia which currently is required for scanning the vast majority of
children under the age of seven when they are scanned in a conventional
lie-down MRI.”

Matters concerning holders of FONAR Corporation stock certificates

Recently, many of our shareholders have received letters from CST (Computer
Share Trust), www.computershare.com, telephone 800-962-4284. It is very
important for investors to respond to these letters or else risk of being
subject to state escheatment laws. Essentially, shareholders holding
older, pre-reverse stock-split certificates must exchange their old
certificates for new ones.

In addition, investors may have changed addresses or appeared to have
abandoned their stock. If this could possibly be you, we urge you to
contact CST to update your information.

Again please call CST at 800-962-4284. For more information on FONAR stock
please visit: www.fonar.com/invest_faq.htm

For investor and other information visit: www.fonar.com.

UPRIGHT® and STAND-UP® are registered trademarks and The Inventor of MR
Scanning™, Full Range of Motion™, pMRI™, Dynamic™,
Multi-Position™, True Flow™, The Proof is in the Picture™,
Spondylography™ Spondylometry™ and Upright Radiology™ are
trademarks of FONAR Corporation.

This release may include forward-looking statements from the company that
may or may not materialize. Additional information on factors that could
potentially affect the company’s financial results may be found in the
company’s filings with the Securities and Exchange Commission.

                  FONAR CORPORATION AND SUBSIDIARIES
                      CONSOLIDATED BALANCE SHEETS

                                ASSETS
                                ------


                                                         June 30,
                                                --------------------------
                                                    2010          2009
                                                ------------  ------------
Current Assets:
  Cash and cash equivalents                     $  1,299,493  $  1,225,619
  Marketable securities                               27,613        22,652
  Accounts receivable - net of allowances for
   Doubtful accounts of $2,289,049 and
   $2,393,326 at June 30, 2010 and 2009,
   respectively                                    4,820,541     5,391,822
  Medical receivables - net of allowances for
   Doubtful accounts of $1,622,000 and
   $1,343,500 at June 30, 2010 and 2009,
   respectively                                       25,225       374,225
  Management fee receivable - net of allowances
   for Doubtful accounts of $5,808,345 and
   $5,093,345 at June 30, 2010 and 2009,
   respectively                                    2,568,526     3,273,756
  Management fee receivable - related medical
   Practices - net of allowances for doubtful
   Accounts of $1,129,818 and $1,094,818 at
   June 30, 2010 and 2009, respectively            1,921,983     2,196,580
  Costs and estimated earnings in excess of          
   billings on uncompleted contracts                 277,384     1,475,706
  Inventories                                      2,826,211     3,172,397
  Current portion of advances and notes to
   related medical practices                          83,423       164,611
  Current portion of note receivable - net of
   allowances for doubtful accounts of $115,000
   and $65,000 at June 30, 2010 and at
   June 30, 2009, respectively                       271,796       517,934
  Prepaid expenses and other current assets          552,800       472,397
                                                 -----------   -----------
      Total Current Assets                        14,674,995    18,287,699

Property and Equipment - Net                       2,108,556     2,892,380

Advances and Notes to Related Medical Practices -
 net of allowances for doubtful accounts of
 $264,791 at June 30, 2010 and at June 30, 2009        -            89,032

Notes Receivable                                       -         1,778,626

Other Intangible Assets - Net                      4,291,419     4,920,241

Other Assets                                         553,875       391,237
                                                ------------  ------------
      Total Assets                              $ 21,628,845  $ 28,359,215
                                                ============  ============


                  FONAR CORPORATION AND SUBSIDIARIES
                      CONSOLIDATED BALANCE SHEETS

                              LIABILITIES
                              -----------


                                                         June 30,
                                                --------------------------
                                                    2010          2009
                                                ------------  ------------
Current Liabilities:
  Current portion of long-term debt and capital
   Leases                                       $    579,436  $    277,494
  Current portion of long-term debt - related
   party                                              87,835        79,509
  Accounts payable                                 3,191,960     3,518,609
  Other current liabilities                        8,065,069     8,460,042
  Unearned revenue on service contracts            5,219,547     5,526,006
  Customer advances                                4,813,327     9,237,921
  Billings in excess of costs and estimated
   earnings on uncompleted contracts               2,743,398     2,026,441

                                                ------------  ------------
      Total Current Liabilities                   24,700,572    29,126,022
                                                ------------  ------------
Long-Term Liabilities:
  Accounts payable                                    62,622       184,168
  Due to related medical practices                   527,891       643,135
  Long-term debt and capital leases, less
   current portion                                 1,566,622       759,211
  Long-term debt, less current portion -
   related party                                      72,341       160,176
  Other liabilities                                  474,763       427,365
                                                ------------  ------------
      Total Long-Term Liabilities                  2,704,239     2,174,055
                                                ------------  ------------
      Total Liabilities                           27,404,811    31,300,077
                                                ------------  ------------
Commitments, Contingencies and Other Matters


                  FONAR CORPORATION AND SUBSIDIARIES
                      CONSOLIDATED BALANCE SHEETS

                       STOCKHOLDERS' DEFICIENCY
                       ------------------------


                                                         June 30,
                                                --------------------------
                                                    2010          2009
                                                ------------  ------------
Stockholders' Deficiency:
  Class A non-voting preferred stock - $.0001
   par value; authorized - 1,600,000 shares;
   issued and outstanding - 313,451 shares
   at June 30, 2010 and 2009                    $         31  $         31
  Preferred stock - $.001 par value;
   authorized - 2,000,000 shares; issued
   and outstanding - none                               -             -
  Common stock - $.0001 par value; authorized -
   30,000,000 shares at June 30, 2010 and 2009,
   respectively; issued - 4,985,850 and
   4,917,918 shares at June 30, 2010 and 2009,
   respectively; outstanding - 4,974,207 and
   4,906,275 shares at June 30, 2010 and 2009,
   respectively                                          497           491
  Class B common stock (10 votes per share) -
   $.0001 par value; authorized - 800,000
   shares; issued and outstanding - 158 shares
   at June 30, 2010 and 2009                            -             -
  Class C common stock (25 votes per share) -
   $.0001 par value; authorized - 2,000,000
   shares; issued and outstanding - 382,513
   shares at June 30, 2010 and 2009                       38            38
  Paid-in capital in excess of par value         172,379,863   172,280,600
  Accumulated other comprehensive loss               (18,489)      (20,995)
  Accumulated deficit                           (177,271,349) (174,258,607)
  Notes receivable from employee stockholders       (191,167)     (267,030)
  Treasury stock, at cost - 11,643 shares
   of common stock at June 30, 2010 and 2009        (675,390)     (675,390)
                                                ------------  ------------
      Total Stockholders' Deficiency              (5,775,966)   (2,940,862)
                                                ------------  ------------
      Total Liabilities and Stockholders'
        Deficiency                              $ 21,628,845  $ 28,359,215
                                                ============  ============


                  FONAR CORPORATION AND SUBSIDIARIES
                 CONSOLIDATED STATEMENTS OF OPERATIONS

                                               For the Years Ended June 30,
                                               ---------------------------
                                                   2010           2009
                                               ------------   ------------
Revenues
  Product sales - net                          $  9,056,307   $ 17,175,417
  Service and repair fees - net                  10,864,927     10,345,091
  Service and repair fees - related parties -
   net                                              220,000        192,500
  Management and other fees                       7,302,216      7,342,614
  Management and other fees - related
   medical practices - net                        3,786,612      2,911,318
  License fees and royalties                        585,493      1,755,493
                                               ------------   ------------
      Total Revenues - Net                       31,815,555     39,722,433
                                               ------------   ------------
Costs and Expenses
  Costs related to product sales                  7,248,756     10,758,201
  Costs related to service and repair fees        3,026,598      3,992,557
  Costs related to service and repair fees
   - related parties                                 61,284         74,293
  Costs related to management and other fees      5,320,756      4,507,587
  Costs related to management and other fees
   - related medical practices                    2,962,826      2,790,745
  Research and development                        2,458,342      3,593,470
  Selling, general and administrative,
   inclusive of compensatory element of stock
   issuances of $99,269 and $4,061 for the
   years ended June 30, 2010 and 2009,
   respectively                                  11,939,223     13,423,066
  Provision for bad debts                         1,378,500      1,286,451
                                               ------------   ------------
      Total Costs and Expenses                   34,396,285     40,426,370
                                               ------------   ------------
      Loss from Operations                       (2,580,730)      (703,937)

Other Income and (Expenses):
  Interest expense                                 (313,416)      (333,229)
  Interest expense - related parties                (74,486)         -
  Investment income                                 249,290        325,688
  Interest income - related parties                  10,926         20,818
  Other income - net                                 45,674        399,662
  Loss on note receivable                          (350,000)         -
  Gain on sale of consolidated subsidiary             -          1,448,196
                                               ------------   ------------
      (Loss) Income Before Provision For
       Income Taxes                              (3,012,742)     1,157,198

Provision for Income Taxes                            -             35,931
                                               ------------   ------------
       Net (Loss) Income                       $ (3,012,742)  $  1,121,267
                                               ============   ============

SAN DIEGO, CA–(Marketwire – October 13, 2010) –  SpectraScience, Inc. (OTCBB: SCIE), a San Diego based medical device company, today announced that Jim Hitchin, the Company’s current Chairman and CEO, resigned as Chairman effective October 8, 2010 and that the Board elected Mark McWilliams to assume the duties of Chairman of the Board of Directors.

Jim Hitchin, SpectraScience’s CEO, said, “The Company is planning its future growth strategy and as a part of best practices and good governance is separating the Chairmanship from the Chief Executive Officer role consistent with Sarbanes-Oxley guidance.”

Mr. McWilliams has served as a Director of the Company since 2004 and brings his expertise in managing and growing technology companies, a strong network of contacts in the medical device industry and experience in technology transactions. Mr. McWilliams also serves as the CEO of Medipacs, Inc., a development stage infusion pump company. Prior to that, from December 2003 to November 2005, he was Director of Cell Imaging and Analysis at Beckman Coulter after the sale of Q3DM to Beckman in December 2003. He was President and Chief Executive Officer and Director of Q3DM, from October 2001 to December 2003, a life-sciences startup that raised several angel and venture capital funding rounds that was acquired by Beckman Coulter. Previously, he was founder and COO of Medication Delivery Devices (“MDD”), an alternate care infusion systems company that was acquired by Baxter Healthcare in 1996. Mr. McWilliams served as a VP of Research and Development at Baxter Healthcare for three years following the sale of MDD. Prior to MDD, he served as Product Development Manager at the founding of Block Medical where he was responsible for bringing the company’s first two FDA approved products rapidly to market. Block was sold to Hillenbrand Industries in 1991. He previously worked for Hughes Aircraft, Vacuum General and Martin Marietta. Mr. McWilliams has expertise in managing and growing small technology companies and has a strong network of contacts within the medical devices industry. He earned his MSME from the Massachusetts Institute of Technology, his BSME from Northeastern University and holds eight utility patents.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience’s actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience’s other reports filed with the Securities and Exchange Commission (“SEC”) that attempt to advise interested parties of the risks and factors that may affect SpectraScience’s business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company’s LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.

HILO, HI–(Marketwire – October 13, 2010) –   Pacific Quest recently held an informational and educational gathering for visiting educational consultants on the Big Island of Hawaii. Educational consultants arrived from the Midwest, East and West Coast, and Southern U.S. to learn about Pacific Quest’s wilderness therapy programs for struggling youth and young adults. Guests were greeted in camp with a welcoming ceremony, drumming circle, and a nutritious lunch prepared by Pacific Quest students. Afterwards, a garden tour of the four organic farms captured the key components and stages of the program for the consultants.

The next morning, Pacific Quest therapists and wellness staff delivered interactive presentations about the wilderness therapy program. Following the educational presentations, the group spent an afternoon engaging on the gardens and with students in the various phases of the wilderness program. Staff and guests put on work gloves and joined students in working in the nursery, transplanting plants, and harvesting mangoes and papayas on the farm. Students shared their experiences and knowledge of the farm with the visitors and were active teachers for the day.

What came from this gathering was an exchange of knowledge between educational consultants and the students and staff at Pacific Quest. Guests were able to experience the students’ daily life and engage in learning about the mind-body-emotion connection. By hosting this event, Pacific Quest was able to share its sustainable growth model through experiential education, informational sessions, and one-on-one interaction with students and staff.

For more information regarding Pacific Quest, please visit www.pacificquest.org or contact Mark Agosto, Outreach Director, at (808) 937-5806 or via email at [email protected]. Read more at: http://www.pacificquest.org/news/3/196/Pacific-Quest-Wilderness-Therapy-Program-Celebrates-First-Annual-Educational-Consultant-Gathering/.

About Pacific Quest:

Pacific Quest is an outdoor behavioral healthcare (“wilderness therapy”) and sustainable treatment program for struggling teens and young adults, located on the Big Island of Hawaii. Their wilderness programs offer a clinical, yet holistic approach to treatment, going beyond traditional therapy and teaching sustainable life skills. Owned and operated by a veteran team of professionals with over 200 years of combined program experience, Pacific Quest offers a unique approach to treatment that is individualized for each student. Through experiential education, clinical services, a dedicated approach to health and wellness, and sustainable gardening, Pacific Quest provides a structured yet flexible outdoor therapy environment that serves the individual needs of each student.

Click here to see all recent news from this company

LEBANON, OR–(Marketwire – October 13, 2010) –  The College of Osteopathic Medicine of the Pacific-Northwest campus has yet to open its doors in Lebanon, Ore., but prospective students are lining up to apply for the 100 slots available in the inaugural class that begins in fall 2011.

More than 1,400 applications have been received, with several months left in the application process. The interview process began on Oct. 9 and applications will be accepted until Feb. 1, 2011.

“The early deluge of applications only codifies our historic belief that there was a significant unmet need both for medical education and health care services in geographic locations outside the major metropolitan areas of Seattle and Portland,” said COMP Dean Clinton Adams, DO.

Thirty-nine applicants, mostly from the northwest region, traveled to Lebanon for their formal interview with the school on Oct. 9. The interview is the final step in the application process to medical school following the primary and secondary written application documents.

The interviews were conducted by leaders who have volunteered to provide support for COMP-Northwest, including state and regional osteopathic physicians, Oregon business leaders, and representatives from Samaritan Health Services. The volunteers were divided into groups of three and conducted interviews for three to four applicants.

The interview day began with opening remarks by Dean Adams, followed by remarks from Paula Crone, DO, Executive Associate Dean for COMP-Northwest. The interviewees then received an orientation and overview of COMP, including presentations from Admissions, Financial Aid, Student Affairs and the COMP curriculum.

The day concluded with a 90-minute bus tour of the area, taking in the cities of Lebanon, Albany and Corvallis and highlighting the history, geography, amenities, activities and hospital facilities in each city.

“It’s very difficult for Oregonians and students from the Northwest to access medical education in the Northwest,” Adams said. “These students coming from the Northwest, educated in the Northwest, offer a significant solution to the health care needs of the Northwest as we face the ever-increasing demand for primary care and specialty services. The creation of a new opportunity for medical education in a small-town, rural environment will go a long way toward achieving our objective of providing health care to the many underserved areas of the Northwest.”

COMP-Northwest will be the first new medical school built in Oregon in more than a century.
The new COMP-Northwest facility is a 54,000-square-foot building due to be completed in spring 2011. The building contains two large lecture halls and four 60-seat classroom spaces, 15 student breakout and study rooms, an anatomy lab, an osteopathic manual medicine lab and significant research space.

COMP-Northwest is the approved new campus in the expansion of the College of Osteopathic Medicine of the Pacific, which was founded in Pomona, Calif. in 1977. COMP is now one of nine colleges that make up Western University of Health Sciences.

MENOMONEE FALLS, WI–(Marketwire – October 13, 2010) –  Assisted Living Concepts, Inc. (NYSE: ALC) announced that it plans to release its 2010 third quarter financial results before the New York Stock Exchange opens on Tuesday, November 2, 2010. The release will be posted on ALC’s website at www.alcco.com. ALC has scheduled a conference call on Tuesday, November 2, 2010 at 10:00 a.m. (EDT) to discuss its financial results for the third quarter. The toll-free number for the live call is (800) 230-1096 or international (612) 332-0335. A taped rebroadcast of the conference call will be available approximately three hours following the live call until midnight on December 2, 2010, by dialing toll free (800) 475-6701 or international (320) 365-3844 and using access code 174903.

About Us
Assisted Living Concepts, Inc. and its subsidiaries operate 211 senior living residences comprising 9,305 units in 20 states in the United States. ALC’s residences typically consist of 35 to 60 units and offer residents a supportive, home-like setting and assistance with activities of daily living. ALC employs approximately 4,100 people.

PLANTATION, FL–(Marketwire – October 13, 2010) – For the second year in a row, DentalPlans.com, the top online source for affordable and easy-to-use alternatives to dental insurance, is proud to donate a portion of the firm’s October proceeds to support breast cancer research and awareness. DentalPlans.com is pleased to reaffirm their commitment to women’s health and fund groundbreaking research, education, screening and treatment during National Breast Cancer Awareness Month. 

“As a leader in discount dental plans, our company is fully committed to the well being of our nation’s oral health,” said Buddy Johnson, CEO of DentalPlans.com, Inc. “We are proud to extend our support to raise public awareness and fund life-saving research to ultimately cure this devastating disease.”

In further support of the company’s campaign, DentalPlans.com has provided select network dentists and their staff members with pink dental scrubs and badges inscribed with a pink ribbon and the word ‘hope.’ “Any small thing we can do to eradicate this disease is a huge step forward,” said Dr. Peter Krimsky, who is proudly setting aside the conventional blue scrubs to wear pink ones along with his staff. “We’re raising awareness and prompting our patients to think.”

Dr. Krimsky’s office sees wearing pink as making a difference, one that will one day contribute to the end of the disease. Others are adopting the same thinking and pink is popping up where one might least expect. This year, the National Football League has teamed with the American Cancer Society to feature players, coaches and referees wearing pink apparel in the name of awareness. 

According to the American Cancer Society, breast cancer is the second leading cause of cancer death in women, after lung cancer. One out of eight American women who live to be 85 years of age will develop breast cancer, a risk that was one out of 14 in 1960. Excluding cancers of the skin, breast cancer is the most common cancer diagnosed among U.S. women, accounting for more than 1 in 4 cancers.

Interviews with DentalPlans.com representatives, members and network dentists are available. For more information about DentalPlans.com and editorial inquiries, please contact Shamin Abas or Elizabeth Rose of Shamin Abas Public Relations at 561.366.1226, [email protected] or [email protected]. 

About DentalPlans.com (www.DentalPlans.com)
DentalPlans.com is dedicated to improving oral health nationwide by making quality dental care affordable and accessible to everyone. DentalPlans.com proudly offers the freedom to choose from an extensive selection of discount dental plans designed to save members money on their dental care needs. With more than 40 years of experience in the dental industry, their devoted team quickly transformed DentalPlans.com into a trusted industry leader and the largest online provider of discount dental plans. Since 1999, DentalPlans.com has offered great value and convenience with an extensive choice of money-saving discount dental plans in one user-friendly website.

Click here to see all recent news from this company

TORONTO, ONTARIO–(Marketwire – Oct. 13, 2010) – Unison Health and Community Services is celebrating its official launch on Thursday, October 14^th, from 4 p.m. to 7 p.m., at its Lawrence Heights site located at 12 Flemington Road in Toronto. 

The entire community is invited to learn about Unison Health and Community Services and enjoy entertainment by local performers. There will also be children’s activities and contests, music and dancing, and refreshments.

In August, Unison Health and Community Services received its formal incorporation approval from Ministry of Government Services. This is the first voluntary merger of two community health centres in Ontario – the amalgamation of New Heights Community Health Centres and York Community Services.

Unison builds on the strengths and best practices of both organizations, aiming to improve access to programs and services for clients and community members. The optimal use of resources of both organizations will enhance the delivery of services in a more efficient and cost-effective manner. In collaboration with partners, the integrated services will provide seamless and comprehensive care to clients.

With extended hours at four full-service locations, clients now can have greater access to a wider variety of services. Unison now serves over 22,000 clients and offers core services that include primary health care, counselling, health promotion, early years programs, legal services, harm reduction programs, housing assistance and adult protective services; special programs like Pathways to Education, Diabetes Education and Prevention, and Aging at Home; and a range of community programs targeted to marginalized groups.

For event information, visit www.unisonhcs.org, or call 416-587-8225 or email [email protected].

BIRMINGHAM, UNITED KINGDOM–(Marketwire – Oct. 13, 2010) – A new study has revealed that the UK is a nation of over eaters and grazers with seven out of 10 people reaching for a snack on a regular basis.

The study, showed that half of Britons graze on food when they are bored whilst 23 per cent eat and snack more at times of crisis, turning to food to help them with their emotional needs.

Out of the 3000 people surveyed it was discovered that twice as many women as men snacked when they were stressed with only one in 10 reaching for a tasty treat when they were actually hungry.

Boredom was one of the key roles in overeating with 57 per cent of women scoffing down chocolaty treats and fatty delights and 40 per cent of men doing the same when they were fed up.

Other interesting reasons behind some of the UK’s snacking habits included eating at times of sadness as a way for people to cheer themselves up.

Those who are worried about being overweight should book a consultation with an expert bariatric surgeon at The Hospital Group.

The Hospital Group is the UK’s biggest provider of weight loss surgery, including gastric bands, gastric bypasses and gastric balloons.

David Ross, Chief Executive of The Hospital Group, said: “We are all guilty of having a snack every now and then especially when so many of us lead hectic lifestyles, a quick snack or readymade item can seem like the perfect choice to keep us going.

“However, it’s when people start to graze on a regular basis that it can be bad for their health. Eating sugary and fatty foods throughout the day can lead to weight gain and means that the body isn’t getting the vitamins or nutritional content that it needs.

“Those who are overweight often find themselves in a vicious circle, they want to lose weight and become more healthy but are locked in a battle with overeating and don’t know how to change their bad and harmful eating habits.

“Our consultants ensure that, as well as having an absolute need for a gastric procedure, the patient understands that weight loss surgery isn’t a miracle cure and they would need to work with the band to achieve the healthier lifestyle they desire.”

Since The Hospital Group was established in 1992, it has risen to become the UK’s biggest weight loss surgery providers, performing more gastric procedures last year than the NHS.

The Hospital Group is committed to providing the very highest standards and all procedures are performed by an expert medical team in state-of-the-art facilities that are second to none.

For further information of The Hospital Group’s range of weight-loss procedures, surgery-seekers should visit the website www.thehospitalgroup.org or call our patient care coordinators on 0845 762 6727.

SAN DIEGO, CA–(Marketwire – October 12, 2010) –  When San Diego resident Paul Henderson was hospitalized last year after a fall and subsequent hip surgery, he realized that even highly trained hospital staff were unable to meet his basic comfort needs — not because of lack of concern, but because as an Amyotrophic Lateral Sclerosis (ALS — more commonly known as Lou Gehrig’s disease) patient, he had lost the ability to speak. 

His week in the hospital ICU followed by two weeks at a rehab facility so impacted Henderson and his family — who had to be present at all times to interpret simple messages such as “I need my pain medication,” or “I need to go to the bathroom,” — that it inspired him to set up a new business designed to help anyone with limited speech ability in a care-giving situation.

Called “HelpMeSpeak, Inc.” (www.helpmespeakcards.com), the new company manufactures and sells reasonably priced message cards that can be used virtually anywhere — in hospitals, nursing facilities, rehab facilities or at home. The two-sided cards come in sets of 15, and have basic “needs” phrases in English and Spanish. They are ideally suited to individuals who have suffered strokes, paralysis, or who have other nerve/muscular-damaging diseases (such as ALS or muscular sclerosis). Henderson plans to donate $1 from every sale to the San Diego ALS Association. 

“I assumed that nursing staff would understand that ALS does not impact my mental capacity, only my ability to move and speak. I also assumed that they would be able to interpret my efforts to communicate, or to at least anticipate my basic needs,” said Henderson. “Unfortunately, I was wrong on all counts. They would talk to me as though as I was mentally impaired, and unfortunately, could not understand my efforts to communicate.

“As a result, I would lay cold in the bed for hours, or in pain, all because they couldn’t understand me.”

Henderson’s idea for HelpMeSpeak cards was so simple, he was sure a product like this must already exist. However, after contacting several hospitals and facilities, none were in use. Any communication products he found were not directed to basic patient care and cumbersome to use. 

The HelpMeSpeak cards are held by a ring that can be attached by a clip to a hospital gown or by a lanyard to a bedrail (or for patients not at risk of tangling, around the neck). The cards are color coded — red for English and black for Spanish. The cards are large enough that even if someone has limited hand mobility, it’s possible to handle them with relative ease. For patients without mobility, the caregiver can show the cards — thumbing through until the patient nods that his or her message has been selected.

HelpMeSpeak messages include: “I need my medications,” “Turn off the light,” “I am hot,” “I am cold,” “I am thirsty,” “I need to go to the toilet,” “I am hungry,” “I am OK,” etc. 

HelpMeSpeak cards can be ordered through the company website, www.helpmespeakcards.com, with individual set prices starting at $25 and per-unit Henderson plans to have a customization option introduced soon that will allow users/orders to expand the sets, or change the sets, with other messages as well.

About HelpMeSpeak
HelpMeSpeak, Inc., a San Diego-based company, is the creator and distributor of HelpMeSpeak cards, which are care cards designed by Paul Henderson, an ALS patient, to assist speech-impaired patients with communicating urgent needs to doctors, nurses and other caregivers. Each set of HelpMeSpeak cards contains 15 cards with messages translated in both English and Spanish. For more information, visit www.helpmespeakcards.com.

MENOMONEE FALLS, WI–(Marketwire – October 12, 2010) –  Assisted Living Concepts, Inc. (“ALC”) (NYSE: ALC) announced today that it entered into an agreement to acquire nine senior living residences from HCP, Inc. (NYSE: HCP). The nine residences are currently leased and operated by ALC under leases expiring between 2010 and 2012. The transaction, which is subject to customary closing conditions, is expected to close on or around October 31, 2010. The purchase price is $27.5 million plus certain transaction costs. The nine residences, two of which are located in New Jersey and seven in Texas, contain a total of 365 units. Occupancy of the nine residences is currently 60.0%. Upon completion of this transaction we expect pre-tax cash flow to improve by approximately $1.0 million because of the differential between current lease payments and expected future interest expense. After accounting for taxes we expect cash flow per share to improve by approximately $0.05 per share.

“We are pleased to have reached agreement with HCP to purchase these properties,” commented Laurie Bebo, President and Chief Executive Officer of Assisted Living Concepts, Inc. “In addition to upside opportunities in the existing portfolio, the better performing properties have excess land that may provide good expansion opportunities in the future. After this transaction is completed we will own 161 of our properties or 76% of our total residences.”

Non-GAAP Financial Measures
Cash Flow per Share

Cash flow is defined as cash provided by operating activities. Cash flow per share is defined as cash flow divided by the weighted average diluted common shares outstanding for a fiscal period. Cash flow per share is not a measure of performance under accounting principles generally accepted in the United States of America, or GAAP. We use cash flow per share as a performance indicator.

We understand that cash flow per share may be used by financial analysts and investors as a performance measure in evaluating a company’s ability to service debt and meet other payment obligations or as a common valuation measurement in the long-term care industry. We believe cash flow per share provides meaningful supplemental information because this measure excludes the effects of non-operating factors related to our capital assets, such as depreciation and amortization related to the assets.

About Us
Assisted Living Concepts, Inc. and its subsidiaries operate 211 senior living residences comprising 9,305 units in 20 states. ALC’s senior living facilities typically consist of 40 to 60 units and offer residents a supportive, home-like setting and assistance with the activities of daily living. ALC employs approximately 4,100 people.

Forward-looking Statements

Statements contained in this release other than statements of historical fact, including statements regarding anticipated financial performance, business strategy and management’s plans and objectives for future operations, including management’s expectations about improving occupancy and private pay mix, are forward-looking statements. Forward-looking statements generally include words such as “expect,” “project,” “point toward,” “intend,” “will,” “indicate,” “anticipate,” “believe,” “estimate,” “plan,” “strategy” or “objective.” Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. In addition to the risks and uncertainties referred to in the release, other risks and uncertainties are contained in ALC’s filings with United States Securities and Exchange Commission and include, but are not limited to, the following: changes in the health care industry in general and the senior housing industry in particular because of governmental and economic influences; changes in general economic conditions, including changes in housing markets, unemployment rates and the availability of credit at reasonable rates; changes in regulations governing the industry and ALC’s compliance with such regulations; changes in government funding levels for health care services; resident care litigation, including exposure for punitive damage claims and increased insurance costs, and other claims asserted against ALC; ALC’s ability to maintain and increase census levels; ALC’s ability to attract and retain qualified personnel; the availability and terms of capital to fund acquisitions and ALC’s capital expenditures; changes in competition; and demographic changes. Given these risks and uncertainties, readers are cautioned not to place undue reliance on ALC’s forward-looking statements. All forward-looking statements contained in this report are necessarily estimates reflecting the best judgment of the party making such statements based upon current information. ALC assumes no obligation to update any forward-looking statement.

Supplementary Financial Information  The following table is limited to financial information for the nine leased residents described above (in thousands, except per share number)

 

BENSALEM, PA–(Marketwire – October 12, 2010) – Healthcare Services Group, Inc. (NASDAQ: HCSG)
reported that revenues for the three months ended September 30, 2010
increased over 9% to $195,114,000 compared to $178,829,000 for the same
2009 period. Net income for the three months ended September 30, 2010
increased approximately 12% to $9,169,000 or $.21 per basic and per diluted
common share, compared to the 2009 third quarter net income of $8,225,000
or $.19 per basic and per diluted common share.

Revenues for the nine months ended September 30, 2010 increased over 12% to
$571,868,000 compared to $510,134,000 for the same 2009 period. Net income
for the nine months ended September 30, 2010 increased approximately 7% to
$25,318,000 or $.58 per basic and $.57 per diluted common share compared to
the 2009 nine month period net income of $23,776,000 or $.55 per basic and
$.54 per diluted common share.

The Board of Directors has declared a third quarter 2010 regular quarterly
cash dividend of $.2325 per common share, payable on November 5, 2010 to
shareholders of record at the close of business October 22, 2010. This
represents an increase over the dividend declared for the 2010 second
quarter, as well as an increase of 16% over the 2009 same period payment.
It is the 30th consecutive regular quarterly cash dividend payment, as well
as the 29th consecutive increase since our initiation of regular quarterly
cash dividend payments in 2003.

Additionally, our Board of Directors has declared a three-for-two stock
split in the form of a 50% stock dividend payable on November 12, 2010 to
holders of record of its Common Stock at the close of business November 8,
2010. All fractional share interests will be rounded up to the nearest
whole number. The effect of this action will be to increase Common Shares
outstanding by approximately 22,000,000 shares.

The Company will host a conference call on October 13, 2010 at 8:30 AM
Eastern Time to discuss its results for the three and nine month periods
ended September 30, 2010. The call in numbers are 888-259-8552 and
913-312-1406 (passcode # 8945410).

Cautionary Statement Regarding Forward-Looking Statements

This release and any schedules incorporated by reference into this report
may contain forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934 (the “Exchange Act”), as amended, which are not
historical facts but rather are based on current expectations, estimates
and projections about our business and industry, our beliefs and
assumptions. Words such as “believes,” “anticipates,” “plans,” “expects,”
“will,” “goal,” and similar expressions are intended to identify
forward-looking statements. The inclusion of forward-looking statements
should not be regarded as a representation by us that any of our plans will
be achieved. We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise. Such forward-looking information is also subject to
various risks and uncertainties. Such risks and uncertainties include, but
are not limited to, risks arising from our providing services exclusively
to the health care industry, primarily providers of long-term care; credit
and collection risks associated with this industry; one client accounting
for approximately 11% of revenues in the nine month period ended September
30, 2010; risks associated with our acquisition of Contract Environmental
Services, Inc., including integration risks or costs, or such business not
achieving expected financial results or synergies or failure to otherwise
perform as expected; our claims experience related to workers’ compensation
and general liability insurance; the effects of changes in, or
interpretations of laws and regulations governing the industry, our
workforce and services provided, including state and local regulations
pertaining to the taxability of our services; and the risk factors
described in our Form 10-K filed with the Securities and Exchange
Commission for the year ended December 31, 2009 in Part I thereof under
“Government Regulation of Clients,” “Competition” and “Service
Agreements/Collections,” and under Item IA “Risk Factors.” Many of our
clients’ revenues are highly contingent on Medicare and Medicaid
reimbursement funding rates, which Congress has affected through the
enactment of a number of major laws during the past decade, most recently
the March 2010 enactment of the Patient Protection and Affordable Care Act
and the Health Care and Education Reconciliation Act of 2010. Currently,
the U.S. Congress is considering further changes or revising legislation
relating to health care in the United States which, among other
initiatives, may impose cost containment measures impacting our clients.
These laws and proposed laws and forthcoming regulations have significantly
altered, or threaten to alter, overall government reimbursement funding
rates and mechanisms. The overall effect of these laws and trends in the
long-term care industry have affected and could adversely affect the
liquidity of our clients, resulting in their inability to make payments to
us on agreed upon payment terms. These factors, in addition to delays in
payments from clients, have resulted in, and could continue to result in,
significant additional bad debts in the near future. Additionally, our
operating results would be adversely affected if unexpected increases in
the costs of labor and labor related costs, materials, supplies and
equipment used in performing services could not be passed on to our
clients.

In addition, we believe that to improve our financial performance we must
continue to obtain service agreements with new clients, provide new
services to existing clients, achieve modest price increases on current
service agreements with existing clients and maintain internal cost
reduction strategies at our various operational levels. Furthermore, we
believe that our ability to sustain the internal development of managerial
personnel is an important factor impacting future operating results and
successfully executing projected growth strategies.

Healthcare Services Group, Inc. is the largest national provider of
professional housekeeping, laundry and dietary services to long-term care
and related facilities.

                      HEALTHCARE SERVICES GROUP, INC.
                          CONDENSED CONSOLIDATED
                           STATEMENTS OF INCOME
                                (Unaudited)


                                                For the Three Months Ended
                                                        September 30,
                                                    2010          2009
                                                ------------- -------------
Revenues                                        $ 195,114,000 $ 178,829,000
Operating costs and expenses:
   Cost of services provided                      168,384,000   155,228,000
   Selling, general and administrative             14,488,000    11,936,000
                                                ------------- -------------
Income from operations                             12,242,000    11,665,000
Other income:
    Investment and interest income                  1,182,000     1,709,000
                                                ------------- -------------
Income before income taxes                         13,424,000    13,374,000
Income taxes                                        4,255,000     5,149,000
                                                ------------- -------------
Net income                                      $   9,169,000 $   8,225,000
                                                ============= =============

Basic earnings per common share                 $         .21 $         .19
                                                ============= =============

Diluted earnings per common share               $         .21 $         .19
                                                ============= =============

Cash dividends per common share                 $         .23 $         .19
                                                ============= =============
Basic weighted average number of
 common shares outstanding                         44,026,000    43,626,000
                                                ============= =============

Diluted weighted average number of
 common shares outstanding                         44,719,000    44,334,000
                                                ============= =============




                      HEALTHCARE SERVICES GROUP, INC.
                          CONDENSED CONSOLIDATED
                           STATEMENTS OF INCOME
                                (Unaudited)


                                                 For the Nine Months Ended
                                                       September 30,
                                                    2010          2009
                                                ------------- -------------
Revenues                                        $ 571,868,000 $ 510,134,000
Operating costs and expenses:
   Cost of services provided                      492,196,000   438,950,000
   Selling, general and administrative             41,539,000    36,328,000
                                                ------------- -------------
Income from operations                             38,133,000    34,856,000
Other income:
    Investment and interest income                  1,549,000     3,803,000
                                                ------------- -------------
Income before income taxes                         39,682,000    38,659,000
Income taxes                                       14,364,000    14,883,000
                                                ------------- -------------
Net income                                      $  25,318,000 $  23,776,000
                                                ============= =============

Basic earnings per common share                 $         .58 $         .55
                                                ============= =============

Diluted earnings per common share               $         .57 $         .54
                                                ============= =============

Cash dividends per common share                 $         .66 $         .54
                                                ============= =============
Basic weighted average number of common shares
 outstanding                                       43,964,000    43,540,000
                                                ============= =============

Diluted weighted average number of common
 shares outstanding                                44,677,000    44,224,000
                                                ============= =============




                      HEALTHCARE SERVICES GROUP, INC.
                  CONDENSED CONSOLIDATED BALANCE SHEETS
                                (Unaudited)


                                                September 30, December 31,
                                                    2010          2009
                                                ------------- -------------
Cash and cash equivalents                       $  26,109,000 $  31,301,000
Marketable securities, net                         44,498,000    52,648,000
Accounts receivable, net                          108,363,000   104,356,000
Other current assets                               24,350,000    23,865,000
                                                ------------- -------------
  Total current assets                            203,320,000   212,170,000

Property and equipment, net                         5,591,000     4,391,000
Notes receivable- long term, net                    6,084,000     4,623,000
Goodwill, net                                      16,955,000    17,087,000
Other Intangible Assets, net                        7,730,000     8,862,000
Deferred compensation funding                      12,510,000    10,783,000
Other assets                                       10,082,000     7,976,000
                                                ------------- -------------

Total Assets                                    $ 262,272,000 $ 265,892,000
                                                ============= =============


Accrued insurance claims- current               $   6,032,000 $   4,844,000
Other current liabilities                          18,186,000    29,873,000
                                                ------------- -------------
  Total current liabilities                        24,218,000    34,717,000

Accrued insurance claims- long term                14,074,000    11,302,000
Deferred compensation liability                    12,837,000    11,099,000
Stockholders' equity                              211,143,000   208,774,000
                                                ------------- -------------

Total Liabilities and Stockholders' Equity      $ 262,272,000 $ 265,892,000
                                                ============= =============

OAKLAND, CA–(Marketwire – October 12, 2010) –  It took vision, years of planning and advocacy; a true labor of love. On Thursday, October 7 Alameda’s newest partner for family members dealing with their own very personal journeys — The Family Education and Resource Center (FERC) (www.askferc.org) — celebrated one year of “being there” for residents of Alameda County. More importantly, the event, called “Partners In This Journey,” celebrated those who worked tirelessly for years setting the stage for this program to finally be funded with Mental health Services Act funds. The event took place at Oakland’s Waterfront Hotel and coincided with National Mental Illness Awareness Week (October 3 – 9, 2010).

“We wanted to thank everyone who participated in the visioning, creation and existence of FERC (www.askferc.org).”

“We’ve been there; we can help,” says Karina Foote, FERC Program Director, noting that every member of the FERC staff have the lived experience of supporting a loved one with mental illness.

As one in four Americans either suffer with a mental illness themselves or has a family member so dealing, the services provided by FERC are crucial. Plus, in challenging economic times, the strain on individuals and families is even greater. To help meet that need — and meet the need in ways that are most comfortable to their clients — FERC provides both in person and telephone support. All services are free. 

“We call it our ‘warm line’ telephone service,” says Foote. “There is still so much misunderstanding, fear and therefore much stigma around issues of mental health and illness; it is sometimes easier for our clients to discuss their needs over the phone.” Also, cultural competency is a vital part of our mission. “We meet our clients where they are in terms of their ability to cope with their own and the struggles of their loved ones,” says Annie Kim, Lead Family Advocate.

Staff at FERC help individuals navigate the often complex web of behavioral health services. When needed, FERC staff will even make the initial contact or appointment with an agency on behalf of an individual. In addition, FERC staff assist with locating resources such as mental health care, housing, day programs, and recreation, and offer guidance about managing family relationships and developing coping strategies. “We direct people to available and appropriate services,” says Kim. People who contact FERC in the midst of a crisis may be directed to the appropriate crisis management services.

As a new program of the Mental Health Association of Alameda County (contracted for service with ACBHCS), FERC has been reaching out to clients and organizations to offer their services. Staff members are available not only on site, but also to facilitate or take part in support groups for other organizations. As FERC continues to grow, staff also plans to develop support groups for transition age youth (15-27) who have a family member with a mental illness and to provide education about mental illness for classroom teachers.

FERC’s main office is in Oakland’s Eastmont Town Center (7200 Bancroft Avenue, Suite 269), with additional offices in Fremont and Hayward. A site in Livermore will open later this fall. Office hours are Monday through Friday, 9am-5pm and people from anywhere in Alameda County are welcome to drop in with questions or to conduct research in the library or on the Internet.

“For many years, we envisioned a safe harbor for people in Alameda seeking mental health services,” said Margot Dashiell, Chairperson of the Alameda County Family Coalition, speaking at the October 7^th event. “FERC has become that safe harbor.”

The Family Education and Resource Center (FERC) is a new and innovative family/caregiver-centered program that will provide information, education and support services to family/caregivers of children, adolescents, transitional age youth, adults or older adults with serious emotional disturbance or mental illness living in all regions of Alameda County. These services will be provided in a culturally competent manner, reaching out to people of all ethnicities. For more information about FERC, call 510-746-1700. To access services, families can call 1-888-896-FERC (3372).

Click here to see all recent news from this company

NEW ROCHELLE, NY–(Marketwire – October 12, 2010) –  Somnia Anesthesia, the premier anesthesiology practice management company, today announced the appointment of John Ansorge to the position of chief financial officer. In this newly created role, Ansorge will assume oversight of the company’s financial operations, with responsibility for accounting, financial planning and reporting, budgets and forecasting. He will report to Somnia President and CEO, Marc E. Koch, MD, MBA.

Mr. Ansorge joins Somnia with more than 20 years’ experience in hospital finance. Most recently, he held the position of interim CFO for Stamford Health System in Stamford, Connecticut, a 305-bed teaching hospital affiliated with the Columbia University Medical School and posting net revenues of $450M. While there, he reorganized the Patient Access Department, initiated and controlled a cost savings plan aimed at reducing expenses, reduced supply costs, and successfully reorganized the hospital’s debt during unfavorable market conditions.

“John is a highly talented healthcare finance professional who rounds out our world-class executive team,” said Dr. Koch. “He brings tremendous business acumen to the organization and we’re confident he will put in place the financial structure needed to support our continued growth in the hospital market.”

Prior to joining Stamford Health System, Mr. Ansorge held the post of chief financial officer at a variety of hospitals including Lincoln Park Hospital and Ephraim McDowell Regional Medical Center, located in Chicago and Kentucky, respectively. While at Lincoln, he reduced cash flow losses and increased collections. He also moved the hospital’s EBITA results into positive territory for the first time in five years.

Earlier in his career, Mr. Ansorge honed his healthcare accounting and finance skills in a series of roles requiring increasing levels of responsibilities at Humana, Inc. and Columbia/HCA Healthcare Corporation.

Mr. Ansorge holds a BS, Healthcare Management, from the University of Alabama.

About Somnia
Somnia Inc., founded in 1996, is the most experienced physician-owned and operated clinical anesthesia management company servicing healthcare facilities nationwide. Somnia specializes exclusively in building and comprehensively managing world-class anesthesia teams that consistently deliver the highest quality of patient care. The company expertly manages all areas of anesthesia including leadership, recruiting, revenue cycle management, payor contracting and quality assurance with the largest in-house management infrastructure in the United States.

For more information visit: www.somniainc.com. Follow us on Twitter: http://www.twitter.com/somniainc.
Add us on LinkedIn: http://www.linkedin.com/in/somniaanesthesia.

Click here to see all recent news from this company

DALLAS, TX–(Marketwire – October 12, 2010) –  For the entire month of October, Pizza Patron will be raising funds in all its stores for the St. Jude Children’s Research Hospital.

Pizza Patron stores have St. Jude posters and counter top displays up that explain why and how to donate. St. Jude is a pediatric treatment and research facility in Memphis, Tennessee which treats children with cancer and other catastrophic diseases. Founded by entertainer Danny Thomas on the premise that “no child should die in the dawn of life,” the hospital is well-known for being the only pediatric cancer center in the country that won’t charge parents for any treatment not covered by their insurance plan. No child is ever turned away from St. Jude’s because of his or her family’s inability to pay.

“We were really amazed by the professionalism and support shown by St. Jude’s team. They visited every Pizza Patrón across the country personally, and provided training to our team members,” said Andrew Gamm, brand director for Pizza Patrón. “The response from our employees has been overwhelmingly positive; everyone is very excited to play a part in helping this amazing charity.”

Gamm explained that donations of any size can be given and the donation will be indicated on the receipt in a separate line item. One-hundred percent of the money raised will go to St. Jude’s. 

In 2010, St. Jude Children’s Research Hospital was named the number one children’s cancer hospital in the United States by U.S. News & World Report. Discoveries at St. Jude have changed how doctors treat children with cancer and other catastrophic illnesses. Since St. Jude was established, the survival rate for acute lymphoblastic leukemia, the most common type of childhood cancer, has increased from 4 percent in 1962 to 94 percent today. St. Jude has treated children from across the U.S. and from more than 70 countries. Doctors around the globe consult with St. Jude on their toughest cases. Additionally, St. Jude has an International Outreach Program to improve the survival rates of children with catastrophic illnesses worldwide through the transfer of knowledge, technology and organizational skills.

About Pizza Patrón
Pizza Patrón, America’s #1 Latin pizza brand, offers traditional pizza, wings and sides in its community based, Latin-influenced stores. Pizza Patrón was founded by restaurateur Antonio Swad in 1986, in Dallas, Texas, and today operates 100 dine-in and carry-out restaurants in seven states with 40 more under development. Pizza Patrón has franchise opportunities available in prime markets throughout the country offering a proven system for hard-working franchisee candidates. In 2007, the brand received international news coverage when it decided to accept Mexican Pesos at all of its locations, gaining over 500,000,000 media impressions worth over $30 million in the U.S. alone. The company’s medium AMIGO PIZZAS® start as low as $4 and X-Large LISTA-NOW READY™ pepperoni pizzas start as low as $6 all day, every day.

Website – www.pizzapatron.com
Facebook – http://www.facebook.com/pizzapatron
Twitter – http://www.twitter.com/pizzapatron
MySpace – http://www.myspace.com/mypizzapatron
YouTube – http://www.youtube.com/user/pizzapatroncorp

Click here to see all recent news from this company

IRVINE, CA–(Marketwire – October 12, 2010) –  SK&A, A Cegedim Company, today announced results of its ongoing survey of U.S. medical offices to determine the policies for allowing pharmaceutical and other medical industry sales-rep access to physicians and other prescribers. The Physician Access survey is based on completed telephone interviews with more than 237,000 medical sites representing 680,000 physicians.

While other similar studies and services are based on sample surveys, projections and manufacturer-based data, SK&A has invested in a comprehensive, ongoing survey to directly profile every U.S. medical office and record their exact policies for contact with sales reps. SK&A surveys its Office-Based Physician database every six months from its Research Center in Irvine, California.

After three years of measuring access to physicians, what has emerged is a portrait of doctors and their willingness to interact with sales representatives. Nearly half of the physicians surveyed say they require or prefer appointments to be made by reps prior to one-on-one meetings, while about 23 percent of doctors refuse to see sales reps at any time at any of their practice locations.

According to the survey, the percentage of doctors who will not allow access unless an appointment is scheduled increases measurably when their practices are owned by hospitals or health systems. In many cases, the appointment must be made through a headquarters location rather than the practice site itself.

“As prescribers become busier and less accessible, understanding physician access preferences is critical to successful sales and marketing resource planning, and execution,” said SK&A’s Dave Escalante, Vice President of Data and Information Solutions. “The information available from SK&A’s up-to-date profiling of physician access gives sales and marketing organizations deeper insight, enabling them to target more efficiently while not jeopardizing important relationships.”

Managing sales-rep calls is a significant part of the physician work week. According to the latest findings of the Physician Access study, most doctors (98 percent) report their offices are visited by up to 20 industry reps per week or one rep an average of every two hours.

Other significant trends found within the survey include:

• Specialty physicians are less likely to grant sales reps access than general practitioners. The top-three most accessible physician areas are allergists/immunologists (4.2% no-see rate), orthopedic specialists (5.1%) and diabetes specialists (7.6%). The least accessible physicians are diagnostic radiologists (92.1% no-see rate), pathologists (91.8%) and neuroradiologists (90.6%).The access rates for these specialists have remained constant for the last two bi-yearly reporting periods.

• Offices with fewer patients seen daily are less likely to see sales reps. Sites with a daily patient volume of one to 10 have a no-access rate of 28.9 percent, while those with a daily patient volume of 31 to 40 have a 13.4 percent no-access rate. Sites that are less busy are often staffed by one physician who is not able to take a break from patient appointments to visit with industry sales reps.

• Health system- and hospital-owned offices are less likely to grant sales reps access. Health system- and hospital-owned offices have no-access rates of 30.8 percent and 29.6 percent, respectively. Non-health system and hospital-owned offices have no-access rates of 21.4 percent and 21.7 percent, respectively.

• Larger practices are less likely to grant sales reps access. Offices with one to two physicians have a no-access rate of 13.3 percent while offices with 10 or more physicians have a no-access rate of 42.2 percent.

• Physician offices in the Western U.S. are least likely to allow sales reps access. The South had the lowest no-access rate of 19.4 percent, and the West had a 28.4 percent no-access rate.

The Physician Access report is available to help healthcare marketers and sales executives in appointment-setting and connecting personally with physicians. SK&A has compiled access data at the physician level and offers custom databases selectable by geography, specialty, office size, patient volume, practice ownership and other variables upon request. 

Editor’s Note: For a copy of the summary findings for publication, please contact Jack Schember, SK&A Director of Marketing, at 800-752-5478, ext. 1259. 
 
About SK&A, A Cegedim Company:
SK&A is a leading provider of healthcare information solutions and research. SK&A, as part of Cegedim’s global OneKey® offering, researches and maintains contact and profiling information for over two million healthcare practitioners, including 800,000-plus prescribers. SK&A also offers the only 100-percent telephone-verified database of email addresses of U.S. prescribers and professionals working at active healthcare sites. SK&A’s customers include many of America’s most recognized healthcare, life sciences and pharmaceutical companies. Please visit www.skainfo.com for more information or www.skalivecounts.com for counts and ordering. 

About Cegedim:
Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, life sciences companies, healthcare professionals and insurance companies. The world leader in life sciences CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs 8,600 people in more than 80 countries and generated revenue of EUR 874 million in 2009. Cegedim SA is listed in Paris (EURONEXT: CGM).
To learn more, please visit: www.cegedim.com

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – October 12, 2010) –  Healthnostics, Inc., (PINKSHEETS: HNSS), a medical manufacturing and biotechnology analytics company, has purchased a major manufacturer of specialty medical products. There will be an immediate positive impact on revenue and earnings commencing in the 1^st Quarter of 2011. Details will be forthcoming in subsequent press releases.

“This accretive purchase directly ties into the Company’s recent acquisition of World Wide Wipes Co., and it will result in even more substantial impact on our profitability and earnings per share,” said Alan Grofe, president.

About Healthnostics

Healthnostics, Inc. is a medical and biotechnology analytics company that provides comprehensive patient clinical monitoring and risk management systems to acute care hospitals and utilizes its Internet portals to deliver medical and biotechnology resource information to industry professionals as well as to the general public. Healthnostics’ major products include: Worldwide Wipes Co., a manufacturer and distributor of medical and other wipes, MedGuardian, a patient care monitoring and risk management system for hospitals that is fully Web-based; and through the MedBioWeb subsidiary, MedBioWorld™, one of the largest professional medical and biotechnology directory resource and reference portal sites on the Internet, and FamilyMedicalNet, a companion consumer healthcare information portal.

For further information please visit Healthnostics www.healthnostics.com, and Worldwide Wipes Co. www.wipesco.com, MedBioWorld www.medbioworld.com, and FamilyMedicalNet www.familymedicalnet.com. And visit us on Facebook at www.facebook.com/Healthnostics.

This press release may contain certain statements that are not descriptions of historical information, but are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934. These forward-looking statements refer to matters that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated.

SAN DIEGO, CA–(Marketwire – October 12, 2010) –  MIR3, the innovator of real-time Intelligent Notification™ and response technology, today announced that Concerro, provider of SaaS-based workforce management and emergency response systems that facilitate real-time information access, has chosen inEnterprise™ software to integrate with their software offerings and to resell as a stand-alone product.

Concerro has been using inEnterprise to add Intelligent Notification to their flexible workforce management system, ShiftSelect™, for more than two years. They have not only renewed their contract, but extended it to include development within their CommandAware™ emergency response and incident management system and have also agreed to act as resellers of the stand-alone inEnterprise platform. Now Concerro is able to offer their customers both a command console with integrated notification and a separate platform that can be used for important message delivery and mass notification.

“With MIR3, we can offer our customers real-time notification that helps communicate important messages among hospital staff wherever they are, no matter what communication device they use,” said Michael Meisel, VP of product management and marketing for Concerro. “Any number of users can be alerted of an urgent staffing need or emergency situation quickly and simultaneously, which saves time and improves communication when it’s needed the most.”

“The partnership between MIR3 and Concerro supports our strategy of penetrating the healthcare and hospital industries and provides solid benefits to both partners,” said Rene Grossrieder, VP, worldwide channels and alliances for MIR3. “Expanding on our partnership, both from a development and reseller standpoint, provides hospitals with the most comprehensive solution on the market. These new solutions will help them to take action more quickly, streamline costs and enhance compliance.”

ShiftSelect is a workforce management system used to improve shift visibility and align organization and workforce needs in a hospital setting. CommandAware is an emergency response and incident management system for hospitals that helps these institutions become HICS IB and NIMS compliant as well as meet Joint Commission preparedness standards.

inEnterprise uses Intelligent Notification technology to decrease time spent on manual and often unreliable means of contacting staff, vendors and partners, allowing users to deliver important messages to hundreds or thousands of people at once, no matter where they are and by a wide variety of communication means. Intelligent Notification technology will provide Concerro customers with an automated way to increase and improve communications, augmenting their workforce management and disaster response systems. 

ABOUT MIR3

MIR3, Inc. is the leading developer of Intelligent Notification and response software, which helps organizations enhance communication abilities, protect assets, and increase operational efficiency. MIR3 technology enables advanced rapid, two-way mass communication for IT, business continuity, and enterprise operations for more than 85 of the FORTUNE 100 companies, as well as government entities, universities, and companies of all sizes in more than 130 countries. For more information, visit www.mir3.com.

ABOUT CONCERRO

Concerro is a healthcare Software-as-a-Service (SaaS) company that provides healthcare workforce and emergency response and incident management systems that improve both quality of life and your bottom line by reducing costs through optimization rather than reduction. The company has won numerous awards and recognition, including being named to the prestigious Inc. 5000 for three consecutive years, and receiving Red Herring’s 100 most promising private technology ventures in North America and Best of SaaS Showplace (BoSS) awards. To learn more, visit www.concerro.com, or follow Concerro on Twitter.

BOCA RATON, FL–(Marketwire – October 12, 2010) –  David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that the Company completed the sale of $2.75 million principal amount, 10% convertible notes due in 2012 and warrants to purchase an aggregate of 6,111,000 shares of Vicor’s common stock on October 8, 2010. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i^® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events, including congestive heart failure patients for cardiac death resulting from arrhythmia or pump failure, diabetics for diabetic autonomic neuropathy (DAN), and trauma victims for imminent death absent immediate lifesaving intervention.

“We’re extremely pleased to have secured this financing, especially given the current state of the economy. We are gratified by our investors’ confidence in the market potential of our non-invasive risk stratification products, which we are beginning to realize. This financing will provide us with the working capital needed to continue to execute our business plan,” stated Mr. Fater.

About Vicor Technologies, Inc.
Vicor Technologies is a biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i^®). The PD2i^® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

Vicor currently has three products employing the PD2i^® nonlinear algorithm. The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability; physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of sudden cardiac death.

Vicor anticipates additional applications employing the PD2i^® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer
The appearance in this release of name-brand institutions, such as the U.S. Army Institute for Surgical Research, does not constitute endorsement by these institutions of the information, products, or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to successfully complete the normal range study for PD2i^®values; our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a claim for the PD2i CA™(Cardiac Analyzer) for risk stratifying congestive heart failure patients at elevated risk of cardiac mortality and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to develop additional applications for the PD2i^®algorithm; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 10-19

Click here to see all recent news from this company

MADISON, WI–(Marketwire – October 12, 2010) – TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for cancer care, saw attendance double over 2009 levels for its annual Asia Pacific User Education Symposium, held October 2-3, 2010, in Incheon, South Korea. More than 190 TomoTherapy^® treatment system users from across the Asia Pacific region convened to share insights on a growing body of clinical evidence of the efficacy of TomoTherapy radiation treatments. The increased attendance underscores the rapid adoption of the solution in the region, where the installed base of TomoTherapy systems has increased by 27 percent in just the last year.

“The Asia Pacific User Education Symposium was extremely valuable for all TomoTherapy users in the region,” said Dr. Yong Chan Ahn, associate professor and chairman of Radiation Oncology at Samsung Medical Center in South Korea, who also served as chairman of the event. “We had the opportunity to see a great deal of excellent clinical research, with many presentations focused on those diseases, such as liver cancer, that are difficult to treat and commonly seen in Asia. I look forward to the maturing of the results we are seeing, further showing the benefits of TomoTherapy in these areas.”

The Asia Pacific region is one of the fastest growing markets for TomoTherapy, with its installed base experiencing consistent growth of about 30 percent annually for the last few years. The key growth drivers for the region have been Korea, Japan and, more recently, China. Also, in the past year, expansion into Malaysia and Australia have added to the growth. Japan remains the largest market in the Asia Pacific region with 19 TomoTherapy systems installed, second overall only to the United States. South Korea is the second largest market in the region, with 14 systems currently installed.

“We were extremely pleased to see the representation of our customers at this meeting. Their presence overwhelmingly confirms that TomoTherapy offers very high quality treatment and is considered the gold standard in radiation therapy,” said H.W. Jang, CEO of Oncology Total Solutions, a distributor of TomoTherapy technology in South Korea and host of the symposium. “We are proud to have a very strong relationship with TomoTherapy to provide the best quality service, which strengthens our bond with our customers and helps them in the delivery of treatment to their patients.”

The User Education Symposium featured a strong scientific program covering topics from treatment of liver and nasopharynx cancers, to sparing of the hippocampus during treatment for brain cancer. Of particular note were two presentations:

• Dr. Chul Seung Kay of Incheon St. Mary Hospital of Korea presented on five years of clinical experience with TomoTherapy technology at his institution, citing multiple areas of investigation. In the treatment of advanced hepatocellular cancer with TomoTherapy, results showed a median survival rate double that of similar patients treated by other means. Other disease studies showed positive response to TomoTherapy treatments, particularly patients with pulmonary metastases who did not respond to multiple cycles of systemic chemotherapy. Researchers also reported on the feasibility of TomoTherapy to treat inoperable, advanced pancreatic cancers, and discussed ongoing studies on extracranial metastases, re-irradiation of recurrent rectal, head and neck cancers and oligometastases from breast cancer.

• Dr. Chikao Sugie of Nagoya City University, Japan detailed his center’s experience with craniospinal treatments on a group of 12 patients, median 14 years of age. For treatment of various brain tumors, TomoTherapy plans were superior to conventional linear accelerator-based plans with regard to the homogeneity and conformality in planning target volume.

“We have treated more than 1,300 patients with a broad spectrum of disease with TomoTherapy since September 2006,” said Dr. Pei-Wei Shueng, chief of Radiation Oncology at Far Eastern Hospital in Taiwan. “We have found that helical TomoTherapy provides us with a flexible treatment fractionation scheme that offers better dose coverage and highly conformal dose distributions, combined with an impressive ability to simultaneously spare multiple critical structures.”

“The degree of clinical interest in TomoTherapy in the Asia Pacific region is very impressive, as evidenced in the participation in our symposium. In just its third year, the Asia Pacific User Education Symposium has grown to be the largest one TomoTherapy hosted this year,” said Fred Robertson, M.D., TomoTherapy’s CEO. “Based on the response to our symposium and the clinical evidence coming out of the region, we believe that the stage is set for continued significant adoption of the TomoTherapy platform throughout the Asia Pacific region.”

The Asia Pacific event is the final in a series of three User Education Symposia held in 2010. The first, for the Americas region, took place in April in San Diego, Calif., and the second, for Europe and the Middle East, was held in May in Marbella, Spain. 

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art^® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD^™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

Forward-Looking Statements
Statements in this release regarding future products or product capabilities, events, expectations and other similar matters, including but not limited to statements using the terms “may,” “should,” “suggests” or “indicates” constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to factors such as our ability to integrate acquired assets, ability to protect intellectual property, risks of interruption due to events beyond the company’s control, and the other risks listed from time to time in TomoTherapy’s filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy’s judgments as of the date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries

TARPON SPRINGS, FL–(Marketwire – October 11, 2010) – Pinnacle Home Care of Pinellas today announced that it has been named one of the top 500 home health agencies in the country, according to the 2010 HomeCare Elite™. Now in its fifth year, the HomeCare Elite identifies the top 25 percent of home health agencies in the United States and further highlights the top 100 and top 500 agencies overall. Winners are ranked by an analysis of performance measures in quality outcomes, quality improvement, and financial performance.

“The 2010 HomeCare Elite winners continue to demonstrate a commitment to providing their patients with the best possible care while performing at the highest level,” said Amanda Twiss, CEO of OCS HomeCare. “We congratulate Pinnacle Home Care of Pinellas on being one of the top home care agencies in the country. In addition, we salute all forward-thinking providers who are already working on measuring and improving their performance using OASIS-C outcomes and process measures and HH-CAHPS results. This important data will also be used in identifying the HomeCare Elite in the future.”

Pinnacle Home Care’s co-owner, Margo McElveen, RN, credits “staff commitment to exceeding both patient and physician expectations as well as the staff’s compassion when delivering quality of care” with the company’s ability to rank as one of the HomeCare Elite. “Our staff’s dedication to individualized patient care and their successful outcome is what sets us apart,” she said.

 “On the fifth anniversary of HomeCare Elite, DecisionHealth would like to congratulate all of the winners who have achieved excellent clinical and financial outcomes, especially during times of such drastic regulatory changes,” added Marci Heydt, executive editor of DecisionHealth’s Home Health Line.

The 2010 HomeCare Elite is the only performance recognition of its kind in the home health industry. The 2010 HomeCare Elite is brought to the industry by OCS HomeCare, the leading provider of homecare information, and DecisionHealth, publisher of home care’s most respected independent newsletter Home Health Line. The data used for this analysis were compiled from publicly available information. The entire list of the 2010 HomeCare Elite agencies can be viewed by visiting the OCS HomeCare website at www.ocshomecare.com.

MUNDELEIN, IL–(Marketwire – October 11, 2010) –  The more than 4,000 healthcare workers and breast cancer survivors who danced in the Pink Glove Dance: The Sequel video are still working to raise awareness for breast cancer prevention — and maybe inspire more people to dance and support the cause. Medline Industries, Inc. — the makers of the pink gloves and creator of the dance videos — has just posted videos from each of the 12 healthcare facilities and breast cancer survivor groups that participated in the Pink Glove Dance sequel. The videos can be viewed at www.pinkglovedance.com.

“Our video involved doctors and nurses, employees, students, survivors and others from the IU Simon Cancer Center, the IU school of nursing and medicine, and Clarian Health,” said Michael Schug, communications specialist at the Indiana University Melvin and Bren Simon Cancer Center. “So, a lot of our people danced to help spread the word about breast cancer awareness. To let our dancers and community know about our custom video, we have done mass e-mailings, posted it on our Facebook pages, YouTube channels, and Flickr accounts. It’s definitely gone viral around here.” 

Linda Rumore, purchasing agent for Thibodaux Regional Medical Center in Thibodaux, Louisiana, and the coordinator of the shoot at the hospital said: “The video is such a morale booster for all of us throughout the hospital because it’s such a great cause. It’s like Christmas Eve here because everyone is so excited and honored to be involved in the video.”

The original Pink Glove Dance video was launched about a year ago with healthcare workers at Providence St. Vincent Medical Center in Portland, Oregon. Because of the overwhelming response from the video (now with more than 11.8 million views on YouTube), Medline went across the country and into Canada to film healthcare workers and breast cancer survivors dancing in pink gloves to raise awareness for breast cancer prevention. The result was The Pink Glove Dance: The Sequel, which was launched September 17, featuring workers from 11 hospitals, three nursing homes and breast cancer survivors in five different locations from the Golden Gate Bridge to New York’s Times Square and several points in between. (See list of participating facilities and locations at the end of this release.)

“I cannot begin to tell you what participating in the video does for someone like me — a survivor. After going through hell and back and being able to have fun, dance and share these moments, it’s amazing and it shows how Medline really cares and thinks about the people they are serving,” said Annette Rodriguez, a New York City resident and participant in the survivor shoot in Times Square. “Being in the video shows that we aren’t just pieces of meat being dealt with, we are people too. People aren’t noticing the lack of hair or how skinny or fat someone is getting from treatments. It made all of us feel beautiful and allowed us to just have fun, let loose.” 

Since the original video was released last November, the Pink Glove Dance has grown way beyond Medline’s efforts. In the past year, more than 80 pink glove videos have been posted on YouTube from around the world (including Germany, The Netherlands and Canada) featuring people dancing in pink gloves to support breast cancer awareness. Some of the more interesting videos feature the Penn State women’s basketball team, students in elementary schools, high school cheerleaders, grandmothers, and even cats and babies wearing pink gloves.

Medline originally developed the pink exam gloves and the Pink Glove Dance video as a way to spread awareness for breast cancer prevention.

“Breast cancer awareness and prevention is now the largest philanthropic cause in our company,” said Andy Mills, president of Medline. “The pink gloves are symbolic of healthcare workers’ connection with breast cancer patients. Prevention and early detection are among the most important ways you can fight breast cancer and that is why our campaign focuses on helping fund mammograms for women who cannot afford them.”

Medline donates $1 to the National Breast Cancer Foundation for every case sold of its pink gloves to help fund mammograms for underserved women. Medline has donated more than a half million dollars to provide education and free mammograms to those in need and continues to make contributions every year.

About Medline
As the nation’s largest privately held manufacturer and distributor of medical supplies, Medline is focused on helping to improve the quality of care for patients and residents. Breast cancer awareness is a natural extension of Medline’s corporate mission to help save lives through the early detection of breast cancer. (Visit www.medline.com/breast-cancer-awareness for details). Based in Mundelein, Ill., Medline manufactures and distributes more than 100,000 products to hospitals, extended care facilities, surgery centers, home care dealers and agencies, and other markets.

Who is in the sequel?
The sequel features more than 4000 healthcare workers and breast cancer survivors from 14 separate facilities in the U.S. and Canada (11 hospitals, 3 nursing homes and 5 separate breast cancer survivor shoots). Here is a list of participating locations:

Providence St. Vincent Medical Center
Portland, Oregon

University of Minnesota Medical Center, Fairview
Minneapolis, Minnesota

Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana

Tallahassee Memorial Healthcare, Inc.
Tallahassee, Florida

Saint Michael’s Medical Center
Newark, New Jersey

The Medical Center of Plano
Plano, Texas

HCA Johnston?Willis Hospital
Richmond, Virginia

Scripps Memorial Hospital La Jolla
La Jolla, California

Sky Ridge Medical Center
Lone Tree, Colorado

Thibodaux Regional Medical Center
Thibodaux, Louisiana

Capital Health
Halifax, Nova Scotia

Burgess Square Healthcare and Rehab Centre
Westmont, Illinois

Isabella Geriatric Center
New York, New York

Lorien Health Systems
Maryland

Breast Cancer Survivor Sites
New York City
Chicago
San Francisco
Minneapolis
Portland

ALEXANDRIA, VA–(Marketwire – October 11, 2010) – The American Diabetes Association launched its first official blog today to help put a face on a disease that kills more people each year than breast cancer and AIDS combined. The blog, called Diabetes Stops Here: Living with Diabetes; Inspired to Stop It, aims to document the Stop Diabetes® movement by reaching and engaging the 23.6 million Americans living with diabetes as well as the 57 million who are at risk for developing type 2 diabetes. 

Diabetes Stops Here will provide snap shots of the people who are committed to putting an end to this disease, from inspiring volunteer stories to moving staff experiences to celebrity stories about how to be successful while living with diabetes. The stories, interviews and news will be shared by the blog’s author, a staff member at the American Diabetes Association, who has lived with type 1 diabetes for nearly ten years. 

The Stop Diabetes movement was launched during American Diabetes Month® in November 2009 as a call to action for people to stand up against this disease and its devastating complications. The Association hopes to have one million people join the movement by the end of 2010.

“There have been so many touching moments in the movement to Stop Diabetes since we launched last year,” commented Larry Hausner, CEO, American Diabetes Association. “People have shared courageous stories of facing their diabetes head on, while others have shared their heart-breaking experiences of losing a loved one because of diabetes. The blog is a new way to raise our collective voices and tell people why we need to Stop Diabetes once and for all.” 

Some of the most vocal diabetes stories come from blogs and other social media platforms which create a broad online community of people who have diabetes or whose loved ones are living with the disease. “By means of this blog,” noted Hausner, “we hope to add our voice to this dialogue and further engage with those who may be well aware of the effects diabetes can have on their lives.”

Today’s first post is titled “Why ‘Stop Diabetes’?” can be found at www.diabetesstopshere.org. This initial post seeks to explain why the Stop Diabetes movement was created and its goal for engaging the public. “The goal of the Stop Diabetes movement is to grow to epic proportions, to be bigger than the disease itself,” the blog explains. “In short, it’s the answer to why the Association does the work that it does.”

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

COLUMBIA, SC–(Marketwire – October 11, 2010) – BDI Pharma, Inc. (BDI), the nation’s fastest growing national distributor of biotech therapies, announced the continuing expansion of the company’s specialty pharmaceutical portfolio with the launch of a new Animal Health Division, 4legPharma. This latest BDI Pharma expansion, focused on the biopharmaceutical needs of the veterinary specialist, is supported by the launch of its own website, www.4legpharma.com, as well as a staff of highly trained representatives dedicated to service this unique marketplace.

“As the Animal Health Division of BDI Pharma, 4legPharma is backed by over 15 years of experience in handling urgent need, critical care pharmaceutical products. We are uniquely positioned to offer veterinary specialists the best of both animal drugs as well as human therapies for extralabel use to treat pets suffering from the same chronic, life-threatening conditions that affect humans. Our customers appreciate that we deliver the safety of a secure product distribution channel and a level of personal service that is unrivaled in the veterinary medical community,” said Angela Phillips, Director of Animal Health.

The US Bureau of Labor Statistics states that the number of veterinary jobs is expected to increase thirty-three percent (33%) by 2018 as a whole, and reports published by the AVMA indicate an average annual increase of eleven percent (11%) in the number of veterinarians seeking board-certification to specialize in the areas of internal medicine, anesthesiology, dermatology, and seventeen other recognized specialties.

“At BDI Pharma, it is our commitment to bring definable value and uncompromising service to our customers and trade partners that sets us apart from others,” stated Edward Stiefel, Jr., Co-President of BDI Pharma. “Our Animal Health Division is a testament to the capabilities and resources we are willing to dedicate to service the specific nature of a growing marketplace.”

About BDI Pharma, Inc.

Since 1995, BDI Pharma has defined its customer-centric approach to serving the nation’s healthcare community through innovative inventory supply solutions, unparalleled customer service, extensive product knowledge, 24/7 emergency availability and urgent need delivery. An open-access resource for reference material, educational literature, market data and online ordering, www.bdipharma.com has become an industry renowned point of reference. Proprietary programs for product consignment (www.consignadvantage.com), flu vaccine pre-booking (www.securiflu.com), vaccine ordering (www.securivax.com) and purchasing/reward programs (www.qoreprogram.com and www.securigam.com) round out a family of solutions tailored to the needs of the healthcare community at large.

BDI Pharma’s portfolio includes branded and generic specialty pharmaceuticals, chemotherapy products, vaccines, albumin, IVIG, coagulation factors, high-titer or “hyper” immune globulins, and other specialty injectables. BDI Pharma is recognized as an “ADR,” or Authorized Distributor of Record, for all of the manufacturers it represents.

DALLAS, TX–(Marketwire – October 11, 2010) –  JC Data Solutions (PINKSHEETS: JCDS), a provider of innovative and cost-effective solutions for digital office workflow and data management focusing on the Oil & Gas, Legal and Healthcare industries, has entered into an agreement to provide their Payment Manager™ services to Legacy Reserves, LP of Midland, TX.

The Payment Manager™ software, designed by JCDS especially for the Oil & Gas Industry, is part of a turnkey service that automates the distribution, delivery and archival of payments and documents to payees through ACH/EFT and posts documents to the web. The service also offers printing checks and/or statements, joint interest billing and other cost-effective data management functions.

Legacy, a public company traded on the NASDAQ under symbol LGCY, is an independent oil and natural gas limited partnership headquartered in Midland, Texas, specializes in Oil & Natural Gas Operations in the Permian Basin and Mid-Continent Regions focusing on the acquisition and development of oil and natural gas properties.

Cary Allen, CEO of JCDS, said, “Legacy Reserves is growing and recognized the need to streamline some of their processes. Payment Manger™ provides several key operational advantages as well as significant reduction of paper and manpower associated with their distribution process.”

Forward-Looking Statements

This press release contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are “forward-looking statements” are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties or other factors which may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as: the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels.

All information in this release is as of the date of this release.

MONMOUTH JUNCTION, NJ–(Marketwire – October 11, 2010) –  CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, was chosen to present at the AdvaMed 2010 MedTech Conference at the Walter E. Washington Convention Center in Washington, D.C. next week. Dr. Phillip Chan, Chief Executive Officer, will speak Wednesday, October 20, 2010 at 10:10AM EDT in Room 204a.

http://www.advamed2010.com/go.cfm?do=Page.View&pid=80

Following the meeting, the presentation will be made available on the company’s investor relations website: http://www.cytosorbents.com/invest.htm

About AdvaMed 2010

AdvaMed 2010 is the premier MedTech conference for business leaders, entrepreneurs, policy-makers, media, financiers, and other industry stakeholders from around the world. In only its third year, AdvaMed 2009 attracted 1,400 industry leaders — including 500+ CEOs, Presidents and C-level executives. For more information, visit www.AdvaMed2010.com.

About CytoSorbents and CytoSorb™

CytoSorbents Corporation, and its operating subsidiary CytoSorbents, Inc., is a critical care focused therapeutic device company in clinical trials to treat severe sepsis, often called “overwhelming infection,” with a novel blood purification device called CytoSorb™. Severe sepsis afflicts more than 1 million people in the United States and an estimated 18 million people worldwide each year, killing one in every three patients despite the best treatment. In the United States, more die from severe sepsis than from either heart attacks, strokes or any single form of cancer. Severe sepsis is typically triggered by bacterial infections like pneumonia, or viral infections like influenza. However, it is the body’s abnormal immune response to the trigger that leads to severe inflammation and the unregulated, massive production of cytokines, often called “cytokine storm,” that then causes multi-organ failure and often death. CytoSorb™ is a cartridge containing highly porous polymer beads that are designed to filter cytokines and treat potentially fatal cytokine storm. As blood is pumped repeatedly through the CytoSorb™ cartridge using standard dialysis equipment, the beads bind and remove cytokines and other toxins from blood. The treated blood is then returned to the patient. The Company is currently conducting its European Sepsis Trial — a multi-center, randomized, controlled clinical trial using CytoSorb™ to treat up to 100 patients with severe sepsis in the setting of respiratory failure. Pending a successful trial, the Company will seek CE Mark approval and commercialization of CytoSorb™ in the European Union. Importantly, cytokine reduction via CytoSorb™ has broad applicability to a number of other critical care diseases where cytokine storm plays a detrimental role, including burn and smoke inhalation injury, trauma, acute respiratory distress syndrome, advanced influenza, acute pancreatitis and other. CytoSorb™ is one of a number of different resins designed for various medical applications, including improved dialysis, the potential treatment of inflammatory and autoimmune disorders, rhabdomyolysis in trauma, removal of chemotherapy during treatment of cancer with high dose regional chemotherapy, drug detoxification and others. Additional information is available for download on the Company’s website: www.cytosorbents.com

Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management’s current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. CytoSorbents Corporation and CytoSorbents, Inc believe that its primary risk factors include, but are not limited to: obtaining government approvals including required FDA and CE Mark approvals; ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company’s medical devices in the marketplace; the outcome of pending and potential litigation; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company’s products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company’s Form 10-K filed with the SEC on April 9, 2010, which is available at http://www.sec.gov.

LOS ANGELES, CA–(Marketwire – October 8, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF) (the “Company”) today announced that David A. Boyden, a member of MMRGlobal’s Board of Directors (the “Board”) since January 2009, has notified the Company of his intent to resign from the Board, effective today. There were no disagreements between the Company and Mr. Boyden which led to his decision to resign.

“Dave joined the Board at the request of the pre-merger Faville, Inc. Board of Directors and has contributed to the Company’s efforts in the exploitation of its biotech assets. He is not resigning due to disagreements with the Company or its officers over operations, policies or practices,” said Robert H. Lorsch, MMRGlobal Chairman and CEO. “We appreciate Dave’s many contributions to the Company since the merger and I will miss his involvement. The Company plans on a search for a replacement director with expertise in biotech, insurance or banking.”

About MMRGlobal, Inc.

MMR Global, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMR Global, Inc. and its products, visit www.mmrglobal.com.

Forward-Looking Statements

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements, and some can be identified by the use of words (and their derivations) such as “need,” “possibility,” “offer,” “development,” “if,” “negotiate,” “when,” “begun,” “believe,” “achieve,” “will,” “estimate,” “expect,” “maintain,” “plan,” and “continue.” MMRGlobal, Inc. disclaims any intent or obligation to revise or update any forward-looking statements. These forward-looking statements are based on MMRGlobal, Inc.’s reasonable expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. The information discussed in this release is subject to various risks and uncertainties related to changes in MMRGlobal, Inc.’s business prospects, results of operations or financial condition, government regulation, and such other risks and uncertainties as detailed from time to time in MMRGlobal, Inc.’s public filings with the U.S. Securities and Exchange Commission.

DENVER, CO and PHOENIX, AZ–(Marketwire – October 8, 2010) –  The Amergence Group (PINKSHEETS: AMNG), a company that focuses on developing, nurturing, and rapidly expanding selected emerging or “disruptive” companies across a wide range of industries and disciplines, announced today that it has completed the successful acquisition of Altitude Organic Licensing Corporation (AO) which is headquartered in Denver, Colorado. Terms for the acquisition will be disclosed in a subsequent release.

The company currently has 5 stores using its Altitude Organic™ Trademark who pay an annual license fee of $15,000 per year. Banding together for strength, the Altitude Organic licensee-dispensaries receive joint-marketing benefits, limited free marketing from corporate, purchasing power on all approved partner products and services, national brand recognition, lobbying efforts, medical marijuana consulting, commercial real estate placement and attorney advisory in addition to booth space at the annual convention.

AO’s prez, Brian Cook, said, “Thanks to the Amergence Group we will now be able to offer a stock compensation plan for all our store owners. I believe this will be a tremendous incentive for prospective dispensary licensees. In addition, our ownership of the National Medical Marijuana Association (NMMA) will put Altitude Organic in ‘pole position’ to provide the best services to our licensees and their customers and enable Altitude Organic to capitalize on this exploding trend. Through this growth process, we must always remain vigilant to defend our high quality standards, developing protocols, and compassionate customer service for our patients.”

Amergence managing director Peter Jacobs stated, “Our acquisition of Altitude Organic Licensing Corp. at this time makes perfect sense for Amergence shareholders. I have been seeing this ‘marijuana legalization wave’ building since 1970 and I sense it is getting ready to crest. The Company’s timing for this acquisition couldn’t be better.”

Altitude Organic Medicine medical marijuana centers are currently located in Denver, CO, Colorado Springs, CO, and San Diego, CA.

The National Medical Marijuana Association (NMMA) commercial can be viewed here: http://www.youtube.com/watch?v=hXQMsPlKJcc

To learn more about the National Medical Marijuana Association visit them here: http://nationalmedicalmarijuanaassociation.org/ 

ABOUT THE AMERGENCE GROUP
The Amergence Group’s (PINKSHEETS: AMNG) provides valuable advice and support to new businesses with its goal of accelerating their intended plans to introduce edgy, disruptive, and/or innovative technologies to the world market. The Company’s 8-year-old Tranzbyte division continues to focus on the development and marketing of its innovative group of optical media enhancement technologies worldwide such as FLASHAlbum, a technology which enables distributors of optic disc media (CDs and DVDs) to combine the best features of both on one USB flash drive.

ABOUT ALTITUDE ORGANIC LICENSING CORPORATION
Altitude Organic Licensing Corporation was founded in Denver during the medical marijuana industry “fever” of early 2010. AO Licensing Corp. generates revenue in the fastest growing industry in the United States without carrying the liability of growing and selling marijuana. The company generates revenue by licensing its “Altitude Organic^™” Federal Trademark to dispensaries. The company also offers medical cannabis advocacy and consulting services to its licensed dispensaries. The corporate website can be found at: www.AltitudeOrganicMedicine.com.

NOTES ABOUT FORWARD-LOOKING STATEMENTS

Except for any historical information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, including those described in the Company’s Securities and Exchange Commission reports and filings. Certain statements contained in this release that are not historical facts constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, and are intended to be covered by the safe harbors created by that Act. Reliance should not be placed on forward-looking statements because they involve unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from those expressed or implied. Forward-looking statements may be identified by words such as estimates, anticipates, projects, plans, expects, intends, believes, should and similar expressions and by the context in which they are used. Such statements are based upon current expectations of the Company and speak only as of the date made. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which they are made.

FLEMINGTON, NJ–(Marketwire – October 8, 2010) –  Ken Glynn, President of SpeechSwitch, Inc. (PINKSHEETS: SSWC), reported today that another of the required SEC documents to bring the company current was submitted today for EDGAR review. The first quarter 2009 Form 10-Q has been completed and submitted to Marketwire for conversion and filing with the U.S. Securities Exchange Commission. This filing will be completed by Marketwire. Additional filings will be made over the next two weeks. The annual report for 2008 (end of year 10-K) will be submitted by the end of next week, as it is still under final attorney review; Second quarter 2009 Form 10Q will be filed within the next week. The company will continue to step up its effort to bring the company current as a pink sheet company as quickly as possible.

Information set forth in this press release contains various “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation reform Act of 1995 (the “Act”) provides certain “safe harbor” provisions for forward-looking statements. The reader is cautioned that such forward-looking statements are based on information available at the time and/or management’s good faith belief with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed statements. Forward-looking statements speak only as of the date the statement was made. We assume no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. Forward-looking statements are typically identified by the use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “should,” “will,” and similar words, although some forward-looking statements are expressed differently. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. 

SAN DIEGO, CA–(Marketwire – October 7, 2010) – Medistem Inc. (PINKSHEETS: MEDS) announced today it has entered into a commercialization agreement with the Indianapolis-based company, General Biotechnology LLC (http://www.gnrlbiotech.com), for sale of its universal donor Endometrial Regenerative Cells (ERC) as a research reagent to qualified academic and corporate institutions. Under the agreement General Biotechnology will harvest menstrual blood from qualified donors, isolate research-grade ERC stem cells, expand and qualify said stem cells and provide a distribution mechanism through its sales network.

“Medistem is a unique company in the area of cellular therapeutics in that its universal donor stem cells have already been used to treat humans,” said Dr. Erik Woods, President and CEO of General Biotechnology LLC. “By making these cells commercially available, scientists around the world will have the ability to compare these cells to existing adult stem cells such as placental, cord blood, and adipose mesenchymal stem cells.”

To date Medistem has reported the use of ERC in treatment of patients with Multiple Sclerosis http://www.translational-medicine.com/content/pdf/1479-5876-7-15.pdf, Duchenne Muscular Dystrophy http://www.ncbi.nlm.nih.gov/pubmed/19917503, and Heart Failure http://www.intarchmed.com/content/pdf/1755-7682-3-5.pdf.

“Since we originally reported the discovery of Endometrial Regenerative Cells in 2007, at least 4 independent groups have used and published on cells with identical or near-identical properties to treat animals with diabetes, Parkinson’s, stroke, and heart failure,” said Dr. Vladimir Bogin, Chairman and President of Medistem. “Given our intellectual property position on these cells, we are confident that by increasing their use in the scientific community we will accelerate our own development efforts, as well as advance the field forward.”

Dr. Michael Murphy, a Harvard-trained vascular surgeon who performs clinical trials using adult stem cells at Indiana University, stated, “The ERC stem cell population represents a treatment for vascular diseases that is novel, highly potent, and easy to integrate into the current standard of care. I am eager to initiate clinical investigations with these cells in treatment of critical limb ischemia.”

Dr. Murphy is the Principle Investigator for an IND filed with the FDA for treatment of critical limb ischemia with Medistem’s ERC stem cells.

About Medistem Inc.

Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company’s lead product, the endometrial regenerative cell (ERC), is a “universal donor” stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

id=”nav_links”>

EVERETT, WA–(Marketwire – October 7, 2010) –  Fluke Corporation, the global leader in portable electronic test and measurement technology, will send a lucky professional and companion to Arlington, Texas for football’s “Big Game,” simply for learning about the innovative new tools Fluke has recently introduced.

The winner of the Fluke football BIG GAME SWEEPS will receive two tickets to attend the biggest bowl game in football come February 6, 2011. The sweepstakes package includes airfare, three nights of lodging, and a complimentary rental car. The winner will be selected by random drawing and announced the first week of January 2011.

The Fluke football BIG GAME SWEEPS marks the start of an exciting season for Fluke customers. Fluke has just announced a new family of innovative, high-performance clamp meters. Other recent introductions include the groundbreaking Fluke 233 Remote Display Multimeter, the first of its kind in the industry; the Fluke 28 II Industrial Multimeter for ultra rugged conditions; and the Fluke Ti32 Thermal Imager with a powerful 320 x 240 sensor. 

To enter the Fluke football BIG GAME SWEEPS, customers simply choose a featured product online at www.fluke.com/footballsweeps, read a short description and then complete a registration form for a chance to win. Contestants are limited to one entry per person. No purchase is required.

Participation in the Fluke football BIG GAME SWEEPS is limited to licensed contractors or individuals in a professional trade who are residents of the U.S. and age 21 or older.

Sweepstakes ends December 31, 2010. See official rules at www.Fluke.com/footballsweeps.

For More Information

Fluke test instruments are distributed in more than 100 countries. For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail [email protected] or visit the Fluke Web site at http://www.fluke.com.

Follow Fluke on Facebook, Twitter, YouTube or Linkedin.

About Fluke

Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools. Fluke tools deliver the testing and troubleshooting capabilities that are critical to keep commerce and industry running smoothly. Fluke customers are technicians, engineers, electricians, metrologists and building diagnostic professionals who install, troubleshoot and manage industrial, electrical and electronic equipment and calibration processes for quality control and building restoration. In the past five years, Fluke tools won more than 50 industry awards, including Test and Measurement World Best in Test, Control Engineering Engineer’s Choice, and Plant Engineering Product of the Year. Fluke is a registered trademark of Fluke Corporation in the United States and/or other countries. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.

EVERETT, WA–(Marketwire – October 7, 2010) – Fluke Corporation, the global leader in portable electronic test and measurement technology, has introduced new iFlex^™ flexible current probes, designed to make current measurement easier, more convenient and more precise for electricians and industrial technicians.

The new Fluke iFlex flexible current probes expand the measurement range of select Fluke meters to 2500 A ac and give technicians the ultimate in measurement flexibility. The large coil allows users to reach around large or awkward-shaped conductors up to 6 inches in diameter, while the small 0.3-inch profile allows the coil to reach between tightly-packed cables and improves access in crowded spaces. A 6-foot cord makes it easier to see readings at a distance from the conductor.

The iFlex probes connect directly to the meter, displaying current measurements without error-prone scaling factors. In addition to ac current measurement, they also work with frequency, inrush, and min/max/avg functions. The iFlex current probes are available in 10-inch and 18-inch sizes.

The iFlex current probe i2500-18 is included with the new Fluke 381 and Fluke 376 Clamp Meters. Both iFlex models — the i2500-18 and the i2500-10 — are compatible with Fluke 374 and Fluke 375 Clamp Meters. US list price for each iFlex probe model is $98.95.

The iFlex current probes are members of a new family of Fluke clamp meters designed to meet users’ requirements for flexibility, safety and performance in the most challenging industrial conditions. This new Fluke family of clamp meters includes:

Fluke 381 Remote Display True-rms AC/DC Clamp Meter with iFlex — The Fluke 381 is a full-featured clamp meter with an important extra: Users can remove the detachable wireless display for even more flexibility, convenience and safety. Now one technician can do jobs that used to require two. US list price is $498.95.

Fluke 376 True-rms AC/DC Clamp Meter with iFlex — With the new Fluke 376 Clamp Meter, users will be ready for any measurement challenge. Designed for the toughest industrial environments, it measures current up to 2500 A ac and 1000 A dc and can troubleshoot even the noisiest motors and drives. US list price is $374.95.

Fluke 374 and 375 True-rms AC/DC Clamp Meters — The new Fluke 374 and 375 clamp meters offer improved performance, perfect for many current measurement situations. With true-rms ac voltage and current measurements, the Fluke 374 and 375 can read up to 600 V and 600 A in both ac and dc modes and handle min/max, average and inrush recording. Both are compatible with the new iFlex flexible current probe (sold separately). US list price for the Fluke 375 is $299.95, for the Fluke 374, $259.95.

Fluke 373 True-rms AC Clamp Meter — The new Fluke 373 clamp meter offers improved performance and maximum value for users requiring ac only current measurement. US list price is $179.95.

The Fluke 381, 376, 375, 374 and iFlex current probes are rated for safe use in hazard category IV (CAT IV) 600V environments (CAT IV 600V, CAT III 1000 V) as defined by safety regulators in the US, Canada and Europe. The Fluke 373 is rated CAT IV 300V, CAT III 600V. Category IV environments include overhead power lines, underground power lines and service entrance power, as well as all outdoor environments.

For More Information

Fluke test instruments are distributed in more than 100 countries. For more information on the entire new Fluke clamp line, go to www.fluke.com/ReadyForAnything. For more information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail [email protected] or visit the Fluke Web site at http://www.fluke.com.

Follow Fluke on Facebook, Twitter, YouTube or Linkedin.

About Fluke

Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools. Fluke tools deliver the testing and troubleshooting capabilities that are critical to keep commerce and industry running smoothly. Fluke customers are technicians, engineers, electricians, metrologists and building diagnostic professionals who install, troubleshoot and manage industrial, electrical and electronic equipment and calibration processes for quality control and building restoration. In the past five years, Fluke tools won more than 50 industry awards, including Test and Measurement World Best in Test, Control Engineering Engineer’s Choice and Plant Engineering Product of the Year. Fluke is a registered trademark of Fluke Corporation in the United States and/or other countries. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.

CHARLOTTE, NC–(Marketwire – October 6, 2010) – Patient Care Technology Systems (PCTS), a subsidiary of Consulier Engineering, Inc. (NASDAQ: CSLR) today announced they have signed a record number of contracts for the year and that 100% of their existing tracking customers have renewed their agreements for ongoing solutions and services.

“There is no stronger endorsement of our company and solutions than the dramatic increase in new contract signings and the continual renewal, and expansion of customer agreements. Every year, our customers almost unanimously renew their agreements. They expand their implementations while finding greater value in our breadth of solutions,” said Tony Marsico, PCTS president and CEO.

Renewals are executed when customers want to extend their agreement with PCTS to provide additional products, maintenance and/or support. So, the 100% renewal rate means that every customer who was with PCTS in January of 2010 will continue their agreements in 2011.

“The renewal of these agreements is extremely important as they not only provide a viable, ongoing stream of revenue that supports enhanced research and development, but also because they provide validation that the company as a whole is approaching the market with the right innovative solutions that are clearly in demand. The benefits of these solutions more than justify the investment the health care organizations are making in PCTS. The financial and performance advantages we offer our clients are what’s driving the accelerating growth we are seeing,” says Warren Mosler, CEO of Consulier Engineering, the primary shareholder of PCTS.

“What is equally exciting, is that almost every customer doesn’t just renew their existing agreement, but actually comes back to us for additional work each year,” states Jaime Ojeda, PCTS vice president of sales and business development. Ojeda says, “In 2010 alone, we will have about 70% of our existing tracking customers expand their PCTS installations. This, combined with the record number of sales we have made to new customers, is what is driving our continued growth and validates PCTS as the ‘go to’ provider of healthcare real time locating and workflow automation systems. PCTS has been supporting the healthcare industry since 1997 and our exceptional growth will allow us to expand our offerings.”

To facilitate and manage this growth, so far in 2010, PCTS has increased employment by almost 20% and is estimating almost double that in 2011.

“That we have been able to increase revenues as much as we have with only a 20% increase in staff is also very encouraging,” says Tony Marsico. “The work we have done to deliver our solutions in as efficient a way as possible is allowing us to enjoy the tremendous growth without excessive increases in overhead or any need to increase prices.”

In February of this year, the company announced the opening of a subsidiary based outside of London that will service the UK and European Union. Patient Care Technology Systems, Ltd. is holding two seminars the week of October 11 that will present innovative techniques for improving accident and emergency department (A&E) productivity, streamlining workflow, and improving overall operational efficiency and quality of practice.

Tony Marsico adds, “Since becoming CEO in April 2005, my emphasis, and hence our company’s emphasis, has been ensuring that our customers realize the complete value of our solutions. This includes much more than just customer service. We are automating hospital workflow through visibility, communication and real-time tracking of interactions between entities, patients and staff. This has successfully allowed our customers to consistently enhance revenue and contain costs, resulting in solid, bottom-line returns on their investment. Our renewal rate shows that they are getting that ROI and our focus is paying off.”

About Patient Care Technology Systems

Patient Care Technology Systems, a subsidiary of Consulier Engineering, Inc. (NASDAQ: CSLR), helps health care providers to improve patient flow, increase capacity and improve patient and staff safety by visualizing the real time location and status of people and equipment throughout their facility. PCTS solutions have supported over 2 million patient visits annually and have shown a proven return on investment in high turnover, high-acuity units such as the emergency department and perioperative suites. The Amelior Enterprise Visibility and Workflow Automation Suite™ is interoperable with all leading locating technologies, including active-RFID, infrared, ultrasound, ultra-wideband, Wi-Fi and ZigBee. PCTS customers have been recognized nationally for improvements in efficiency and clinical excellence. For more information, visit www.pcts.com and connect to PCTS on Facebook and Twitter.

This press release contains forward-looking statements within the meaning of federal securities laws. PCTS and CSLR caution you that any statements contained in this press release which are not strictly historical statements constitute forward-looking statements. Such forward-looking statements include, but are not limited to, those related to PCTS’s and CSLR’s expectations regarding continued business growth. These statements are neither promises nor guarantees, and involve risks and uncertainties that could cause actual results to differ materially from such forward-looking statements, (copies of which may be obtained at the SEC’s website at: http://www.sec.gov) — could impact the forward-looking statements contained in this press release. Readers should not place undue reliance on any such forward-looking statements, which speak only as of the date they are made. PCTS and CSLR disclaim any obligation to publicly update or revise any such statements to reflect any change in PCTS and CSLR’s expectations, or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Click here to see all recent news from this company

VICTORIA, BRITISH COLUMBIA–(Marketwire – Oct. 6, 2010) – Vigil Health Solutions Inc. (“Vigil”) (TSX VENTURE:VGL) is pleased to announce its selection as one of the fastest-growing companies in B.C. by Business In Vancouver newspaper. Vigil, and other award recipients, were honoured at the Top 100 Fastest Growing Companies reception held last night in Vancouver. Vigil was ranked 40th among 100 of the fastest growing companies in B.C. based on revenue growth for the five-year period between fiscal 2005 and 2009.

About Vigil Health Solutions Inc.

Vigil offers a proprietary technology platform combining software and hardware to provide comprehensive solutions to the expanding seniors’ housing market. Vigil has established a growing presence in North America and an international reputation for being on the leading edge of systems design and integration. The Vigil Integrated Care Management System™ (Vigil® System) includes the award-winning Vigil Dementia System, a nurse call system, bed monitoring, resident check in, and the latest development the Vigil Wireless call system. The first to supply dementia specific care technology, Vigil facilitates the highest standard of care for cognitive residents while helping dementia residents enjoy a higher quality of life and greater dignity.

PHILADELPHIA, PA–(Marketwire – October 6, 2010) –  There is much focus on patient recruitment, specifically finding patients willing to participate in clinical trials. However, the second phase of recruitment is often overlooked: pulling prospective patients through the referral pipeline and into the study center. This phase occurs after patients pass a pre-screener that matches them to the study’s criteria. It is during this phase that pre-screened patients wait for site follow-up that often does not occur.

To streamline the recruitment ‘pull-through’ process and increase recruitment success, MediciGlobal introduces the Study Resource Center™ and welcomes Pat Patterson, RN, CCRC as its Director. Pat is a certified clinical research nurse with nearly 20 years of clinical research experience at academic, hospital and community based research settings. Pat has seen first-hand the need for a central resource providing sites with services that save time on processing patient referrals.

MediciGlobal established the Study Resource Center in response to growing numbers of requests from study coordinators and site marketing managers to directly provide services that support finding patients, pulling those patients most likely to randomize through the referral pipeline, and retaining patients long term.

The Study Resource Center is a place for sites to go when they need recruitment-retention support. Pat contends that study coordinators like to know they are dealing with someone who understands their issues. MediciGlobal has supported sites indirectly through study sponsors, but now these services can be accessed directly by sites, and include:

1. Education: building effective recruitment-retention programs
2. Efficient pre-screening
3. Logistical support: appointment scheduling, patient follow up
4. Problem solving: innovative recruitment approaches. 
5. Advertising and eMarketing support
6. Retention: during and post active treatment
7. Lost-to-follow up: Find missing patients

The Study Resource Center integrates MediciGlobal’s Site Support team with the services of its in-house patient contact center, ProtoCall^®. Centralizing these functions enhances the coordination of critical recruitment-retention support services to study sites.

Ms. Patterson was one of the first to undergo the Association of Clinical Research Professionals’ (ACRP’s) qualification process for a certified clinical research coordinator (CCRC). Recognized as a consistent performer for studies conducted for major biopharmaceutical sponsors, Pat served on numerous national and international study advisory boards.

About MediciGlobal
MediciGlobal based in the U.S. and U.K., is a specialty patient recruitment — retention company, developing programs for clinical trials of all sizes in countries around the globe. www.mediciglobal.com

DUBAI, UNITED ARAB EMIRATES–(Marketwire – Oct. 6, 2010) – The recent re-launch of a global networking web-site has attracted thousands of healthcare industry affiliated professionals keen to share information on-line. The website, www.GlobalHealthcareNetwork.com was revamped last month to help facilitate (showcase/broadcast) research, provide business & networking opportunities and act as an easily accessible forum for healthcare issues and challenges (around the world to be discussed) The site is also proving popular as an informal tool that allows members to socialise with their healthcare peers in other countries.

“This is the age of social networking and a great deal of information is now being traded (exchanged) on-line using this method,” said Dr. Prem Jagyasi, renowned global healthcare consultant and founder of the Global Healthcare Network. “There are many general purpose social networking sites with millions of users, but we were encouraged by healthcare professionals across the world to create a site designed especially with the sector in mind,” he added.

The www.GlobalHealthcareNetwork.com is unique in that it has customised settings so that healthcare professionals can participate in specific activities. Healthcare professionals using the site can join various special interest groups in the sector; such as Healthcare Management, Healthcare Marketing, Healthcare Insurance, Pharmaceutical, Medical Equipment, Healthcare Finance, Healthcare Journalist and, Medical Tourism (Health Tourism / Healthcare Travel / Medical Travel), amongst others.

The site also aggregates the latest news from around the world to provide easy access of vital healthcare information at one place, as well as offering all the standard networking benefits that include connections, blogging, forum discussions, media uploads and event updates. The network is integrated with Facebook and Twitter so members can post to other networking sites from Global Healthcare Network. The Global Healthcare Network also has group/fan pages on LinkedIn, Facebook and Twitter, with more than 1750 members actively communicating.

Dr. Jagyasi believes that the advantage of the Global Healthcare Network is that it allows for health professionals to share information easily, which in turn breaks down barriers and improves cooperation between healthcare providers. “Even the small links that are established through purely social interaction can develop into bigger links over time, as channels of communication become progressively embedded,” he said. “We can see from the buzz and chatter happening on the site that connections are being made that should lead to the forging of relationships that can only benefit healthcare in the future. I believe that this site will act as an important adjunct to the continued growth of the sector worldwide,” he added. 

The site provides us with updated information about all upcoming healthcare events worldwide at one place.

Dr Prem Jagyasi, recently presented the topic ‘ Social Media Marketing’ at the World Medical Tourism and Global Healthcare Association 2010 in Los Angeles, USA. The presentation provided a prescriptive roadmap for Online Media and Social Media Success while discussing best practices and answering the biggest questions faced by health care marketers in the field of Social Media Marketing. His presentation is also available to view on www.slideshare.net/jagprem or www.GlobalHealthcareNetwork.com or www.DrPrem.com.

Anyone, health professional or otherwise, can access the Global Healthcare Network by logging on to http://www.globalhealthcarenetwork.com and creating a user account. They will then be able to connect to health workers from around the world.

Below are quick links:

Global Healthcare Network Site: www.GlobalHealthcareNetwork.com

Members: http://www.globalhealthcarenetwork.com/profiles/members/

Notes & News http://www.globalhealthcarenetwork.com/notes/index/allNotes

Forums http://www.globalhealthcarenetwork.com/forum

Blogs http://www.globalhealthcarenetwork.com/profiles/blog/list

Facebook Page http://www.facebook.com/pages/Global-Healthcare-Medical-Tourism-Health-Tourism/105868006128124

LinkedIn http://www.linkedin.com/groups?mostPopular=&gid=2997546

Twitter http://twitter.com/Globalhcn

About Global Healthcare Network

Global Healthcare Network is a unique social networking platform for Healthcare Professionals. Join the group now to Network, share & learn. There is a total of 1750+ Network members across all Global Healthcare Networking sites/pages including facebook & linkedin.

The network allows you to create blog, start discussion, join various healthcare groups, promote your services.

About Dr Prem Jagyasi

A successful entrepreneur and experienced strategic professional, Dr Prem Jagyasi is a renowned Chartered Management, Healthcare Marketing and Medical Tourism Consultant. Providing high-profile consultancy services to Government authorities and private healthcare organizations, Dr. Prem Jagyasi is a noticeably leading Global Healthcare and medical tourism consultant in the world.

Apart from running a successful healthcare solution firm and consultancy business, he has initiated several innovative healthcare awareness projects such as Family Health Festival, No Tobacco Campaign, Summer Health Festival, Ahlan Ramadan and Diabetes Events. His initiatives are endorsed and recognized by the country’s ministry of health and other government authorities. On a global front, he is also working on Medical Tourism Guide, Educational Events, Global Health Directory, and workshops on quality practice for international patients. etc.

Currently, Dr Prem Jagyasi is MD & CEO of ExHealth, a Dubai HealthCare City based firm engaged in offering multi-dimensional healthcare solutions in international domain. He also serves the Medical Tourism Association (also known as Global Healthcare Association) —a Non Profit organization based in USA as Honorary Chief Strategy Officer. He is also the Chief Editor of UAE’s leading health magazine – HealthFirst, published in association with one of the leading English dailies of the region.

LOS ANGELES, CA–(Marketwire – October 6, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF) (MMR) announced today that its MMR Stimulus Program will be expanded to include the MMRPro Insurance Advance Program. This program is an expansion of the existing MMRPro Stimulus Program launched in the first quarter of 2010 which rewards MMRPro users when their patients upgrade to the MyMedicalRecords Personal Health Record. 

The Insurance Advance Program is designed to help MMRPro healthcare professionals smooth out cash flow during their transition to achieving meaningful use. MMRPro users will be paid advances on the uncollected commercial third-party amounts they billed each preceding week to the extent permitted by federal and state laws and regulations. They must use an MMRGlobal approved Stage 1-Certified Meaningful Use practice management and billing system to be eligible to receive payments under the MMRPro Stimulus Insurance Advance Program. The program will be part of the Company’s previously announced plans to offer one or more EMR products, which could include applications for iPad and PC-based platforms in addition to its MMRPro and MyMedicalRecords Personal Health Record products. 

“We recognize that converting an existing billing system to one that enables the practice to achieve meaningful use could affect a practice’s cash flow, which could also affect the lifeblood of the practice,” said Robert H. Lorsch, Chairman and CEO of MMRGlobal. “One of the largest problems doctors and hospitals face today is reimbursement for their services. Our goal is to assist doctors, hospitals and medical groups in maintaining control of their finances while transitioning to meaningful use at the same time healthcare reform is being implemented.”

Additionally, MMRPro users and their patients continue to receive protection under MMRGlobal’s million dollar Cyber Liability Insurance Policy, which, among other things, protects healthcare professionals using MMRPro defend themselves in the event of a violation of the expanded HIPAA regulations under the Health Information Technology for Economic and Clinical Health Act (HITECH). 

The underlying Cyber Liability policy is underwritten by an A-rated insurance company by A.M. Best to cover damages arising from the use and deployment of the Company’s personal and professional health record products and services. The coverage extends to MMRGlobal’s corporate clients that offer MMR’s products and services as an employee benefit and to individuals who sign up to receive MMR’s services over the Internet.

About MMRGlobal, Inc.

MMR Global, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMR Global, Inc. and its products, visit www.mmrglobal.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as “need,” “possibility,” “offer,” “development,” “if,” “negotiate,” “when,” “begun,” “believe,” “achieve,” “help,” “will,” “estimate,” “expect,” “maintain,” “plan,” and “continue,” or the negative of these words. Factors that could cause or contribute to such differences include, but are not limited to, the risk the Company’s products and programs are not adopted or viewed favorably by the healthcare community; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; variations in our quarterly operating results; timing and volume of sales and installations; length of sales cycles and the installation process; market acceptance of new product and program introductions; ability to establish and maintain strategic relationships; ability to identify and integrate acquisitions; relationships with licensees; competitive product offerings and promotions; changes in government laws and regulations and future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; acceptance of the Company’s marketing and promotional campaigns; risks related to a security breach by third parties; maintaining, developing and defending our intellectual property rights including those pertaining to our biotechnology assets; risks associated with recruitment and retention of key personnel; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company’s filings with the Securities and Exchange Commission. Additionally, we are a developing early-stage company and many variables can affect revenues and/or projections, including factors out of our control. The Company is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Click here to see all recent news from this company

BOCA RATON, FL–(Marketwire – October 6, 2010) – David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Vicor has selected Dell’s Healthcare and Life Sciences division to serve as its worldwide hardware partner for the Company’s PD2i Analyzer™ and PD2i CA™ (Cardiac Analyzer). According to the terms of the agreement, Dell will create Vicor-labeled laptop computers specifically customized to Vicor’s specifications and package them for Vicor’s worldwide distribution. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i^® nonlinear algorithm and software. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i^® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events, including congestive heart failure patients for cardiac death resulting from arrhythmia or pump failure, diabetics for diabetic autonomic neuropathy (DAN), and trauma victims for imminent death absent immediate lifesaving intervention.

“Dell Healthcare and Life Sciences is proud to be chosen as Vicor’s worldwide IT solutions provider. Dell is committed to developing and supporting healthcare IT solutions to improve care and delivery,” stated Scott Jenkins, PhD, Vice President, Dell, Inc.

 “We’re thrilled to have Dell as our worldwide IT solutions partner. Dell’s well-established reputation for creating innovative technologies and business solutions, strong internal development capabilities, global reach, and consumer-centric approach make it the perfect worldwide IT solutions partner for Vicor,” stated Mr. Fater. 

“Given the growing amount of positive feedback we’re receiving from physicians and cardiologists using the PD2i Analyzer™ to enhance diagnosis of those at risk of cardiac death from arrhythmia or pump failure, as well as autonomic neuropathy, we’re extremely optimistic about the prospects for the PD2i Analyzer™ and PD2i CA™ worldwide. These diagnostics have enabled the physicians and cardiologists using them to use existing CPT codes for reimbursement, strengthened their ability to diagnose difficult to identify conditions, and enabled early, sometimes life-saving treatment,” Mr. Fater concluded.

About Vicor Technologies, Inc.
Vicor Technologies is focused on commercializing innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i^®). The PD2i^® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability. Physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in various clinical trials, identifies patients at elevated risk of cardiac death resulting from arrhythmia or pump failure.

Vicor anticipates developing additional applications utilizing the PD2i^® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer
The appearance in this release of name-brand institutions, such as Dell and the U.S. Army Institute for Surgical Research, does not constitute endorsement by these institutions of the information, products, or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a marketing claim for the PD2i CA™(Cardiac Analyzer) for testing patients for cardiovascular disease and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to obtain the necessary regulatory approvals to market in the People’s Republic of China; our ability to develop additional applications for the PD2i^®algorithm; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to successfully complete the normal range study for PD2i^®values; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 10-18

Click here to see all recent news from this company

KANKAKEE, IL–(Marketwire – October 5, 2010) – Riverside Medical Center has now joined the Illinois Hospital Association’s (IHA) “Raising the Bar” initiative to continue improving the level of quality of South Chicago Illinois healthcare and patient safety. Two hundred hospitals including Riverside are participating in the “Raising the Bar” initiative to make Illinois a national leader in healthcare. 

Riverside leaders pledged to share best practices through the IHA Quality Care Institute. The pledge includes implementing innovative methods to prevent and reduce infections and other complications leading to unnecessary hospital re-admissions. Riverside signed the Raising the Bar: A Call to Action pledge, proving this Kankakee County hospital is dedicated to patient safety and success.

Phil Kambic, President and CEO of Riverside, stated, “Our signature on the pledge is further evidence of Riverside’s everyday mission to provide remarkable, quality healthcare experience to every one of our patients and their families. Riverside is continually recognized as a leader in patient care and safety. And the standards we subscribe to make that possible.”

Over the next three years, Illinois hospitals will be “Raising the Bar” on current standards. Hospitals joining the pledge must reduce re-admissions and infections acquired in hospitals along with other complications. Riverside and other Illinois hospitals are “Raising the Bar” to develop and implement key programs to achieve these goals. 

The “Raising the Bar” initiative seeks to help hospitals improve quality in major areas such as lowering 30-day hospital readmission rates for pneumonia, heart attack and congestive heart failure and minimizing infections and conditions acquired in hospitals such as surgical-site infections, C. difficile, Methicillin-resistant Staphylococcus aureus (MRSA), catheter-associated urinary tract infections (CAUTI), central-line associated bloodstream infections and pulmonary embolism and deep vein thrombosis following select orthopedic procedures.

By working through IHA’s Quality Care Institute, Riverside has access to tools, best practices and essential data from across the state as well as from state and national experts. These facilities help the Southern Chicago suburbs hospital offer better quality and improve patient safety through developing practical approaches for improving patient care and active advocacy to coordinate care.

To find out more about how Riverside Medical Center is “Raising the Bar,” visit www.RiversideMC.net. To learn more about IHA and the Quality Care Institute, visit www.illinoishospitals.org.

Click here to see all recent news from this company

WASHINGTON, DC–(Marketwire – October 5, 2010) –  Did you know that birth defects occur in 7 out of every 10,000 live births in the U.S.? And Spina Bifida is the most common permanently disabling birth defect? In honor of October being Spina Bifida Awareness Month, the Spina Bifida Association is asking folks to take a few minutes today and get involved in the awareness month by educating loved ones.

The first question many have: What exactly is Spina Bifida? In short, Spina Bifida happens when the spinal column doesn’t close completely.

And how many births each day are affected? Well, it’s hard to believe, but eight births each day are affected by Spina Bifida or a similar birth defect of the brain and spine. If you think about it, there are currently over 65 million women in the U.S. who could become pregnant and each one of these ladies is at risk of having a baby born with Spina Bifida. So because Spina Bifida occurs during the first month of pregnancy (that’s even before most women know they’re pregnant!) it is that much more important to take proper precautions to help try to prevent it now. 

Okay. So what type of precautions can help in prevention, you may wonder?  
Although at this time there is no known cause of Spina Bifida, research has shown that if a woman takes 400 mcg of folic acid every day and before she becomes pregnant, she reduces her risk of having a baby with Spina Bifida or another neural tube defect by as much as 70%! That fact is reason enough to encourage women (and men) to get out there this month and spread awareness.

Families with a history of Spina Bifida should take extra dosages of folic acid prior to pregnancy. Hear one mom’s message: http://www.youtube.com/watch?v=qshRfegnGD4

And in honor of October’s Spina Bifida Awareness Month, SBA will also be launching some great new online resources, including:

1. SB University (SBU) (www.sbuniversity.org), a new online educational program featuring taped sessions from the 2010 National Conference as well as monthly live seminars conducted by Spina Bifida medical professionals from around the country. During Awareness Month, SBU will debut new sessions each Monday.

2. SBTween2Teen (www.sbtween2teen.org) a new Web site for tweens and teens with Spina Bifida. Complete with blogs, videos, real stories, fact sheets, and an Ask the Expert feature, the interactive site helps tweens and teens navigate the difficult road to adulthood. There is even a social networking component run through Facebook, allowing tweens and teens to interact with one another and build peer-to-peer relationships!

3. Preparations, a new transition-focused Web site launching in late October allowing parents, caregivers, and clinicians to answer specific questions with regard to a child’s developmental milestones. This tool can even help young adults remedy some transitional challenges.

For even more information, tips and resource, you may visit: www.spinabifidaassociation.org
And be sure to join the Spina Bifida Association on Facebook: www.facebook.com/spina.bifida.learn

The Spina Bifida Association (SBA) serves adults and children who live with the challenges of Spina Bifida. Since 1973, SBA has been the only national voluntary health agency solely dedicated to enhancing the lives of those with Spina Bifida and those whose lives are touched by this challenging birth defect. Its tools are education, advocacy, research, and service. Through its network of chapters, SBA has a presence in more than 125 communities nationwide and touches thousands of people each year. For more information visit: www.spinabifidaassociation.org.

id=”nav_links”>

MIAMI, FL–(Marketwire – October 5, 2010) –  CareCloud, a provider of on-demand software and services for the healthcare industry, today announced it has closed a $5 million round of investment capital. Investors include a cadre of prominent entrepreneurs and business leaders. The Company has raised in excess of $7.8 million to date.

“We are delighted with the outpouring of support from our investors. They share our passion and vision to revolutionize the healthcare experience with our digital ecosystem,” said CareCloud President and CEO, Albert Santalo. “This funding is validation of the tremendous progress the company has made since closing its first round in January of 2010. We are experiencing explosive growth since our product launch in March of 2010, and we plan to use this capital to invest in our software development and service infrastructure while fueling additional growth.”

CareCloud offers a suite of web-based apps that allow physicians to manage their business and also allows them and their patients to communicate and collaborate with each other in real time across multiple points of care via the company’s web-based digital ecosystem. By leveraging the power of cloud computing to deliver technology-enabled services to healthcare providers, CareCloud is creating an integrated environment where all participants share a common commitment to reducing inefficiency and providing excellence in care.

CareCloud received global attention recently for winning top honors at IBM’s SmartCamp competition, an exclusive mentoring program through which IBM seeks to identify and support innovative new technology companies. As the winner of the Silicon Valley SmartCamp event, CareCloud will be competing against other winners from around the globe for the title of “World’s Smartest Startup,” as well as for the attention of many of the world’s most prominent venture capitalists.

About CareCloud
CareCloud is a web-based software and services company that modernizes the workflow in a medical practice. Visit CareCloud online at www.carecloud.com, blog.carecloud.com, or www.twitter.com/carecloud.

Click here to see all recent news from this company

OXFORD, UK–(Marketwire – October 5, 2010) –

Mirada Medical Limited
(“Mirada” or “the Company”)

Mirada Medical Announces the Release of its Advanced XD3 PET-CT and Fusion Package on Sectra PACS

Oxford, UK and Pennsylvania, US, 5 October 2010: Mirada Medical Limited, the fast growing international company focused on advanced oncology imaging, announced today that its latest XD3 multi-modality image fusion analysis package is now available as an option to users of Sectra PACS. 

The latest version of Mirada XD3 is now available fully integrated into the Sectra workflow. This delivers greatly improved levels of productivity to radiologists and other users of medical imaging who want to access the most advanced tools and products from one workstation and without having to copy large quantities of image data from one location to another.

Using XD3,Sectra users can now be offered advanced quantification of PET, CT, MRI and SPECT including SUV measurements and access to standard disease response protocols such as RECIST for CT and PERCIST for PET and PETCT. The Mirada software supports comparison of two or more PET/CTs and also allows users to fuse MRI with PET, SPECT or CT. Mirada’s XD3 application also incorporates the latest versions of Mirada’s leading deformable image registration algorithms, which allow any combination of image modalities to be registered non-rigidly allowing for corrections to be made where patient positioning is inconsistent, or patient anatomy has changed over time.

Commenting on the new product release, Hugh Bettesworth, CEO of Mirada Medical, said: “It is central to Mirada’s philosophy that we make the advanced technologies available to the widest range of clinical users. By tightly integrating our XD3 application on Sectra PACS, users of this system can experience what we believe are the leading multi-modality workflows in the world, and do so in a way that can significantly boost productivity allowing more scans to be accurately analysed and reported.”

Commenting for Sectra, Per Elmhester, Product Manager Clinical Solutions said: “Sectra strives to constantly improve the offering to our customers. With this release our customers can now fully enjoy the benefits of the Mirada XD3-package.”

About Mirada Medical

Mirada Medical Limited develops internationally recognised medical imaging analysis applications that provide clinicians with advanced software applications for the quantification of images which are typically used in cancer diagnosis and treatment response assessment. Mirada Medical’s technology has broad applicability across nuclear medicine, diagnostic radiology, radiation oncology and medical oncology. Mirada Medical also markets products in neurology and cardiology. Mirada specialises in offering comprehensive and quantifiable analysis for the diagnosis, staging, treatment planning and assessment of treatment response in oncology. Mirada’s advanced technology allows medical images acquired using MRI, CT, SPECT or PET scanners to be combined into one, a process known as image fusion. Image fusion is useful in clinical interpretation as it allows different qualities of information to be combined into a single picture, for example, functional information such as metabolic activity, to be combined with anatomical information showing the precise location of pathology relative to bones and organs. This provides clinical users with a more complete picture, thereby improving the quality of information available when managing a patient’s condition. Mirada’s products are designed to support the comparison of multi-modal images acquired over any number of follow up visits by the patient, making them particularly well suited to the analysis of treatment response in longer term treatment plans such as those typical when treating cancer.

Mirada Medical was formed out of Oxford University by Professor Sir Michael Brady, one of the world’s leading medical imaging scientists. The Company is ISO 13485 certified and its technology has been supplied globally to customers in countries including the US, Japan, and Europe since 2001. Mirada’s products are sold by Mirada but also by major healthcare players such as McKesson, Siemens, Sectra, Carestream and Vital Images.

The Mirada team is a combination of world class scientists and exceptional engineers sourced from both Oxford University and leading blue-chip companies. For more information about Mirada Medical, please visit www.mirada-medical.com.

About XD3

Mirada’s XD3 multi-modality clinical reading application empowers radiologists and oncologists with the image analysis they need to diagnose disease and assess follow up to treatment. XD3 combines powerful registration technologies with serial review of acquisitions acquired over time. Key product features include disease specific oncology workflows and fast, accurate and reproducible image quantification, Mirada’s world class image registration engine powers multi-modal fusion and registration across time. XD3 facilitates advanced clinical decision support and may be deployed on PACS, workstation or laptop, providing the most flexible workflow integration available anywhere. Mirada Medical continues to develop superior products to suit the needs of clinicians for reviewing images in diagnosing, staging and evaluating disease progression and response to therapy. Mirada’s XD3 product provides comprehensive levels of analytical power to the clinical user. Featuring powerful disease specific oncology workflows and fast, accurate and reproducible image quantification, XD3 facilitates advanced clinical decision support. XD3 may be deployed on PACS, home workstation or laptop, providing the most productive workflow integration available anywhere.

About the Sectra Group

Sectra successfully develops and sells cutting-edge products in the expansive niche segments of medical systems and secure communication systems. The company was founded in 1978 and has its roots in Linköping University in Sweden. Today, Sectra has offices in twelve countries and operates through partners worldwide. Sales in the 2009/2010 fiscal year totaled SEK 848 million. The Sectra share is quoted on the NASDAQ OMX Stockholm AB exchange. For more information, visit www.sectra.com.

About Sectra’s medical operations

Sectra develops and sells IT-systems and products for radiology, mammography and orthopedics. More than 1,100 hospitals, clinics and imaging centers worldwide use the systems daily, together performing over 52 million radiology examinations annually. This makes Sectra one of the world-leading companies within systems for handling digital radiology images. In Scandinavia, Sectra is the market leader with more than 50% of all film-free installations. Sectra’s systems have been installed in North America, Scandinavia and most major countries in Europe and the Far East.

http://hugin.info/143183/R/1448965/391019.pdf

METHUEN, MA–(Marketwire – October 5, 2010) – A ribbon cutting event is occurring at Suntron Corporation’s new manufacturing facility. Join Ed Wheeler, CEO of Suntron; Lt. Governor Timothy P. Murray; Congresswomen Niki Tsongas; Mayor Manzi III and Jose Bevilacqua in the opening event at 1pm, facility tour to follow.

Date:         October 5, 2010        
                                     
Time:         1:00 p.m.              
                                     
Location:     Suntron Corporation    
              300 Griffin Brook Drive
              Methuen, MA 01844      

SAN FRANCISCO, CA–(Marketwire – October 4, 2010) –  Presidiohealth, which offers real-time, mobile computing performance management solutions for healthcare providers, announced today the launch of PerformCycle™, a new patient care management tool that provides an interactive, measurable action plan for pediatric asthma patients.

Presidio is launching the core service this month in the Pediatric Emergency Department at California Pacific Medical Center in San Francisco. Daily monitoring of the child’s status, triggers, and medication use seeks to provide better quality care, reduce emergency visits and hospitalizations, and lower overall healthcare and social costs. The PerformCycle platform combines evidence-based care guidelines, the Asthma Action Plan, and post-care patient tracking (CareTracker) solutions to offer home monitoring of a child’s post-care progress and share direct patient feedback with healthcare providers in the emergency department and the pediatrics office. For patients whose parents don’t have smartphones, the basic service delivers daily monitoring and reminders via two way communication with text message and e-mail. For iPhone users, CareTracker integrates the free AsthmaMD™ app.

“We are proud to be part of the first wave of healthcare innovation that brings the patient into the middle of the care cycle,” said Presidiohealth founder and president Douglas Evans. “As an ER physician, I know firsthand why delivering high quality care demands an interaction between provider best practices, enhanced patient education, and ongoing patient engagement. By combining our PerformCycle solutions with the exploding marketplace of mobile apps, we expect to offer health care providers and their patient communities new tools for enhancing care quality and clinical outcomes.” 

“All signs indicate healthcare is at the beginning of a revolution, called mHealth,” said Peter Waegemann, CEO of Medical Records Institute. “Communication-enhanced healthcare is a major part of this development. As new disease management methods emerge that integrate continuous sensing of data, provider monitoring and patient reporting, quality of care will improve and healthcare costs will be lowered. This has been proven in diabetes and hypertension management, but applies equally to asthma management.”

PerformCycle will be available immediately to pediatric asthma patients at California Pacific Medical Center, and beyond CPMC later this year. It will eventually expand to other high-cost-burden diseases. Dr. Evans will present the PerformCycle pilot project on the “Tools for Care Management” panel at the Health 2.0 Conference in San Francisco on October 7 and 8, 2010.

About Presidiohealth
Presidiohealth was founded in 2004 with the primary mission of providing performance management solutions for healthcare providers. Using SaaS and cloud technologies, the company consolidates critical business information so clients can manage clinical and revenue performance in one system. In addition to PerformCycle, Presidio’s services include PerformPOS™, PerformMD™, and PerformRN™ solutions. For more information, visit www.presidiohealth.com.

Click here to see all recent news from this company

HOUSTON, TX–(Marketwire – October 4, 2010) – SHAPE, The Society for Heart Attack Prevention and Eradication (http://www.shapesociety.org), a nonprofit organization that promotes the early detection and treatment of heart attack risk in apparently healthy people, today announced three clinics have achieved certification as SHAPE/HeartHealth Centers of Excellence. The newly certified clinics are Bon Secours Reynolds Crossing Imaging Center in Richmond, Va., Bon Secours St. Francis Hospital in Midlothian, Va., and St. John’s Heart Institute in Springfield, Mo.

The SHAPE/HeartHealth Centers of Excellence initiative encourages best practices in heart attack screening. To be considered for SHAPE/HeartHealth Centers of Excellence certification, a clinic must be committed to improving patient outcomes through early detection and primary prevention of coronary artery disease (CAD). Unlike traditional cardiovascular clinics that are primarily focused on preventing a second heart attack, SHAPE/HeartHealth Centers of Excellence focus on the prevention of a first heart attack — especially in the vulnerable population, those at risk of a near future heart attack.

“We congratulate these clinics on helping to advance preventive cardiology through the responsible practice of cardiovascular screening,” said JoAnne Zawitoski, chairwoman of the SHAPE Board of Directors. “Through these SHAPE/HeartHealth Centers of Excellence we are making progress toward preventing and, ultimately, eradicating heart attacks, but we have a very long way to go.”

SHAPE/HeartHealth Centers of Excellence adhere to the First SHAPE Guideline for screening to identify hidden CAD in apparently healthy individuals. The First SHAPE Guideline established standards for the careful and responsible implementation of scientifically proven atherosclerosis tests to detect hidden plaque buildup in coronary and carotid arteries, and recommended the tests be incorporated into routine screening for at risk men and women as they age.

In addition to the newly certified clinics, other SHAPE/HeartHealth Centers of Excellence are located in Arizona, Florida and Pennsylvania.

The SHAPE/HeartHealth Centers of Excellence Program coincides with SHAPE Provider Certification. For more information about these certification programs for your practice or hospital, please contact Dr. Jeff Fine at (803) 360-4756 or [email protected].

About SHAPE

Based in Houston, the Society for Heart Attack Prevention and Eradication (SHAPE) is a non-profit organization that promotes education and research related to prevention, detection, and treatment of heart attacks. SHAPE is committed to raising public awareness about revolutionary discoveries that are opening exciting avenues to prevent heart attacks. SHAPE’s mission is to eradicate heart attacks in the 21st century. Additional information is available on the organization’s Web site at www.shapesociety.org.

Click here to see all recent news from this company

ATLANTA, GA–(Marketwire – October 4, 2010) –  Uni-Ter Underwriting Management Corporation (UUMC), builder and manager of Risk Retention Groups in the healthcare industry, won the Computer Sciences Corporation (CSC) award for innovation in the process of customizing the CSC RISKMASTER X policy administration and claims processing software to reduce UUMC operational costs and increase efficiency.

According to the award citation, “Integrating all facets of the business will improve continuity and structure within the organization. UUMC has used the expertise that CSC has earned through its 50 years of industry experience to evaluate its business practices and establish guidelines to ensure that day-to-day operations are handled consistently and adequately. As a result of this process, UUMC has determined that integrating additional CSC products may be desired to achieve the all-inclusive system that would set UUMC apart from its competitors. A second phase project plan has already been initiated.”

The award was presented at CSC’s annual Connect Conference held in Kissimmee, Fl. The conference was attended by some 1,500 representatives of companies that do business with CSC.

KANSAS CITY, MO–(Marketwire – October 4, 2010) –  The Ewing Marion Kauffman Foundation will release several studies over the next month on various aspects of health care. Topics range from a call for a personalized health manifesto to employer-based health insurance effects on business creation and an analysis of the costs and benefits of the health care reform bill’s expanded comparative effectiveness research. Highlights of these studies are outlined below. Please contact us if you are interested in specific reports or would like advance copies.

• The Personalized Health Manifesto. Billed as “an old-fashioned call to arms and action plan for a new age of health care,” the paper says there is a “new urgency for scientists to work together to focus on the whole human organism… and for society to absorb and implement scientific discoveries.” The Manifesto is an outgrowth of a larger study, and it calls on the life science community, policymakers, patients and society at large to take a list of actions to accelerate a transformation to personalized health.

• Is Employer-based Health Insurance a Barrier to Entrepreneurship? This study asks whether employer-based health insurance has a negative effect on business creation by causing “job lock” in which workers may be reluctant to risk health coverage by leaving their jobs to start a company. The study examines the issue from several demographic factors, including gender and age, and raises concerns about how the bundling of health insurance and employment impacts business creation.

• Promoting Comparative Effectiveness Research. This study addresses how to make the new health care reform law’s expansion of the comparative effectiveness research (CER) work best or to cause the least amount of harm. CER is research that attempts to analyze which treatment options are more effective than others in terms of quality and cost. A major focus of this study is on market-oriented, patient-centered approaches for disseminating and implementing CER to enhance health outcomes efficiently while preserving patient choice.

• The New Role of Academia in Drug Development. The process for taking scientific discoveries from university labs to the market is stagnant and faces many obstacles. This paper outlines observations presented at a recent town hall meeting held at the Kauffman Foundation and presents recommendations for policymakers and thought leaders on how new collaboration models will benefit cancer cures and treatments. More information on the town hall meeting can be found here.

About the Kauffman Foundation
The Ewing Marion Kauffman Foundation is a private nonpartisan foundation that works to harness the power of entrepreneurship and innovation to grow economies and improve human welfare. Through its research and other initiatives, the Kauffman Foundation aims to open young people’s eyes to the possibility of entrepreneurship, promote entrepreneurship education, raise awareness of entrepreneurship-friendly policies, and find alternative pathways for the commercialization of new knowledge and technologies. In addition, the Foundation focuses on initiatives in the Kansas City region to advance students’ math and science skills, and improve the educational achievement of urban students, including the Ewing Marion Kauffman School, a college preparatory charter school for middle and high school students set to open in 2011. Founded by late entrepreneur and philanthropist Ewing Marion Kauffman, the Foundation is based in Kansas City, Mo. and has approximately $2 billion in assets. For more information, visit www.kauffman.org, and follow the Foundation on Twitter at @kauffmanfdn and Facebook.

Click here to see all recent news from this company

LAS VEGAS, NV–(Marketwire – October 4, 2010) –  MedEx, Inc. (PINKSHEETS: MDXX) is pleased to announce a shareholder update in light of missing the date of the previously announced audit. Because of the unique position that MedEx is in with its clients, namely Medicare, Medicaid, Workman’s Compensation, and various Insurance companies, it was in a position to conduct an audit that includes the month of September, which allowed the company to complete its 3^rd quarter numbers. The audit will be released as soon as it is verified and signed off by management and the accounting firm.

“With September being particularly strong, we are excited to be able to include these numbers in our audit,” said Mr. Paul Protzman, President of MedEx, Inc.

“We would like to thank all of our existing shareholders for their patience. It is our goal to be as transparent as possible and we look forward to completing this milestone of becoming a fully reporting company. The company is currently negotiating with a number of potential acquisitions and it is important that we are current with our financials to assist in a smooth transition as we look to continue to acquire companies that we feel bring synergies to our core goal. That is to consolidate a number of DMEs (durable medical equipment) companies that are all in good standing with Medicare, Medicaid, Workman’s Comp. etc. and any other like businesses.”

About MedEx, Inc.

MedEx, Inc. is a development stage Nevada-based medical support services company, which plans to grow through acquisitions of medical supply companies, medical technology companies, and assisted living and care facilities worldwide. For additional information, see www.medexsynergies.com.  

Safe Harbor Statement:

This release contains “forward-looking statement” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan,” or “planned,” “will,” or “should,” “expected,” “anticipates,” “draft,” “eventually,” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

AUSTIN, TX–(Marketwire – October 1, 2010) –
El sábado, 2 de octubre, se realizarán más de 1.000 eventos en todo el mundo para marcar el Día LIVESTRONG, el día mundial anual de acción para celebrar la sobrevivencia y los esfuerzos hacia un mundo sin cáncer.

El 2 de octubre también marca el décimo cuarto aniversario del diagnóstico de cáncer y el inicio de su vida como defensor del cáncer del LIVESTRONG fundador y presidente, sobreviviente de cáncer y campeón de ciclismo, Lance Armstrong.

“La lucha contra el cáncer no sucede en un laboratorio”, dijo Armstrong. “Se lleva a cabo en nuestros hogares y comunidades mientras las familias luchan por combatir esta enfermedad. Este año, el cáncer se proyecta como la principal causa de muerte, cobrando más de ocho millones de vidas. El Día LIVESTRONG, las comunidades en todo el mundo se unirán para apoyar a las personas que viven con cáncer y hacer un llamado de acción renovada de nuestros líderes para combatir esta crisis de salud mundial”.

Más de 1.000 eventos, desde paseos en bicicleta a iniciativas ?Use Amarillo”, a venta de pasteles y galletas horneadas y mucho más, tendrán lugar en los 50 estados de Estados Unidos y en 57 países el Día LIVESTRONG mientras las personas y las comunidades se mantienen unidas en solidaridad para crear mayor conciencia y recaudar fondos para la lucha contra el cáncer. Los eventos incluyen:

• Una vigilia con barras luminosas en las escalinatas el Capitolio de Colorado en Denver donde los seguidores celebrarán la supervivencia y recordaran a sus seres queridos ya perdidos
• Un evento de paseo en bicicleta y concienciación del cáncer en Boston donde los participantes pedalearán en pos de la lucha contra el cáncer
• Un evento de ciclismo de 24 horas en Atlanta donde los ciclistas recaudarán fondos para programas e investigaciones de cáncer
• Una fiesta para ver un partido de futbol de Texas/Oklahoma en la sede de LIVESTRONG en Austin donde el equipo de LIVESTRONG educará a la comunidad acerca de sus recursos
• Un evento para crear mayor conciencia y de aprendizaje en una escuela primaria en Los Ángeles donde los niños escribirán con tiza en el parque de juegos y compartirán sus ideas sobre lo significa vivir fuerte

LIVESTRONG también se asoció con Nike para crear mayor conciencia acerca del cáncer en el juego de fútbol de Red River Rivalry en Dallas entre The University of Texas en Austin versus The University of Oklahoma. Los aficionados realizarán una cartomagia centrada en el cáncer patrocinada por Nike durante el juego. La cartomagia creará una experiencia memorable para los aficionados y ayudarán a unirlos en la lucha contra el cáncer.

LIVESTRONG y RadioShack crean aún mayor conciencia sobre el cáncer el Día LIVESTRONG reclutando la ayuda de los defensores a través de Facebook y Twitter. El 2 de octubre, por cada persona que añada el número “28” a sus fotos de perfil en Facebook y Twitter para apoyar a los 28 millones de sobrevivientes de cáncer en todo el mundo, RadioShack donará $1 a LIVESTRONG hasta $100,000.

RadioShack también revelará una versión digital gigante del “Mosaico Equipo 28” en Times Square de Nueva York el Día LIVESTRONG por un solo día. El mosaico se basa en la fotografía icónica de Lance tomada en la etapa final de su Gira por Francia en 2010. El Mosaico Equipo 28 está compuesto por fotos de todos los seguidores de Facebook y Twitter que marcaron sus fotos de perfil con el símbolo del Equipo 28 (ver #team28 o http://twb.ly/team-28 vía Twitter). El vídeo de la pancarta de Military Island de Times Square se transmitirá en vivo online durante el día en http://team28.RadioShack.com, permitiendo que los seguidores vean sus imágenes de perfil agrandadas en el mosaico digital mientras las añaden.

También se motiva a los seguidores que usen Amarillo, el símbolo universalmente reconocido de la lucha contra el cáncer, Lance el Día LIVESTRONG se unirá en un testimonio mundial de fortaleza y coraje y demostrará su apoyo a los sobrevivientes de cáncer en todo el mundo. Más de 7.000 personas ya se han comprometido a usar Amarillo el Día LIVESTRONG.

El impacto del cáncer en todo el mundo aumenta todos los días. La American Cancer Society y LIVESTRONG recientemente unieron fuerzas para divulgar el primer estudio único en su tipo sobre el costo económico de todas las causas de muerte en el mundo, incluyendo el cáncer y otras enfermedades no contagiosas y contagiosas. Los datos de este estudio revelaron que el cáncer tiene el impacto económico más devastador que cualquier otra causa de muerte en el mundo, con un costo para la economía mundial de cerca de un billón de dólares al año.

El Día LIVESTRONG es una oportunidad para las personas de todo estrato social para luchar por el objetivo en común de asegurar que los sobrevivientes de cáncer en todo el mundo tengan la información, los recursos y el apoyo que necesitan para vivir con fortaleza y dignidad.

“Hoy tenemos una poderosa oportunidad para cambiar la manera en que las personas piensan acerca del cáncer”, dijo Doug Ulman, presidente y CEO de LIVESTRONG . “Toda persona que se une en la lucha contra el cáncer nos acerca hacia nuestro objetivo de un mundo libre de la enfermedad”.

To learn more, visit www.LIVESTRONG.org.

Acerca de LIVESTRONG
LIVESTRONG, fundada en 1997 por el sobreviviente de cáncer y campeón de ciclismo Lance Armstrong y centralizada en Austin, Texas, lucha por los 28 millones de personas en todo el mundo que viven con cáncer hoy en día. LIVESTRONG conecta a las personas con el apoyo que necesitan, utiliza fondos y recursos para estimular la innovación y compromete a las comunidades y líderes para impulsar un cambio social. Conocida por su icónica banda amarilla, la misión de LIVESTRONG es inspirar y empoderar a cualquier persona afectada por el cáncer.

AUSTIN, TX–(Marketwire – October 1, 2010) –
Sábado, dia 2 de outubro, mais de 1.000 eventos em todo o mundo serão realizados para marcar o Dia LIVESTRONG, o dia anual mundial de ação para comemorar a sobrevivência e trabalho em prol de um mundo sem câncer.

O dia 2 de outubro também é o aniversário de 14 anos do diagnóstico e câncer do sobrevivente de câncer e ciclista camprão Lance Armstrong, fundador e chairman do LIVESTRONG e do início da sua vida como lutador contra o câncer.

“A luta contra o câncer não acontece em um laboratório”, disse Armstrong. “Ela acontece nas nossas casas e comunidades com a luta das famílias para vencer esta doença. Este ano, o câncer deve ser a principal causa de mortes, ceifando mais de oito milhões de vidas. No Dia LIVESTRONG, as comunidades de todo o mundo se unirão para dar suporte para quem vive com câncer pedindo ação renovada dos nossos líderes para o combate a esta crise de saúde mundial”.

Mais de 1.000 eventos — passeios de bicicleta, iniciativas “Wear Yellow” (usem amarelho), vendas de doces e outras — serão realizados nos 50 estados dos EUA e em 57 países no Dia LIVESTRONG com as pessoas e as comunidades se unindo em solidariedade para disseminar o conhecimento da luta contra o câncer. Os eventos são:

• Uma vigília com uma haste brilhante nas escadas do Capitólio de Colorado em Denver para comemorar a sobrevivência e lembrar a perda de entes queridos.
• Um passeio de bicicleta em grupo e um evento de informação sobre o câncer em Boston onde os participantes irão pedalar para lutar contra o câncer.
• Um evento de ciclismo de 24 horas em Atlanta onde os ciclistas angariarão fundos para programas e pesquisa sobre o câncer.
• Uma festa para assistir o jogo de futebol americano do Texas/Oklahoma na sede da LIVESTRONG em Austin onde a equipe da LIVESTRONG irá informar a comunidade sobre os seus recursos.
• Um evento de aprendizado e disseminação de informação em uma escola de ensino fundamental em Los Angeles onde as crianças desenharão com giz no chão do playground e compartilhar suas ideias sobre o que elas acham ser ter uma vida forte.

LIVESTRONG também fez uma parceria com a Nike para disseminar o conhecimento do câncer em um jogo de futebol americano Red River Rivalry em Dallas da University of Texas at Austin e The University of Oklahoma. Os fãs farão uma apresentação com quadros sobre o câncer patrocinada pela Nike durante o jogo. A apresentação será uma experiência memorável para os fãs e irá ajudá-los na luta contra o câncer.

LIVESTRONG e RadioShack irão disseminar ainda mais o conhecimento sobre o câncer no Dia LIVESTRONG ao solicitar a ajuda de simpatizantes no Facebook e Twitter. No dia 2 de outubro, para cada pessoa que adicionar o número “28” nas fotos dos seus perfis no Facebook e Twitter em apoio aos 28 milhões de sobreviventes de câncer em todo o mundo, o RadioShack fará uma doaç ao de $1 dólar para LIVESTRONG com um máximo de $100.000,00.

RadioShack também fará uma apresentação digital do “Team 28 Mosaic” (Mosaico do número 28 da equipe) na Times Square de Nova York sobre o Dia LIVESTRONG apenas um dia. O mosaico está baseado na fotografia icônica de Lance tirada na etapa final da Tour de France de 2010. O Team 28 Mosaic é composto de fotos de todos os simpatizantes do Facebook e do Twitter que incluíram nas fotos do seu perfil o símbolo Team 28 (veja #team28 ou http://twb.ly/team-28 no Twitter). O vídeo do outdoor da Ilha Militar da Times Square será transmitido online ao vivo durante o dia no http://team28.RadioShack.com, para que os simpatizantes possam ver as imagens gigantescas dos perfis no mosaico digital à medida que são adicionadas.

Os simpatizantes também devem usar amarelho, o símbolo reconhecido mundialmente da luta contra o câncer, juntamente com Lance no Dia LIVESTRONG em uma demonstração mundial de força e coragem em apoio aos sobreviventes do câncer em todo o mundo. Mais de 7.000 pessoas já se comprometeram a usar amarelo no Dia LIVESTRONG.

O impacto do câncer em todo o mundo continua a aumentar diariamente. A American Cancer Society e LIVESTRONG recentemente se uniram para publicar o primeiro estudo sobre o custo econômico de todas as causas da morte no mundo, incluindo o câncer e outras doenças comunicáveis e não comunicáveis. Os dados deste estudo mostram que o câncer tem o impacto mais devastador do que qualquer causa de morte no mundo, custando quase três milhões de dólares ao ano para a economia global.

O Dia LIVESTRONG é uma oportunidade para as pessoas de todas as áreas trabalharem em prol de um objetivo comum de garantir que os sobrevivente do câncer de todo o mundo tenham acesso à informação, recursos e suporte necessários para que elas possam viver a vida com forá e dignidade.

“Hoje, temos a grande oportunidade de mudar a forma como as pessoas pensam sobre o câncer”, disse Doug Ulman, Presidente e CEO da LIVESTRONG. “Cada indivíduo que se úne à luta contra o câncer nos leva cada vez mais próximos ao nosso objetivo de um mundo sem esta doença”.

Para mais informações, acesse www.LIVESTRONG.org.

LIVESTRONG
Fundada em 1997 pelo sobrevivente de câncer e campeão de ciclismo Lance Armstrong e baseada em Austin, Texas, a LIVESTRONG luta pelas 28 milhões de pessoas que vivem com câncer no mundo todo hoje. A LIVESTRONG conecta indivíduos para atender suas necessidades, aproveitar os financiamentos e recursos para impulsionar a inovação e envolver as comunidades e líderes na mudança social. Conhecida por sua pulseira amarela icônica, a LIVESTRONG tem por missão inspirar e capacitar qualquer pessoa afetada pelo câncer.

WICHITA, KS–(Marketwire – October 1, 2010) –  Pulse Systems, Inc. announced today that 2011 Pulse Complete EHR, Version 2011, is 2011/2012 compliant and was certified as a Complete EHR on September 30, 2010 by the Certification Commission for Health Information Technology (CCHIT®), an ONC-ATCB, in accordance with the applicable eligible provider certification criteria adopted by the Secretary of Health and Human Services. The 2011/2012 criteria support the Stage 1 meaningful use measures required to qualify eligible providers and hospitals for funding under the American Recovery and Reinvestment Act (ARRA).

“I am certain our clients will be at the front of the line when the incentive payments begin in April 2011 — the first of five payments totaling up to $44,000. This is because our EHR product is in the first group to receive this landmark certification. This mirrors our industry-leading accomplishment in being the first to receive the full comprehensive CCHIT 2011 certification in December of 2009,” said Basil Hourani, President and CEO of Pulse Systems. 

“We built our EHR software with the capability to be used in a meaningful way to help our clients provide more efficient patient care before that concept was even legislated,” he said. “This foresight is the primary reason that we were able to receive certification so promptly.”

The ONC-ATCB 2011/2012 certification program tests and certifies that Complete EHRs meet all of the 2011/2012 criteria and EHR Modules meet one or more — but not all — of the criteria approved by the Secretary of Health and Human Services (HHS) for either eligible provider or hospital technology.

“CCHIT is pleased to be testing and certifying products so that companies are now able to offer these products to providers who wish to purchase and implement certified EHR technology and achieve meaningful use in time for the 2011-2012 incentives,” said Karen M. Bell, M.D., M.S.S., Chair, CCHIT.

2011/2012 certification conferred by CCHIT does not represent an endorsement of the certified EHR technology by the U.S. Department of Health and Human Services nor does it guarantee the receipt of incentive payments.

The clinical quality measures to which 2011 Pulse Complete EHR has been certified include:

2011 Pulse Complete EHR version 2011 is also certified in CCHIT’s separate and independently developed certification program. 2011 Pulse Complete EHR version 2011 is a CCHIT Certified® 2011 Ambulatory EHR, additionally certified for Child Health. Pulse Systems has certified its EHR technology in both programs to provide greater assurance to its customers.

About Pulse Systems, Inc.
Pulse offers Electronic Health Records (EHR), Practice Management, ePrescribing and Revenue Cycle Management (Billing Services) used nationwide in more than 26 medical specialties. Pulse Practice Management and EHR products have both earned five star ratings from AC Group. Since 1982 Pulse has developed, marketed and supported healthcare practice workflow solutions that are easier to purchase, implement, learn, utilize and upgrade. This focus on making things easier for clients is the key to a remarkable 95% client renewal rate. Pulse is a part of Cegedim Healthcare Software (CHS), a division of $1.1 billion global healthcare technology company Cegedim Group. For more information, please visit www.pulseinc.com.

About CCHIT
The Certification Commission for Health Information Technology (CCHIT®) is an independent, 501(c)3 nonprofit organization with the public mission of accelerating the adoption of robust, interoperable health information technology. The Commission has been certifying electronic health record technology since 2006 and is approved by the Office of the National Coordinator for Health Information Technology (ONC) of the U.S. Department of Health and Human Services (HHS) as an Authorized Testing and Certification Body (ONC-ATCB). More information on CCHIT, CCHIT Certified® products and ONC-ATCB certified electronic health record technology is available at http://cchit.org.

About ONC-ATCB 2011/2012 certification
The ONC-ATCB 2011/2012 certification program tests and certifies that EHR technology is capable of meeting the 2011/2012 criteria approved by the Secretary of Health and Human Services (HHS). The certifications include Complete EHRs, which meet all of the 2011/2012 criteria for either eligible provider or hospital technology and EHR Modules, which meet one or more — but not all — of the criteria. ONC-ATCB certification aligns with Health Information Technology: Initial Set of Standards, Implementation Specifications, and Certification Criteria for Electronic Health Record Technology published in the Federal Register in July 2010 and strictly adheres to the test procedures published by the National Institute of Standards and Technology (NIST) at the time of testing. ONC-ATCB 2011/2012 certification conferred by the Certification Commission for Health Information Technology (CCHIT®) does not represent an endorsement of the certified EHR technology by the U.S. Department of Health and Human Services nor does it guarantee the receipt of incentive payments.

“CCHIT®” and “CCHIT Certified®” are registered trademarks of the Certification Commission for Health Information Technology.

Click here to see all recent news from this company

SUNRISE, FL–(Marketwire – October 1, 2010) –  Interim HealthCare® Inc., the nation’s first and finest healthcare and in-home senior care franchise company, is donating in-home, non-medical care to the Lutz family of East Setauket, NY, in the Town of Brookhaven, as part of the October 3^rd episode of ABC’s Emmy-winning hit show Extreme Makeover: Home Edition. The local Interim HealthCare in New York, owned and operated by Jim Watson, is providing the family’s six young adult children, all of whom have Down syndrome, with a staff member to assist with companionship and homemaker care. The in-kind donation totals 20 hours per week for a year.

“Interim HealthCare became aware of the needs of the Lutz family several months ago, and as an in-home care company specializing in services the Lutz family needed, we felt compelled to help,” said Jim Watson, owner of Interim HealthCare of Greater New York. “We know firsthand the struggles that families encounter when they are the primary caregivers for their relatives, and we knew Interim HealthCare could certainly be of assistance in this case.”

Unable to have any children of their own, Grace and John Lutz gave their hearts to 18 adopted children, including seven with Down syndrome. After the couple unexpectedly passed away, their daughter Kathleen, gladly gave up her career and came home to take care of her six Down syndrome siblings who currently range in age from 20 to 25 years old. Everyone agreed that putting the kids in a group home or institution was not an option. It was a good plan, until Kathleen unexpectedly had a grand mal seizure and was diagnosed with inoperable cancer. Her brother John Jr., was next to help, sacrificing his career as a gymnastics coach to move home and care for his sister and other siblings. Kathleen’s health is now stabilized and both brother and sister care for their family as a team.

For more information about Interim HealthCare in Stony Brook, NY please contact Ellen Hamburger, Branch Administer at 631-689-8920. The local office is open from 8:00 am – 5:00 pm Monday – Friday, and can be reached 24 hours a day, seven days a week.

About Interim HealthCare:
Founded in 1966, Interim HealthCare® is the nation’s oldest proprietary national health care franchise organization providing health care personnel at all skill levels in all settings. Through a comprehensive network of more than 300 independently owned franchise offices, Interim HealthCare® franchisees are the largest combined provider of community-based home care (skilled and non-medical) and health care staffing. Interim HealthCare is unique in combining the commitment of local ownership with the support of a national organization that develops innovative programs and quality standards that improve the delivery of service through franchisees who employ more than 75,000 health care workers who serve 50,000 people each day. For more information or to locate an Interim HealthCare office, visit www.interimhealthcare.com.

About Extreme Makeover: Home Edition
The Emmy award winning reality program “Extreme Makeover: Home Edition,” is entering its 7th season, is produced by Endemol USA, a division of Endemol Holding. It’s executive-produced by Brady Connell and George Verschoor. David Goldberg is Chairman, Endemol North America. The show airs Sundays from 8:00-9:00 p.m., ET on ABC.

Click here to see all recent news from this company

AUSTIN, TX–(Marketwire – October 1, 2010) –  On Saturday, October 2nd, more than 1,000 events throughout the world will take place to mark LIVESTRONG Day, the annual global day of action to celebrate survivorship and work toward a world without cancer.

October 2 also marks the 14^th anniversary of LIVESTRONG founder and chairman, cancer survivor and champion cyclist Lance Armstrong’s cancer diagnosis and the beginning of his life as a cancer advocate.

“The fight against cancer doesn’t happen in a lab,” said Armstrong. “It takes place in our homes and communities as families struggle to beat this disease. This year, cancer is projected to become the world’s leading cause of death, claiming more than eight million lives. On LIVESTRONG Day, communities throughout the world will unite to support those living with cancer and call for renewed action by our leaders to combat this global health crisis.” 

More than 1,000 events — from bike rides and “Wear Yellow” initiatives, to bake sales and beyond — will take place in all 50 U.S. states and across 57 countries on LIVESTRONG Day as individuals and communities stand unified in solidarity to raise awareness and funds for the fight against cancer. Events include:

• A glow stick vigil on the Colorado Capitol steps in Denver where supporters will celebrate survivorship and remember lost loved ones
• A group bike ride and cancer awareness event in Boston where participants will pedal to fight cancer
• A 24-hour cycling event in Atlanta where cyclists will raise funds for cancer programs and research
• A Texas/Oklahoma football game watching party at LIVESTRONG headquarters in Austin where LIVESTRONG staff will educate the community about its resources
• A learning and awareness building event at an elementary school in Los Angeles where children will chalk up the playground and share their ideas about what it means to live strong

LIVESTRONG has also partnered with Nike to raise cancer awareness at the Red River Rivalry football game in Dallas featuring The University of Texas at Austin versus The University of Oklahoma. Fans will perform a cancer-focused card stunt sponsored by Nike during the game. The stunt will create a memorable experience for fans and help unite them in the fight against cancer.

LIVESTRONG and RadioShack are further raising cancer awareness on LIVESTRONG Day by enlisting the help of supporters through Facebook and Twitter. On October 2, for every person who adds the number “28” to their Facebook and Twitter profile pictures to support the 28 million cancer survivors around the world, RadioShack will donate $1 to LIVESTRONG up to $100,000.

RadioShack will also unveil a giant digital rendition of the “Team 28 Mosaic” in New York’s Times Square on LIVESTRONG Day for one day only. The mosaic is based on the iconic photograph of Lance taken at the final stage of the 2010 Tour de France. The Team 28 Mosaic is comprised of photos of all the Facebook and Twitter supporters who have tagged their profile photos with the Team 28 symbol (see #team28 or http://twb.ly/team-28 via Twitter). Video of the billboard at Times Square’s Military Island will be streamed live online during the day at http://team28.RadioShack.com, allowing supporters to view larger-than-life profile images on the digital mosaic as they are added.

Supporters are also encouraged to wear yellow, the universally recognized symbol of the fight against cancer, with Lance on LIVESTRONG Day to join in a global statement of strength and courage and show support for cancer survivors around the world. More than 7,000 people have already committed to wearing yellow on LIVESTRONG Day.

The impact of cancer around the globe is growing every day. The American Cancer Society and LIVESTRONG recently joined together to release a first-of-its-kind study on the economic cost of all causes of death globally, including cancer and other noncommunicable diseases and communicable diseases. The data from this study revealed that cancer has the most devastating economic impact of any cause of death in the world, costing the global economy nearly a trillion dollars a year.

LIVESTRONG Day is an opportunity for people from all walks of life to work toward the common goal of ensuring that cancer survivors around the world have the information, resources and support they need to live with strength and dignity.

“Today we have a powerful opportunity to change the way people think about cancer,” said Doug Ulman, LIVESTRONG President and CEO. “Every single person who joins the fight against cancer brings us closer to our goal of a world free from the disease.”

To learn more, visit www.LIVESTRONG.org.

About LIVESTRONG
Founded in 1997 by cancer survivor and champion cyclist Lance Armstrong and based in Austin, Texas, LIVESTRONG fights for the 28 million people around the world living with cancer today. LIVESTRONG connects individuals to the support they need, leverages funding and resources to spur innovation and engages communities and leaders to drive social change. Known for the iconic yellow wristband, LIVESTRONG‘s mission is to inspire and empower anyone affected by cancer.

NEW YORK, NY–(Marketwire – October 1, 2010) –  Hearst Corporation announced today that Gregory H. Dorn, MD, MPH, has been named president of First DataBank, a subsidiary of Hearst Business Media. Dorn succeeds Donald M. Nielsen, MD, who has been appointed chairman of the First DataBank Advisory Board and senior health advisor. The appointments were announced today by Frank A. Bennack, Jr., vice chairman and CEO of Hearst Corporation, and Richard P. Malloch, president of Hearst Business Media, and are effective immediately.

Most recently, Dorn was executive vice president of Zynx Health, another Hearst health-care property. In this management position, Dorn focused on point-of-care clinical decision support solutions. Zynx Health has grown under Hearst’s ownership to serve more than 1,700 hospitals in the U.S.

“Over the past six years, Greg has contributed to Zynx’s extraordinary success and expansion, which has resulted in revenue growth each year of about 70 percent,” Malloch said. “In the coming years, with the growing adoption of electronic health records and e-prescribing, we see First DataBank as well poised for significant growth, and Greg is the right leader to see that through.”

Dorn has numerous peer-reviewed publications and is co-author of a pending patent and a lecturer on quality improvement for the UCLA Center for Health Services Management. He has a bachelor’s degree from the Columbia University School of Engineering and received his medical doctorate from the College of Physicians and Surgeons at Columbia University. Dorn served as house officer at UCLA Medical Center after which he went on to obtain his master’s in health services from the UCLA Center for Health Services Management. Dorn will be based out of First DataBank’s offices in San Francisco.

In his new role as chairman of the First DataBank Advisory Board, Nielsen will focus on strengthening First DataBank’s long-standing commitment to patient safety and health-care data quality issues. Nielsen also will be working on initiatives related to drug reimbursement.

“Don has done an outstanding job driving First DataBank’s leadership position in patient safety and health care quality during the past four years,” Malloch said. “I’m thrilled to have Don now leading two very important areas at First DataBank. There is no one as well qualified as Don to advocate for quality in data and patient care and his extensive knowledge and understanding of drug reimbursement practices will be of great value to Hearst as a whole as we build out those areas of business.”

About First DataBank
First DataBank, a subsidiary of Hearst Corporation, drives patient safety and health care quality by providing drug databases that are used within information systems that touch every aspect of health care. For 30 years, First DataBank has partnered with system developers to integrate and optimize its drug information to improve user workflow and enhance clinical decision-making by those entrusted with treating patients at the point-of-need. Together with its development partners, First DataBank helps reduce the incidence of medication errors and adverse drug events, which promises to lower health-care costs and improve patient care. For more information about First DataBank, call 800-633-3453 or visit www.firstdatabank.com.

About Hearst Corporation
Hearst Corporation (www.hearst.com) is one of the nation’s largest diversified media companies. Its major interests include ownership of 15 daily and 38 weekly newspapers, including the Houston Chronicle, San Francisco Chronicle, San Antonio Express-News and Albany Times Union; nearly 200 magazines around the world, including Good Housekeeping, Cosmopolitan and O, The Oprah Magazine; 29 television stations, which reach a combined 18% of U.S. viewers; ownership in leading cable networks, including Lifetime, A&E, History and ESPN; as well as business publishing, including a minority joint venture interest in Fitch Ratings; Internet and marketing services businesses, television production, newspaper features distribution and real estate.

id=”nav_links”>

NEWPORT BEACH, CA–(Marketwire – October 1, 2010) –  NVISION Laser Eye Centers, formerly part of TLC Laser Eye Centers, announced today that Dr. Tom Tooma has been selected by Goldline Research as one of the leading Laser Eye Surgeons of the United States for 2010. The list of leading Laser Eye Surgeons of the United States was published this week in Forbes Magazine.

“It is a great honor to be selected by Goldline Research and to receive this distinction as one of only ten LASIK surgeons to be listed in Forbes Magazine in 2010,” said Dr. Tom Tooma, the Medical Director for NVISION Laser Eye Centers, formerly part of TLC Laser Eye Centers, and renowned eye surgeon who has performed more than 100,000 vision correction procedures.

“There are more than 10,000 laser eye surgeons in the United States. The practices that we selected provide outstanding patient care that exceeds the industry standard,” said Victoria Coryelle, Analyst, Goldline Research. “We believe that these practices are setting the benchmarks for patient service for the industry as a whole.”

Goldline Research, an independent, third-party research firm specializing in evaluating special services firms, undertook an extensive research process, including individual company interviews, qualitative analysis of company data and customer reference checks to determine high-quality patient care. Dr. Tom Tooma, NVISION Laser Eye Centers, was the only practice chosen in California due to his remarkable service and overall patient satisfaction in the industry.

About NVISION Laser Eye Centers
NVISION Laser Eye Centers, formerly part of TLC Laser Eye Centers, has eight locations throughout Southern California from San Diego to Camarillo. With more than 1,300 eye doctors who refer their patients and trust their own eyes to NVISION affiliate surgeons, we are the Eye Doctors’ #1 Choice, and serve the counties of San Diego, Los Angeles, Orange, Riverside, Ventura and San Bernardino. For more information, visit our new web site at www.NVISIONCenters.com or call 1-877-91NVISION (1-877-916-8474).

Click here to see all recent news from this company

SILVER SPRING, MD–(Marketwire – October 1, 2010) –  The Association of Public Health Laboratories (APHL) is proud to announce the dedication of the new comprehensive New Mexico public health laboratory. On September 29, 2010, the New Mexico Scientific Laboratory Division dedicated their beautiful, state-of-the-art facility which will double their space and greatly expand testing capabilities.

“This new laboratory is the crown jewel of state government,” said Arturo L. Jaramillo, cabinet secretary of the New Mexico General Services Department.

A LEED-certified green facility, this cutting edge laboratory boasts accreditations by numerous agencies. For the first time, the New Mexico public health laboratory will have onsite training facilities. Agreements have already been finalized with the Centers for Disease Control and Prevention to do Laboratory Response Network (LRN) training, the Food and Drug Administration for their dairy analyst training, and the University of New Mexico law school to teach new judges the scientific methods of DWI testing.

“It takes a special laboratory to help shape the future — a specially equipped facility staffed with highly qualified and trained experts, one like the laboratory here,” said APHL’s Executive Director, Scott Becker who attended the dedication. “Who knows — this new space could uncover the clues of some of our most pressing public health issues.”

This year marks the 90th anniversary of the New Mexico public health laboratory. From its origin in 1920 with one visionary employee in a one-room facility, the new building will house state-of-the-art clinical, environmental and forensic analytical services in support of public health across the state and nation.

Press tours of the new public health laboratory will take place on Friday, October 1, 2010.

The Association of Public Health Laboratories is a national non-profit located in Silver Spring, MD, that is dedicated to working with members to strengthen governmental laboratories with a public health mandate. By promoting effective programs and public policy, APHL strives to provide public health laboratories with the resources and infrastructure needed to protect the health of US residents and to prevent and control disease globally.

Click here to see all recent news from this company

LOUISVILLE, CO–(Marketwire – October 1, 2010) –  GlobeImmune Inc. today announced that an abstract related to GI-5005, its Phase 2 investigational hepatitis C virus (HCV) product candidate, has been accepted for a late breaking oral presentation at the 61^st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which will take place October 29 through November 2, 2010, in Boston.

At the AASLD annual meeting, GlobeImmune will present end-of-study data, including sustained virologic response (SVR) rate from prior non-responders, from a Phase 2 clinical study investigating the safety and efficacy of GI-5005. The study compared GI-5005 plus peg-interferon (peg-IFN) and ribavirin, the current standard of care (SOC), versus SOC alone in patients with chronic type 1 hepatitis C infection. Prior non-responders were defined as those patients who did not achieve viral negativity by PCR after a minimum of 12 weeks of SOC. Patients that had achieved viral negativity by PCR during prior SOC but had relapsed during or after completion of SOC therapy were excluded from the study.

The abstract, titled “GI-5005 Therapeutic Vaccine Plus PEG-IFN/Ribavirin Improves Sustained Virologic Response Versus PEG-INF/Ribavirin in Prior Non-Responders With Genotype 1 Chronic HCV Infection,” is published online at the AASLD Web site.

Dr. Paul J. Pockros of Scripps Clinic is the lead author of the abstract that will be presented as part of a late breaker oral session beginning at 6 p.m. EDT on Monday, November 1, 2010 in the Hynes Auditorium. The presentation will include complete response and sustained virologic response rates for patients who received the GI-5005 plus SOC as well as SOC patients in the control arm of the study.

Additionally, Dr. John M. Vierling of Baylor College of Medicine will present a poster titled “GI-5005 Therapeutic Vaccine Improves Deficit in Cellular Immunity in IL28B Genotype T/T, Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 When Added to Standard of Care PEG-IFN-Alfa-2A/Ribavirin,” on Tuesday, November 2, 2010 in the Hynes Exhibit Hall C.

GI-5005 is a therapeutic vaccine candidate that the company believes generates HCV specific T-cell responses and improves virologic responses in patients with chronic hepatitis C infection. 

About GlobeImmune
GlobeImmune Inc. is a private company developing active immunotherapies called Tarmogens for the treatment of cancer and infectious diseases. Tarmogens generate activated killer T cells that are designed to locate and eliminate cancer cells and/or virally-infected cells. The Company’s lead product candidate, GI-5005, is a Tarmogen being developed for the treatment of chronic hepatitis C infection (HCV). GI-5005 is designed to complement both the current standard of care and emerging novel therapies for HCV. The Company’s lead oncology program, GI-4000, targets cancers caused by mutated versions of the Ras oncoprotein. GI-4000 is being investigated in clinical trials for the treatment of pancreas cancer as well as other cancers that contain mutated Ras, including non-small cell lung cancer and colorectal cancer. In May 2009, the Company announced a global partnership with Celgene focused on the discovery, development and commercialization of multiple product candidates for the treatment of cancer.

For additional information, please visit the company’s Web site at www.globeimmune.com.

This news release and the anticipated presentation contain forward-looking statements that involve risks and uncertainties, including statements relating to initiation and progress of the Company’s clinical trial programs and the results from the clinical trials. Actual results could differ materially from those projected and the Company cautions readers not to place undue reliance on the forward-looking statements contained in the release and anticipated presentation.

SPRINGFIELD, OH–(Marketwire – October 1, 2010) –  AdCare Health Systems, Inc. (NYSE Amex: ADK), a recognized innovator in senior living and health care facility management, has closed the previously announced purchase agreement for two privately-held nursing homes in Gladsden, Alabama for $18.5 million.

The two facilities have a total of 306 beds, which currently generate about $18 million in annualized revenue and are expected to be immediately accretive to earnings. Combined with other transactions closed earlier in the year, AdCare’s estimated annualized revenue run-rate now exceeds $96 million, which represents an increase of approximately 261% from $26.7 million in the year ended 2009.

AdCare financed this purchase through a local bank, with a guarantee by the United States Department of Agriculture (USDA). The guarantee is provided through a program developed by the government to supply long-term financing for rural projects at favorable rates.

“This transaction is the fourth we’ve closed since we began our M&A campaign at the end of last year,” said Chris Brogdon, AdCare’s vice chairman and chief acquisitions officer. “We expect all of our new facilities to be significant cash generators for AdCare, especially as they come under our highly capable management and benefit from our larger economy of scale.”

“As we move toward closing the remaining transactions we announced, additional opportunities continue to emerge in the southern region of the U.S. as well as in the Midwest,” said Brogdon. “We are working to establish the terms and necessary financings for several new potential acquisitions in our pipeline of equal or greater potential.”

Brogdon joined AdCare in September 2009 when the company announced a new M&A growth strategy to build upon its strong reputation for operational efficiency and high-quality living environments.

About AdCare Health Systems
AdCare Health Systems, Inc. (NYSE Amex: ADK) is a recognized innovator in senior living and health care facility management. AdCare develops, owns and manages assisted living facilities, nursing homes and retirement communities, as well as provides home health care services. Since its inception in 1988, AdCare’s mission has been to provide the highest quality of healthcare services to the elderly. For more information about AdCare, visit www.adcarehealth.com.

Important Cautions Regarding Forward-Looking Statements
Statements contained in this press release that are not historical facts may be forward-looking statements within the meaning of federal law. Such statement can be identified by the use of forward-looking terminology, such as “believes,” “expects,” “plans,” “intends,” “anticipates” and variations of such words or similar expressions, but their absence does not mean that the statement is not forward-looking. Statements in this announcement that are forward-looking include, but are not limited to, statements that the company expects all of these new facilities to be significant cash generators for AdCare. Such forward-looking statements reflect management’s beliefs and assumptions and are based on information currently available to management. The forward-looking statements involve known and unknown risks, results, performance or achievements of the Company to differ materially from those expressed or implied in such statements. Such factors are identified in the public filings made by the Company with the Securities and Exchange Commission and include the Company’s ability to secure lines of credit and/or an acquisition credit facility, find suitable acquisition properties at favorable terms, changes in the health care industry because of political and economic influences, changes in regulations governing the industry, changes in reimbursement levels including those under the Medicare and Medicaid programs and changes in the competitive marketplace. There can be no assurance that such factors or other factors will not affect the accuracy of such forward-looking statements.

Click here to see all recent news from this company

METHUEN, MA–(Marketwire – September 30, 2010) –  A ribbon cutting event is occurring at Suntron Corporation’s new manufacturing facility. Join Ed Wheeler, CEO of Suntron; Lt. Governor Timothy P. Murray; Congresswomen Niki Tsongas; Mayor Manzi III and Jose Bevilacqua in the opening event at 1pm, facility tour to follow.

MENOMONEE FALLS, WI–(Marketwire – September 30, 2010) – Assisted Living Concepts, Inc. (“ALC”) (NYSE: ALC) announces the expansion and extension of a loan agreement with TCF National Bank (“TCF”). The revised loan agreement increases the loan from $14.0 million to $26.25 million and extends the maturity from June 12, 2014 to September 30, 2015. The loan bears interest at the rate of 6.5% and is secured by mortgages on six of ALC’s senior housing residences.

“We are pleased to have completed a second round of financing with TCF,” commented Laurie Bebo, President and Chief Executive Officer of Assisted Living Concepts, Inc. “Appraisals on the three properties added to secure this loan were in excess of $100,000 per unit, once again demonstrating the value of our business model for owned properties. We own 46 additional unencumbered properties.” 

About Us
Assisted Living Concepts, Inc. and its subsidiaries operate 211 senior living residences comprising 9,280 residents in 20 states. ALC’s senior living facilities typically consist of 40 to 60 units and offer residents a supportive, home-like setting and assistance with the activities of daily living. ALC employs approximately 4,100 people.

Forward-looking Statements
Statements contained in this release other than statements of historical fact, including statements regarding anticipated financial performance, business strategy and management’s plans and objectives for future operations, including management’s expectations about improving occupancy and private pay mix, are forward-looking statements. Forward-looking statements generally include words such as “expect,” “point toward,” “intend,” “will,” “indicate,” “anticipate,” “believe,” “estimate,” “plan,” “strategy” or “objective.” Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. In addition to the risks and uncertainties referred to in the release, other risks and uncertainties are contained in ALC’s filings with United States Securities and Exchange Commission and include, but are not limited to, the following: changes in the health care industry in general and the senior housing industry in particular because of governmental and economic influences; changes in general economic conditions, including changes in housing markets, unemployment rates and the availability of credit at reasonable rates; changes in regulations governing the industry and ALC’s compliance with such regulations; changes in government funding levels for health care services; resident care litigation, including exposure for punitive damage claims and increased insurance costs, and other claims asserted against ALC; ALC’s ability to maintain and increase census levels; ALC’s ability to attract and retain qualified personnel; the availability and terms of capital to fund acquisitions and ALC’s capital expenditures; changes in competition; and demographic changes. Given these risks and uncertainties, readers are cautioned not to place undue reliance on ALC’s forward-looking statements. All forward-looking statements contained in this report are necessarily estimates reflecting the best judgment of the party making such statements based upon current information. ALC assumes no obligation to update any forward-looking statement.

CORAL SPRINGS, FL–(Marketwire – September 30, 2010) –  Valiant Health Care, Inc. (OTCBB: VHCI) (PINKSHEETS: VHCI) announces that it has executed a term sheet with Atlantic Medical Supply, Inc., a Florida corporation (“AMS”), under which it will acquire all of the outstanding shares of AMS in exchange for cash, shares of Valiant’s common stock and options to purchase shares of Valiant’s common stock. 

Atlantic is a Joint Commission Accredited, Medicare Certified firm serving South Florida’s home medical equipment and supply needs since 1993. As one of the area’s largest retail suppliers of home health products and services, they provide superior customer service and top quality, state-of-the-art medical equipment and supplies.

The parties intend to quickly negotiate the stock purchase agreement and hope to close the transaction as quickly as possible, but no later than six months from the signing of the term sheet. Specific terms of the purchase will be provided when the stock purchase agreement is completed and filed with the SEC as required.

Ms. Salem, Co-founder of Accessible stated that “Acquisition of Atlantic a DME provider is the next important step toward achieving our objective of being a “One Stop Provider” of home health care” she continued “We are looking forward to having the Founders of Atlantic join our team, they bring 17 years each of successful experience in the home health care industry.”

About Valiant Health Care, Inc.
Through our Accessible Home Health Care division, we offer and sell a proven one of its kind franchise opportunity to establish and operate a full service medical and personal care Accessible Home Health Care franchise, under our distinctive brand and system. As of the date of this press release, there are 96 Accessible Home Health Care franchise units and one company-owned unit in 24 states, as well as in India and Kenya.

Accessible’s business model is designed to lead and direct the 21st Century demands of the long term home health care industry by offering a “Complete Home Healthcare Package™” and being a “One Stop Provider™.” Accessible’s primary mission is to provide the highest quality home health care services and products to its patients while adding value to the payers by reducing direct costs and the potential for fraud. Accessible’s next phase of growth includes an expansion of its company owned units by acquisition of Medicare certified home health care providers in strategic geographic markets.

Forward-Looking Statements
This release is not an offer to purchase or sell securities and may contain statements that are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Certain statements herein are or may be based on current estimates and projections about Valiant’s business, which are derived in part on assumptions of its management, and are not guarantees of future performance, as such performance is difficult to predict. Valiant assumes no obligation to update information concerning its expectations.

TAMPA, FL–(Marketwire – September 30, 2010) –  eFUEL EFN, Corp. (PINKSHEETS: EFLN) is pleased to announce that Riverside Assisted Living, Inc. (RAL) and eFUEL have executed a Letter of Intent and Understanding with regard to the following:

• It is the intention of eFUEL and RAL that within forty-five (45) days of the execution of the Letter of Intent and Understanding dated September 24, 2010, that they will enter into a Stock Exchange Agreement.

• The Principles of RAL agree to cause RAL to merge into eFUEL as a wholly owned subsidiary of eFUEL.

• The sole asset of RAL at the time of the aforementioned merger will be a 244,000 square ft. mortgaged hospital building on 16 acres located in Warren, Ohio.

About eFUEL EFN, Corp.:

eFUEL EFN, Corp. (“eFUEL”) is a publicly traded company listed on Pink Sheets under the symbol EFLN. eFUEL is an internet services company offering a wide variety of products including but not limited to background screening and verification sites, including www.ValiMate.com, www.VeritasID.com, and www.FastandEasyID.com, www.BackgroundAnswers.com and also www.VerifiAmerica.com, on-line dating sites www.outRAGEousEncounters.com and www.PositiveLove.com, and recently launched a new service called Easy ID, the fastest, easiest ID verification available on the internet. This product will be offered to all new members who purchase any www.eFUELstore.com service. Simply enter a person’s full name and birthday and the background information will be provided. This service is also available at the company’s main site www.eFUELstore.com or www.ValiMate.com. For additional Product information, go to our corporate site at www.eFUELcorp.com

Safe Harbor Statement: Certain Statements in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are subject to risks and uncertainties including, without limitation, changes in levels of competition, possible loss of customers, and the company’s ability to attract and retain key personnel.

BOCA RATON, FL–(Marketwire – September 30, 2010) –  XenaCare Holdings, Inc. (OTCBB: XCHO) announced today that it has signed a private label marketing agreement with Renaissance Publishing LLC covering three of its clinical supplement products.

Under the terms of the agreement XenaCare will supply Renaissance with finished product for private label marketing in the United States with packaging and branding provided by Renaissance.

Commenting on the agreement, Frank Rizzo, President and CEO of XenaCare, states, “We are very pleased to be working with Renaissance for U.S. private label marketing of these proprietary clinical supplement products. They fit into Renaissance’s growing portfolio of anti-aging dietary supplements that promote increased health, well-being, and life expectancy and allow us to concentrate our efforts and resources on Cobroxin™. We believe that the Renaissance strategy of providing education about its products along with its direct response sales model will result in greater awareness and sales of these unique products and look forward to a successful relationship with Renaissance.”

XenaCare expects to strengthen its distribution matrix for future product introductions through a strategic relationship with Renaissance. Renaissance currently has an established 150,000 customer base and is a multimillion dollar company.

For further information:

http://www.XenaCareHoldings.com

Cautionary Note Concerning Forward Looking Statements

Except for the historical and present factual information contained herein, the matters set forth in this document, including statements regarding our anticipated future sales results for our products are forward looking statements. Investors are cautioned that these forward-looking statements are not guarantees of future performance. Actual events or results may differ from the Company’s expectations. There are many risks, uncertainties and other factors that can prevent the achievement of our goals or cause results to differ from those expressed or implied by these forward-looking statements including, without limitation, the risks described in greater detail in filings made by the Company with the Securities and Exchange Commission. The Company assumes no obligation to publicly update or revise its forward-looking statements even if experience or future events make it clear that any of the anticipated results expressed or implied herein will not be realized. The Company’s filings may be accessed at the SEC’s Edgar system at www.sec.gov.

IRVINE, CA–(Marketwire – September 30, 2010) –  Sun Healthcare Group, Inc. (NASDAQ: SUNH) today announced that it will be holding a special stockholder meeting on Thursday, Nov. 4, 2010 at the Irvine Hilton Hotel. At this meeting, stockholders will vote on the previously announced restructuring pursuant to which Sun is separating its operating assets and its real property assets by means of a distribution of SHG Services, Inc. stock. SHG Services, Inc. will own all of Sun’s operating assets and will be renamed Sun Healthcare Group, Inc. Stockholders will also be asked to vote on the merger of Sun with and into Sabra Health Care REIT, Inc., which will own substantially all of Sun’s real property assets, and intends to elect to be treated as a real estate investment trust effective Jan. 1, 2011. As previously announced, Sun expects that the restructuring will be completed in the fourth quarter of 2010.

The record date for stockholders entitled to vote at the meeting is Sept. 15, 2010. Sun expects that a proxy statement/prospectus describing the restructuring transactions will be mailed to stockholders on or about Oct. 4, 2010.

Richard K. Matros, Sun’s Chairman and Chief Executive Officer, commented, “We look forward to the opportunity to create increased shareholder value by separating into two publicly-held companies with independent growth strategies. This meeting is a significant step in the restructuring process.”

About Sun Healthcare Group, Inc.

Sun Healthcare Group, Inc.’s (NASDAQ: SUNH) subsidiaries provide nursing, rehabilitative and related specialty healthcare services principally to the senior population in the United States. Sun’s core business is providing, through its subsidiaries, inpatient services, primarily through 166 skilled nursing centers, 16 combined skilled nursing, assisted and independent living centers, 10 assisted living centers, two independent living centers and eight mental health centers. On a consolidated basis, Sun has annual revenues of $1.9 billion and approximately 30,000 employees in 46 states. At June 30, 2010, SunBridge centers had 23,209 licensed beds located in 25 states, of which 22,427 were available for occupancy. Sun also provides rehabilitation therapy services to affiliated and non-affiliated centers through its SunDance subsidiary, medical staffing services through its CareerStaff Unlimited subsidiary and hospice services through its SolAmor subsidiary. 

Forward-Looking Statements

Statements made in this release that are not historical facts are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995) that involve risks and uncertainties and are subject to change at any time. These forward-looking statements may include, but are not limited to, statements containing words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “hope,” “intend,” “may” and similar expressions. Factors that could cause actual results to differ are identified in the public filings made by the Company with the Securities and Exchange Commission (SEC) and include the company’s ability to successfully complete the restructuring on terms and conditions satisfactory to Sun, as well as other risks and uncertainties, including those detailed from time to time in Sun’s SEC Commission filings. More information on factors that could affect the business and financial results are included in the company’s public filings made with the SEC, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, copies of which are available on Sun’s web site, www.sunh.com. The forward-looking statements involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Sun’s control. Investors are cautioned that any forward-looking statements made by Sun are not guarantees of future performance. Sun disclaims any obligation to update any such factors or to announce publicly the results of any revisions to any of the forward-looking statements to reflect future events or developments.

Additional Information

In connection with the transactions described in this release, SHG Services, Inc. has filed with the SEC a Registration Statement on Form S-1 and Sabra Health Care REIT, Inc. has filed with the SEC a Registration Statement on Form S-4, each containing an identical prospectus and proxy statement for the special meeting. The definitive proxy statement/prospectus is being mailed to Sun stockholders on or about October 4, 2010. Before making any voting or investment decision, Sun stockholders and investors are urged to read the proxy statement/prospectus and other documents filed with the SEC carefully and in their entirety when they become available because they will contain important information about the proposed transactions. Stockholders will be able to obtain these documents free of charge at the SEC’s web site at www.sec.gov. In addition, investors and stockholders of Sun may obtain free copies of the documents filed with the SEC by contacting Sun’s investor relations department at (505) 468-2341 (TDD users, please call (505) 468-4458) or by sending a written request to Investor Relations, Sun Healthcare Group, Inc. 101 Sun Avenue N.E., Albuquerque, N.M. 87109. Investors and stockholders may also obtain a copy of these documents by requesting them in writing from Sun’s proxy solicitation agent, Innisfree M&A, at 501 Madison Avenue, New York, NY 10022, or by telephone at (212) 750-5833. 

Sun and its directors and executive officers and other members of its management and employees may be deemed to be participants in the solicitation of proxies from the stockholders of Sun in connection with the transactions described in this release. Information about the directors and executive officers of Sun and their ownership of shares of Sun common stock are set forth in the Annual Report on Form 10-K for the year ended December 31, 2009 filed with the SEC on March 5, 2010 and in the definitive proxy statement relating to Sun’s 2010 Annual Meeting of Stockholders filed with the SEC on April 30, 2010. These documents can be obtained free of charge from the sources indicated above. Additional information regarding the interests of these participants is also included in the definitive proxy statement/prospectus regarding the proposed transactions that is being mailed to Sun stockholders on or about October 4, 2010.

METHUEN, MA–(Marketwire – September 30, 2010) –  Suntron Corporation, a leader in the area of integrated Electronics Manufacturing Solutions (EMS) and Commercial Off-The Shelf (COTS) technology, with facilities across the US and in Mexico, will cut the ribbon at its new manufacturing site in Methuen, MA at 1:00 PM, October 05, 2010.

This new facility is the culmination of months of effort to combine the work previously done in two separate sites, into a larger, newer, state of the art facility. “The move to combine our northeast services under one roof clearly demonstrates Suntron’s commitment to the region and to our customers,” Roger White, VP and General Manager of the Eastern Region, stated. “We have expanded our box build manufacturing footprint and with significant capital investment, we are expanding our circuit card capacity and capabilities. I look forward to introducing everyone to the exciting new facility.”

Mike Churchill, VP of Operations for Suntron, commented on the teamwork needed to put this together. “We had amazing cooperation from so many local people and organizations, including our team of realtors from Colliers Meredith and Grew, the City of Methuen, the local Merrimack Chamber of Commerce, and the Massachusetts Business Development and Business Services groups. Their total support and guidance allowed us to accomplish our objectives in a very timely manner and we look forward to introducing everyone to our exciting new facility.”

The grand opening and ribbon cutting ceremony will be hosted by Ed Wheeler, President and CEO of Suntron. Lt. Governor Timothy P. Murray, Congresswoman Niki Tsongas, Mayor William M. Manzi, III and Joe Bevilacqua, President and CEO of the Merrimack Chamber of Commerce will all participate at the event. Factory tours will begin immediately following the ceremony.

For further information on this event and the day’s agenda, please visit http://www.suntroncorp.com.

About Suntron Corporation:
Suntron delivers complete manufacturing services and solutions to support the entire life cycle of complex products in the medical, aerospace & defense, Industrial, Networking & telecommunications, and semiconductor capital equipment market segments. Headquartered in Phoenix, Suntron operates four full-service manufacturing facilities and two quick-turn facilities in North America. Suntron’s services include engineering services, printed circuit card assembly, box build, large scale and complex system integration, COTS and test.

PERTH, AUSTRALIA–(Marketwire – September 29, 2010) –  After three years of collaborative research involving patients from The Busselton Health Study, drug discovery company Proteomics International announced the identification and analytical validation of 13 protein biomarkers for a significant complication of diabetes — diabetic nephropathy (kidney disease). In a presentation at the Human Proteome Organisation’s World Congress in Sydney, Australia, Dr. Richard Lipscombe, Managing Director of Proteomics International, revealed the findings that could benefit many of the 250 million people worldwide who have diabetes.

“Applying our uniquely accredited proteomics biomarker expertise to patient samples (plasma) from the Busselton Health Study and the Fremantle Diabetes Study allowed us to analyze three well characterized clinical cohorts of selected disease groups (adults who had Type II diabetes and diabetic nephropathy),” said Dr. Lipscombe. “The protein biomarkers that we found could now allow for the prediction of those patients who would progress to the development of kidney disease and provide new targets for drug therapies that prevent the onset of this serious complication.“

Proteomics International is actively seeking partners to further qualify and commercialize its patented diabetes biomarker portfolio.

The protein biomarker discovery and validation approach included the analysis of pooled plasma samples for differential protein expression, i.e. proteins that are found at different levels in the diabetic disease state relative to the normal diabetic state. Candidate biomarkers were identified from iTRAQ labelled samples by 2D-LC MALDI TOF/TOF mass spectrometry, an emerging technique in proteomics. This discovery phase identified 130-200 proteins per cohort and across all studies over 50 proteins showed significant differences in concentrations. Biomarker candidates were validated in a second approach using the advanced mass spectrometry technique Selected or Multiple Reaction Monitoring (SRM/MRM) to carry out concentration analysis on individual patient plasma samples. Statistical data analysis of the validation phase identified 13 putative protein biomarkers for diabetic nephropathy across the studies, including proteins involved in metabolism, inflammation and oxidative stress. The complexity of the diabetic kidney disease suggests that there would not necessarily be one biomarker but a set of biomarkers (signature) in varying degrees to characterize the diabetic nephropathy state. These biomarkers can be used as diagnostic tools or new drug targets.

About Proteomics International Pty Ltd
Proteomics International is both a drug discovery company and contract research service provider. Proteomics International combines the most advanced high throughput mass spectrometry instrumentation (MALDI TOF-TOF and LC-MS/MS) and a team of qualified scientists with proven expertise in protein and peptide chemistry. Proteomics International is the only company globally to achieve laboratory accreditation to International Standard ISO/IEC 17025:2005 for provision of proteomics services. The accreditation is a widely used benchmark for US Federal testing facilities and strengthens the company’s licensing position to deliver drug development data that is of the highest scientific integrity. The company has two focal research activities: new peptide drugs from venoms, and the discovery and use of biomarkers; both analyses build upon its proprietary transformative Bioven process.

HOUSTON, TX–(Marketwire – September 29, 2010) –  DHEA (Dehydroepiandrosterone) is the most abundant base building block for hormones in our bodies. We gradually make more and more DHEA until about age 25; then produce less and less as time passes. By age 35, the right DHEA supplement can provide noticeable advantages to help us look and feel our best and diminish many aspects of aging. But it must be used correctly.

Medical research shows DHEA must be delivered to the body as a transdermal cream rather than as a pill supplement.

Oral DHEA taken as a pill is destroyed by the “first-pass effect” of the liver. The liver filters out most DHEA before it can do any good; what does get into the bloodstream is DHEA-S (DHEA sulphate).

DHEA-S is a different pro-hormone and has different benefits than DHEA. Medical research shows DHEA is converted into DHEA-S, but not the other way around. DHEA-S is not converted by the body into DHEA. (Hammer et al)

Twist 25 supplements DHEA rather than DHEA-S.

Most research studies of “DHEA” were done using oral DHEA. As a consequence these studies showed little significant benefit to “DHEA”(sulphate) supplementation. No wonder: These studies did not test DHEA with the proper method of administration.

DHEA must be delivered to the body properly as a transdermal DHEA cream – Twist 25.

Medical research shows the human body metabolizes most DHEA into other hormones in the skin (the dermis). The skin is where we use most of the DHEA we make. So Twist 25 cream actually provides exactly what the body produces naturally (bioidentical DHEA) where we use it (in the skin). (Labrie et al)

This is the other key reason DHEA should be provided to the body as a transdermal DHEA cream – Twist 25.

Twist 25 DHEA supplement cream is the highest quality most effective anti-aging health product available. Twist 25 is tested for safety and efficacy.

About Health2Go, Inc.
Health2Go, Inc. develops, manufactures and provides leading-edge top quality anti-aging products. To learn more about Health2Go, Inc. or their anti-aging and wellness products, please visit www.twist25.com or http://store.twist25.com

Fabian Hammer, Sandra Subtil, Philipp Lux, Christiane Maser-Gluth, Paul M. Stewart, Bruno Allolio and Wiebke Arlt. No Evidence for Hepatic Conversion of Dehydroepiandrosterone (DHEA) Sulphate to DHEA: In Vivo and in Vitro Studies. Journal of Clinical Endochrinology and Metabolism Vol. 90, No. 6 3600-3605

Fernand Labrie, Alain Belanger, Rene Berube, et al. University of Toronto Medical School. The Journal of Steroid Biochemistry and Molecular Biology Vol 103, Issue 2, February 2007, Pgs 178-188

Click here to see all recent news from this company

MUNDELEIN, IL–(Marketwire – September 29, 2010) –  Despite traditional differences among the chief constituents of long-term care, the new survey process can be a “win-win” for everyone, which will drive significant quality improvements in our nation’s nursing homes, said Kansas Governor Mark Parkinson and the incoming president of the American Health Care Association and National Center for Assisted Living (AHCA/NCAL), the nation’s largest long-term care association. Governor Parkinson made these comments while speaking at Medline Industries, Inc.’s second annual Long-Term Care Quality Summit, in New York City. More than 150 leaders from the nation’s long-term care community are attending the two-day forum focused on how nursing homes can meet the changing expectations for quality among their residents and families.

“Historically there has been mistrust among providers, regulators and advocacy groups over the traditional survey process and what its goals are,” said Governor Parkinson. “But I am optimistic now because we all want quality care in our nursing homes, and the new Quality Indicator Survey (QIS) process can help make this happen.”

Governor Parkinson said the QIS is more objective than the traditional survey process and focuses on important quality criteria, including a robust care plan, promoting a safe environment and keeping residents active. He emphasized that for resident quality to improve, it was crucial that these criteria be measured and homes be held accountable to maintaining high standards.

In addition to Governor Parkinson, topics being discussed at the Summit include the changing regulatory expectations for the long-term care industry and how nursing homes can implement a system to continuously improve quality of care and life for their residents.

Other speakers include: Anthony Rodgers, new CMS Deputy Administrator for the Center for Strategic Planning; Robert F. Kennedy, Jr.; Andy Kramer, MD, chief executive officer of Nursing Home Quality and professor of medicine, University of Colorado; Neil Pruitt, Jr., chairman and CEO, UHS Pruitt Corporation; Jim Foy, president and CEO, St. John’s Riverside Healthcare System, Yonkers, NY; Barbara Baylis, senior vice president of clinical operations, Kindred Healthcare, Inc.; Mary Ousley, president of Ousley & Associates; Elizabeth Ayello, president of Ayello, Harris and Associates; and Kevin Yankowsky, partner in the health law litigation group of Fulbright & Jaworski L.L.P.

About Medline Industries, Inc. 
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest-growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities and on-staff clinicians.

TAMPA, FL–(Marketwire – September 29, 2010) –  Sage North America today announced that the Sage Healthcare Division, a major provider of electronic health records (EHR) and practice management software serving approximately 80,000 physicians throughout the United States, has been named a preferred vendor by the Ohio Health Information Partnership to make available the Sage Intergy Meaningful Use Edition to all of the Regional Extension Center’s (REC) thousands of participating healthcare providers.

The Ohio Health Information Partnership (OHIP) is a nonprofit, funded through a combination of state funds and federal grants, whose mission is to advance the adoption, implementation and meaningful use of health IT among health care providers to improve the safety, quality, accessibility, availability and efficiency of healthcare for the citizens of Ohio. The organization was created by the American Recovery and Reinvestment Act (ARRA).

Fred Richards, CIO and COO of OHIP, said, “We look forward to working with Sage Healthcare to help us achieve our mission to improve the quality and value of health in Ohio by increasing the use of EHRs.”

The Ohio partnership will provide services that will offer practices EHR implementation assistance making the selection of an EHR system easier for healthcare providers, as well as helping providers meet meaningful use standards. Meeting these standards is necessary for physicians to qualify for financial incentives through Medicare and Medicaid.

The overall goal of OHIP is to improve healthcare quality, outcomes and experience for the citizens of Ohio. OHIP is committed to assisting more than 6,000 physicians adopt and meaningfully use an EHR by 2012.

As a Preferred Vendor for OHIP, Sage will be offering its electronic health record products and services to OHIP provider members. “The Sage mission echoes that of the Ohio Information Partnership in that our ultimate goal is to improve healthcare outcomes throughout the United States through the implementation of affordable and effective health information technology,” said Ken Ernsting, Vice President of Business Development for Sage Healthcare. “Because of this mission, Sage is dedicated to serving regional extension centers and the provider community here in Ohio and beyond.”

The Sage Intergy Meaningful Use Edition is a comprehensive clinical, financial and administrative health information technology solution that assists physicians in continuing to advance the quality and efficiency of care they deliver. The Sage Intergy family of products includes integrated practice management, electronic health records, clinical and business intelligence and tools for online patient engagement. Providers can access Sage Intergy from multiple practice locations, from home, or other remote locations either through a central patient database server, or as a Sage-hosted solution on a monthly subscription basis.

Sage Intergy easily tracks the details of a patient’s clinical history, shares and manages clinical information and combines complex medical practice functions into easy-to-navigate menus. Sage Intergy features centralized financial operations including billing, reporting, task management, and fully integrates with EDI services, Sage Intergy Practice Portal, Sage Intergy RIS and Sage Practice Analytics.

Clinics eligible to utilize Ohio Health Information Partnership’s subsidized services include Priority Primary Care Providers (PPCP) in the area of family medicine, obstetrics, and gynecology, general internal or pediatric medicine. In addition, practices must be either individual or a small group practices (defined as 10 or fewer professionals with prescriptive privileges in the practice) primarily focused on primary care; public and critical access hospitals; and community health centers and rural health clinics.

About Ohio Health Information Partnership
Ohio Health Information Partnership mission is to advance the adoption, implementation and meaningful use of health IT among healthcare providers and facilitate and develop an electronic health information exchange (HIE) to improve the safety, quality, accessibility, availability and efficiency of healthcare for the citizens of Ohio while creating a secure, sustainable health information exchange that ensures the protection of all patient records, enables providers to access necessary, patient-authorized health information and improves the overall level of health care provided throughout the state of Ohio.

About Sage Healthcare Division
Sage Healthcare Division provides integrated electronic health records, EDI applications and practice management systems to approximately 80,000 physicians and thousands of ambulatory care practices throughout North America. These systems enable physicians and practice managers to better manage their practices and improve profitability. Sage Healthcare Division is based in Tampa, Fla., and is a division of Sage North America. For more information, please visit www.sagehealth.com or call (877) 932-6301.

About Sage North America
Sage North America is part of The Sage Group plc, a leading global supplier of business management software and services. Sage North America employs 4,000 people and supports 3.1 million small and midsized business customers, including medical practices in the United States. The Sage Group plc, formed in 1981, was floated on the London Stock Exchange in 1989 and now employs 13,100 people and supports 6.2 million customers worldwide. For more information, please visit the Web site at www.sagenorthamerica.com.

© 2010 Sage Software, Inc. All rights reserved. Sage, the Sage logos, and the Sage product and service names mentioned herein are registered trademarks or trademarks of Sage Software, Inc. or its affiliated entities. All other trademarks are the property of their respective owners.

BETHESDA, MD–(Marketwire – September 29, 2010) –  GetWellNetwork, Inc. today announced that Sharp Memorial Hospital, a Magnet hospital and part of Sharp HealthCare, a Malcolm Baldrige National Quality Award recipient, has selected the Company’s award-winning interactive patient care solution to enhance the patient care experience and streamline clinical workflows. Sharp Memorial Hospital in San Diego, California will use the GetWellNetwork^® solution to provide superior patient education, high-tech amenities and enhanced communication with their caregivers.

“When we evaluated our goals against solutions on the market, it became very clear that GetWellNetwork was our best option,” said Susan Stone, chief nursing officer, Sharp Memorial Hospital. “GetWellNetwork clients have documented impressive improvements in clinical outcomes, patient safety and patient satisfaction. In addition, the company offered something other solutions lacked — proven integration with our EMR system for efficient automation of nursing workflows and the ability to extend The Sharp Experience when patients go home.”

The GetWellNetwork system will provide Sharp Memorial Hospital with a systematic and consistent approach to patient education and communication with caregivers and hospital staff. By integrating with the hospital’s Cerner^® EMR system, patients will access personalized medical information as soon as they arrive in their rooms and will be encouraged to learn about their diagnosis, treatment plan and any upcoming medical procedures through the GetWellNetwork system.

In addition, clinicians will be able to track patients’ progress and comprehension of their treatment plans and prescribed education materials, which will be documented automatically into patients’ records through the bi-directional integration with the Cerner EMR. The result is a consistent process for documentation of patient records, which in turn offloads non-clinical tasks from clinicians. 

The GetWellNetwork solution will also provide a wide range of entertainment features to help patients relax and stay connected with their tech-savvy friends and families. Patients can watch a variety of Hollywood movies, play video games, listen to music on Pandora, and surf the Internet, as well as stay connected via email and social media sites.

“Sharp has earned a national reputation for delivering exceptional patient care, and we had a unique opportunity to work intimately with their leadership team as they evaluated potential partners for the new hospital,” said Michael O’Neil, CEO and founder of GetWellNetwork, Inc. “We are very proud to be selected as the interactive patient care solution of choice by Sharp, and we look forward to collaborating as we implement a digital platform that will impact patient outcomes throughout the patient journey.”

About GetWellNetwork
GetWellNetwork, Inc. uses the bedside TV to entertain, educate and empower hospital patients and caregivers to be more actively engaged in their care. This patient-centered approach improves both satisfaction and outcomes for patients and hospitals. GetWellNetwork is the leader in interactive patient care solutions and exclusively endorsed by the American Hospital Association. More information about GetWellNetwork can be found at www.GetWellNetwork.com.

About Sharp Memorial Hospital
With a tradition of excellence since 1955, Sharp Memorial Hospital is recognized internationally for outstanding programs in emergency and trauma services, surgery, cardiac and vascular care, cancer treatment, rehabilitation, orthopedic and neurological services, women’s health, weight loss surgery, multi-organ transplantation and home care.

A Magnet-designated facility for nursing excellence, Sharp Memorial completed an expansion in January 2009 to become San Diego’s first hospital with all private patient rooms. The new 315,000-square-foot, 334-bed structure, named the Stephen Birch Healthcare Center, is also the first hospital in San Diego to open since 1993. 

Sharp Memorial is part of Sharp HealthCare, the region’s largest health care provider and a 2007 Malcolm Baldrige National Quality Award recipient. To learn more about Sharp Memorial, visit www.sharp.com/memorial or call 1-800-82-SHARP (1-800-827-4277).

Click here to see all recent news from this company

CAMPBELL, CA–(Marketwire – September 29, 2010) –  Saama Technologies, Inc., a pure-play business intelligence (BI) solution provider, and MeLLmo, Inc., provider of innovative mobile BI apps including Roambi, today announced a system integrator partnership that will allow mobile workers from the world’s leading organizations to more easily — and usefully — access data residing in business intelligence solutions from their iPhones, iPads and other mobile devices, providing for more agile decision making. Saama will demonstrate its new end-to-end mobile BI solution, Saama mBI™, at the ASUG BusinessObjects User Conference, on Oct 4-7 in Orlando, Florida, where it is an event sponsor.

According to Murali Pabbisetty, head of Saama’s mobile business intelligence practice group, mobile workers have the same information needs as office staff, but retrieving this critical information, in a format that is usable, has been a significant challenge for enterprise organizations, one that is made more complicated by the proliferation of devices of varying shapes, sizes and technical characteristics.

“Our offering, which includes proprietary automation software and an innovative data visualization methodology, partnered with the Roambi solution — which is well known to be the leading system for extending critical business reports and data out to mobile devices via dashboards — helps enterprises overcome these challenges and realize a level of proactive decision making previously unavailable,” said Pabbisetty. “Together, we can provide a combination of mobile business intelligence experience, skills and software that is unique in the industry and a tremendous asset to our customers.”

“Saama has implemented business intelligence solutions for many of the world’s largest organizations and will be an excellent system integrator partner, given the firm’s dedicated Mobile BI Practice,” said Santiago Becerra, MeLLmo co-founder and CEO. “There’s more to a mobile BI implementation than shrinking reports to fit a mobile device. Enterprises need to understand how the data is going to be used and how that is impacted by a device’s size, shape, orientation, speed, resolution and network. They also need to understand that they have new options, like Roambi, for visualizing their critical data in ways never before available. Having worked through the process many times before, MeLLmo and Saama have a unique appreciation for these issues, and we’ve mastered the art of helping organizations achieve maximum value from their mobile business intelligence implementations.”

Saama will demonstrate its new end-to-end BI solution, Saama mBI, from its booth — #208 — at the ASUG BusinessObjects User Conference October 4-7, 2010 in Orlando, Fl.

Saama is also leading three of the educational sessions within the co-located ASUG Fall Focus: Roadmap to ROI conference, along with customers Cisco Systems and Affiliated Computer Services (a Xerox Company). The three sessions, all held on Tuesday, October 5^th, are detailed below:

• Change Management for an Enterprise powered by SAP BusinessObjects
  • Time: 2:45 PM – 3:45 PM
  • Speakers: Timothy Beaver, Affiliated Computer Services (ACS), a Xerox Company, and Murali Pabbisetty, Saama Technologies
• Connecting Heterogeneous BI Silos: A Cisco Story
  • Time: 4:00 PM – 5:00 PM
  • Speakers: Tim Chandler and Milind Joshi, Cisco Systems, and Balaji Rajagopalan, Saama Technologies
• Ensuring a Timely and Efficient Implementation of SAP ESS/MSS
  • Time: 1:30 PM – 2:30 PM
  • Speaker: Bhushan Dadia, Saama Technologies 

About MeLLmo
Founded in 2008, MeLLmo is reinventing the mobile business application to improve the productivity and decision-making of on-the-go employees. The company’s flagship product, Roambi, is an iPhone/iPad application that makes business data and reports easy to access, navigate and interact with right from a handheld device. Headquartered in San Diego, CA, MeLLmo has a worldwide customer base of Fortune 500 companies and SMBs across a diverse range of industries including: telecommunications, biotechnology, pharmaceuticals, consumer technology, packaged goods, and others. For more information about MeLLmo visit http://www.mellmo.com.

About Saama Technologies
 Saama Technologies, Inc. is a pure-play business intelligence solution provider which continues to revolutionize the way organizations make decisions through business intelligence. Since 1997, the company has combined its extreme BI technology expertise, unique intellectual property portfolio and strong relationships with the industry’s leading technology providers to deliver pure business intelligence to the world’s largest information-focused organizations. Saama’s customers are Fortune 500 organizations within a wide range of industries, including life sciences, technology, financial services, and the public sector. Saama recently acquired data-integration software and NIEM-conformance pioneer Sypherlink, which operates as an independent, wholly-owned subsidiary. For more information, visit www.saama.com.

Saama Technologies and Pure Business Intelligence are trademarks of Saama Technologies, Inc. The names of other actual companies, organizations and/or products/services mentioned herein may be the trademarks of their respective owners.

ALISO VIEJO, CA–(Marketwire – September 29, 2010) – Enclarity Inc., a leading healthcare information solutions company, today announced its October 2010 tradeshow schedule. The company will exhibit and attend three shows to educate payers about the importance of maintaining accurate provider records.

“These industry tradeshows allow us to share our expertise in cleansing provider databases,” said Scott Marber, senior vice president, sales and marketing, Enclarity. “We use the outings to raise awareness and offer cost-effective solutions to the problems created by inaccurate provider data. Increasing the accuracy of your provider data can save a payer hundreds of thousands, if not millions, of dollars per year.”

Oct. 5-8, 2010 Blue Cross Blue Shield Association Blue National Summit
Enclarity will exhibit in booth #316. The show will be attended by Marber as well as Enclarity team members Jasson Griswold, sales director, and Stephanie Rose-Belcher, vice president, payer solutions.

Oct. 13-14, 2010 National Association of Health Data Organizations 25th Annual Conference
Enclarity will exhibit in booth #4. The show will be attended by Enclarity team members Tom Nicholson, sales director, and Sioban McCoy, senior account manager.

Oct. 18-20, 2010 California Association of Health Plans 25th Annual Conference
Enclarity will exhibit in booth #510. The show will be attended by Marber and Griswold.

About Enclarity
Enclarity^® solves healthcare’s provider information problem. The company delivers correct, current and comprehensive provider information solutions by blending thousands of data sources, advanced analytics and healthcare expertise. As a result, its clients improve results in many areas, including claims processing, provider directories, regulatory compliance and market analysis. Named one of the Top 100 private technology companies in North America by Red Herring magazine and awarded the Global Healthcare Information Technology Excellence Award by Frost & Sullivan, Enclarity is headquartered in Aliso Viejo, Calif. For more information, visit www.enclarity.com.

Click here to see all recent news from this company

ASHEVILLE, NC–(Marketwire – September 29, 2010) –  Jaan Ferree, an interior designer based in Asheville, NC specializes in designing public spaces for healthcare, colleges, churches and retreats. Asheville City Council appointed Ferree to the Public Art Board. Her interior design ideas include work by Western North Carolina (WNC) artists and craftsmen.

North Carolina Arts for Health invited Ferree to speak at the Spirit of Place, Places of Spirit conference on October 16, 2010, co-sponsored by Mountain Area Health Education Center (MAHEC). She will present an overview of her intentional process of creating healing environments for health care professionals, patients and families. In these sacred spaces, the public can meditate, nurture their spirits, and connect with the divine in a soothing environment. Participants will tour Mission Hospital chapels. 

Ferree recently completed the interior design of Saint Joseph’s Chapel, a three-year process bringing an interfaith focus to Mission Hospital chapels. To the right of the entrance, the Chapel of Mercy resembles a mini church design, with chairs, kneelers, pew and Stations of the Cross. A glass case across from this room holds symbols of various religions: Buddha, Shiva/Shakti, sage bundles and a feather, a Quran, prayer rug, and Islamic prayer beads and a Menorah. The chapel incorporates signatures of Ferree’s work — a labyrinth walk, journaling table, original stained glass pieces hanging from the skylight, an enlarged photograph of an apple tree in bloom, and a murmuring fountain to complete the overall feeling of calm and serenity. 

“What drew us to Jaan was her inclusion of local artistry and nature in her design aesthetic, her experience in designing labyrinths, and her dedication to creating a space which invites all to enter and encounter the holy,” commented Jerene Broadway, Staff Chaplain for Mission Hospital. “We were delighted to discover that her design and leadership embodied our vision to weave diverse religious traditions into a single tapestry,” she added.

Ferree has designed indoor and outdoor labyrinths, meditation gardens and sacred interior spaces for churches and retreat centers, including Valle Crucis Conference Center, Davidson College and Carpe Diem Farms. She will design an outdoor pavilion for use as a meditation and yoga center at Horse Sense of the Carolinas, where equine therapy is practiced.

To view samples of Jaan Ferree’s interior designs, or for a consultation, visit Intentional Designer, email [email protected] or call 828-252-8718. 

DURHAM, NC–(Marketwire – September 29, 2010) – Mi-Co announced today the release of a new white paper providing a snapshot of what different enterprise users look for in mobile data collection devices and software systems. The white paper serves as a follow-up analysis of a survey recently conducted by Mi-Co, on the same topic. The paper also provides a brief overview of the state of Enterprise Mobility today including findings that would be of interest to software companies, enterprises with mobility interests, governmental organizations and more.

Read what’s popular in electronic data collection for organizations based on Mi-Co’s survey results of 8,500 professionals. Understand the nuances and characteristics end-users favor in data input platforms. For example, the survey showed that touch-filled forms are highly preferred (61.5%) versus electronic forms populated through a keyboard (51.9%) or stylus (48.1%), yet the use of a Tablet PC on a Windows OS trumps all other types of mobile devices such as the iPad and Blackberry on preference ratings. 

Elodia Cole, Mi-Co customer at Medical University of South Carolina says, “The ability to quickly assess data quality and monitor study processes is a prime motivation for our interest in moving towards enterprise mobility for conductance of clinical trials data collection. Our ultimate goal is to minimize data queries, an often time consuming and under budgeted aspect of clinical trial activities. We are currently assessing various technologies that better integrate the data collection and data management processes so that study monitors can review data as it is being collected and intervene as necessary.“

Learn more about how applying electronic mobility to your data collection processes can streamline and positively impact workflows in your enterprise. Visit us at: www.mi-corporation.com or to request a copy of the white paper or email us at [email protected]. 

About Mi-Co
Mi-Co, a leading provider of mobile data collection solutions, provides software to automate paper forms-based business processes. Mi-Co’s enterprise Mi-Forms Software System provides flexible electronic forms design for data capture using digital ink and has proven capabilities for the communication of forms-based data. Mi-Forms support Tablet PCs, Digital Pens, iPads, Pocket PCs, signature capture devices and industry standard software technologies. Mi-Co reaches historically paperwork intensive markets such as healthcare and government and supports an extensive network of channel partners. For more information on Mi-Co, visit www.mi-corporation.com

Click here to see all recent news from this company

LOS ANGELES, CA–(Marketwire – September 29, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF) (www.mmrglobal.com) announced today it has filed a patent application for an open integration tool by which patient data from any practice management system can be seamlessly uploaded into the Company’s MMRPro system (www.mmrprovideos.com) or other electronic records systems. Called the Practice Management System Integration Application (PMSIA), the tool is being designed for administrators in physician offices, hospitals and alternative care sites to facilitate the efficient population of patient information from a healthcare provider’s practice management system into the MMRPro Web-based application. Once patient data is transferred to MMRPro, that patient’s records can be scanned and deposited into an MMRPro virtual patient chart where it can be retrieved over any Internet-connected computer on demand.

The Company believes that one of the biggest challenges physician offices face is moving patient data from their practice management system to an electronic medical records (EMR) system effortlessly. The new integration tool is designed to make it easier for any healthcare professional to convert their office to a new EMR-type system quickly and securely.

Robert H. Lorsch, Chairman and CEO of MMRGlobal, said, “This universal tool represents a way that can help accelerate the growth of health information technology while allowing a faster, more efficient integration of MMRPro into any healthcare professional’s office.”

MMRGlobal’s integration tool will work with any file format, including .csv, .txt, flat file or HL7, and extract data from any open data connectivity (ODBC) compliant data source.

“The flexibility offered by the integration tool also makes it a universal solution for transferring data from practice management systems to most electronic medical records systems, opening the door for MMRGlobal to position its products as a patient portal to competitive EHR systems and potentially creating opportunities for incremental licensing revenue,” Lorsch added.

The applet is expected to be delivered with MMRPro implementations during the fourth quarter. For additional information about the Company and its products and services, visit www.mmrglobal.com and follow Bob Lorsch’s blog at http://blog.mymedicalrecordsinc.com/.

About MMRGlobal, Inc.

MMR Global, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMR Global, Inc. and its products, visit www.mmrglobal.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as “need,” “possibility,” “offer,” “development,” “if,” “negotiate,” “when,” “begun,” “believe,” “achieve,” “will,” “estimate,” “expect,” “maintain,” “plan,” and “continue,” or the negative of these words. Factors that could cause or contribute to such differences include, but are not limited to, the risk the Company’s products are not adopted or viewed favorably by the health care community; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; timing and volume of sales and installations; length of sales cycles and the installation process; market acceptance of new product and feature introductions; ability to establish and maintain strategic relationships; ability to identify and integrate acquisitions; relationships with licensees; competitive product offerings and promotions; changes in government laws and regulations and future changes in tax legislation and initiatives in the health care industry; undetected errors in our products; possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; acceptance of the Company’s marketing and promotional campaigns; risks related to a security breach by third parties; maintaining, developing and defending our intellectual property rights including those pertaining to our biotechnology assets; risks associated with recruitment and retention of key personnel; and additional risks discussed in the Company’s filings with the Securities and Exchange Commission. The Company is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Click here to see all recent news from this company

SAN CLEMENTE, CA–(Marketwire – September 29, 2010) –  Micro Identification Technologies, Inc. (OTCBB: MMTC) (MIT) announces that it has entered into a Securities Purchase Agreement in the form of an 8% convertible note with a New York-based privately held investment banking firm. The Note matures on May 18, 2011 and is convertible into common shares. The firm may convert any or the entire unpaid principal note prior to the maturity date, commencing 180 days following the date of the Note.

This funding is in addition to our recent announcement of the equity financing commitment from Dutchess Capital. MIT expects to receive additional funding from this or other firms under similar conditions in the upcoming months to accelerate its planned production launch and marketing campaign later this year. MIT’s Chairman and CEO, Michael Brennan, stated, “This funding will significantly help MIT achieve its near term goals and, together with expected future funding, will enable MIT to exceed its short and medium term plans.”

MIT will be hosting a Webinar at 1:00 PM PDT today to provide an update of its current business and future plans. Attendees may register for this Event at: https://www3.gotomeeting.com/register/427693966

About Micro Identification Technologies:

MIT is a California-based public company that has developed and patented a rapid microbial identification (ID) System that revolutionizes the pathogenic bacteria ID process and can annually save thousands of lives and tens of millions of dollars. The System IDs bacteria in minutes, not days, and at a significant per test cost savings when compared to any conventional method. It does not rely on chemical or biological agents, conventional processing, fluorescent tags, gas chromatography or DNA analysis. The process is totally GREEN requiring only clean water and a sample of the unknown bacteria. Revenues for all rapid testing methods exceed $5 billion annually — with food safety accounting for over $3 billion — having expanded at a rate of 9.2 percent annually since 1998. Current growth projections are at 30 percent annually with test demands driven by major health, safety and homeland security issues. www.micro-identification.com

MIT has demonstrated the ability to detect and identify, within several minutes, the microbes Escherichia coli, Listeria, Salmonella, Staphylococcus aureus, and other pathogenic bacteria. MIT has performed over 300 tests for the identification of the aforementioned contaminants and scored 95% accuracy. The System can currently identify 23 species of bacteria and is easily expandable. The identification process has been verified by North American Science Associates, Inc. (NAMSA), an independent, internationally recognized biological testing laboratory. The NAMSA Test Report is available from the Company and, in MIT’s opinion, demonstrates the accuracy, speed and cost effectiveness of the System over conventional processes. www.namsa.com

This release contains statements that are forward-looking in nature. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions are forward-looking statements. These statements are made based upon information available to the Company as of the date of this release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to dependence on suppliers; short product life cycles and reductions in unit selling prices; delays in development or shipment of new products; lack of market acceptance of our new products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; our ability to attract and retain qualified employees; inability to expand our operations to support increased growth; and declining economic conditions, including a recession. These and other factors and risks associated with our business are discussed from time to time within our filings with the Securities and Exchange Commission.

EDEN PRAIRIE, MN–(Marketwire – September 29, 2010) –  Sunshine Heart Inc. (ASX: SHC), a global medical device company focused on innovative technologies for moderate to severe heart failure, today announced that it has engaged two leading industrial design and software firms to develop the next generation electronic power and software driver for its C-Pulse^® Heart Assist System. By miniaturizing the separately-housed controller and driver and combining them into one compact unit, Sunshine Heart is broadening future clinical and commercialization opportunities for C-Pulse.

The Company has entered joint development programs to develop a smaller, quieter and lighter single-control system for use in the U.S. pivotal clinical trial, which is expected to commence once the FDA approved IDE feasibility study is completed. The new C-Pulse design will integrate the power driver and battery pack into one unit, significantly reducing the size and the weight of external components. These external design changes will greatly improve mobility and comfort for the patient without altering C-Pulse implantable components or the way in which the device functions inside the body. The new single unit will also feature a number of software enhancements that are intended to allow medical professionals to collect additional data to improve patient management.

Sunshine Heart Chief Executive Officer Dave Rosa said, “Due to its small internal components, the C-Pulse can ideally be implanted through minimally invasive procedures as opposed to a full sternotomy procedure. Now, with the redesign of C-Pulse external components, the system will be more ergonomically appealing and comfortable for patients. Our ultimate goal is to make the C-Pulse a fully-implantable system which, much like a pacemaker, can be easily implanted and effortlessly managed by patients.”

Co-principal medical investigator for Sunshine Heart’s FDA approved IDE feasibility study, William T. Abraham, MD, Professor of Medicine and Chief of the Division of Cardiovascular Medicine at The Ohio State University Heart Center in Columbus, Ohio, said, “Reducing the size and bulk of the external system combined with a less-invasive surgical procedure will dramatically expand the use of the C-Pulse among physicians. This treatment has the potential to transform the way in which heart failure is treated and I am eager to see this treatment reach more patients.”

The C-Pulse heart assist system is designed to treat patients suffering from the debilitating effects of moderate to severe heart failure caused by a failing left ventricle (the left heart chamber). The C-Pulse System features a unique balloon counterpulsation technology that is designed to assist the left ventricle by reducing the workload required to pump blood throughout the body. In addition, it increases blood flow to the coronary arteries. Combined, these potential benefits may help reverse the heart failure process or maintain the patient’s current condition, thereby preventing the need for later stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants.

The C-Pulse System is an earlier intervention than other mechanical therapies, such as LVADs. This device does not make direct contact with patient’s blood and it can be turned on or off at any time, allowing patients intervals of freedom to perform certain activities. The C-Pulse System can also be implanted as a minimally invasive procedure, thereby potentially reducing procedural time, hospital stays, overall cost and patient risk as compared to a traditional sternotomy.

About the C-Pulse^® Heart Assist System
The C-Pulse Heart Assist System uses proprietary balloon counterpulsation technology to increase the amount of blood pumped by the heart and to reduce the workload on the heart. The C-Pulse System is implanted in the patient’s chest through a sternotomy or through a small incision when performed as a minimally invasively procedure. During the procedure, there is no need to place the patient on a heart-lung machine as the patient’s heart remains beating continuously.

Once implanted, the C-Pulse cuff is positioned on the outside of the patient’s ascending aorta above the aortic valve. An ECG sense lead is then attached to the heart to determine timing for cuff inflation and deflation in synchronization with the heartbeat. The C-Pulse cuff and lead are connected to a single line that is run through the abdomen to connect to a power driver outside the body. Because the C-Pulse System remains outside the blood system, there is potentially less risk of blood clots and stroke in comparison to other mechanical devices, such as left ventricle assist devices (LVADs).

About Sunshine Heart^®

Sunshine Heart^® (ASX: SHC) a global medical device company committed to the commercialization of the C-Pulse^® Heart Assist System, a minimally invasive, implantable, non-blood contacting, heart assist therapy for the treatment of moderate heart failure. C-Pulse^® relieves the symptoms of heart failure through the use of counterpulsation technology which enables an increase in cardiac output, an increase in coronary blood flow and a reduction in the heart’s pumping load. The Company has received approval from the U.S. Food and Drug Administration (FDA) to conduct a 20-patient U.S. clinical trial with the C-Pulse^® System and the study will reach seventy-five percent enrollment by September 30, 2010. Sunshine Heart is a Delaware-based Corporation headquartered in Minneapolis with a subsidiary presence in Australia. The Company has been listed on the ASX since September 2004. For more information, please visit www.sunshineheart.com.

Click here to see all recent news from this company